

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**Cumulative Supplement 11
November 2016**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 11
November 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

BD RX INC
(BD RX)

CITRON PHARMA LLC
(CITRON PHARMA LLC)

PROSAM LABS LLC
(PROSAM LABS)

HIKMA MAPLE LTD
(HIKMA MAPLE)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

FRESENIUS KABI USA LLC
(FRESENIUS KABI USA)

CASPER PHARMA LLC
(CASPER PHARMA LLC)

OXFORD PHARMACEUTICALS LLC
(OXFORD PHARMS)

EUROHEALTH INTERNATIONAL SARL
(EUROHLTH INTL SARL)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)	17528 2664 (15.2%)	17765 2665 (15%)	
MULTISOURCE	14487 (84.5%)	14558 (84.4%)	14864 (84.8%)	15100 (85%)	
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)	14731 (84%)	14968 (84.3%)	
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)	133 (0.8%)	132 (0.7%)	
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)	73 (0.4%)	73 (0.4%)	
NEW MOLECULAR ENTITIES APPROVED	28	9	20	8	
NUMBER OF APPLICANTS	1011	1007	1023	1027	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA		HETERO LABS LTD III	EQ 20MG BASE/ML	A201107	001	Sep 26, 2016	Sep NEWA
		ZIAGEN					

AA	+	VIIV HLTHCARE	EQ 20MG BASE/ML	N020978	001	Dec 17, 1998	Sep CFTG
----	---	---------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

ABACAVIR SULFATE

>D>	AB	STRIDES ARCOLAB LTD	EQ 300MG BASE	A091050	001	Oct 28, 2016	Nov CAHN
	AB		EQ 300MG BASE	A091050	001	Oct 28, 2016	Oct NEWA
>A>	AB	STRIDES PHARMA	EQ 300MG BASE	A091050	001	Oct 28, 2016	Nov CAHN

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		TEVA PHARMS USA	EQ 600MG BASE;300MG	A079246	001	Sep 29, 2016	Sep NEWA
		EPZICOM					

AB	+	VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Sep CFTG
----	---	---------------	---------------------	---------	-----	--------------	----------

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB	+	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	May CRLD
----	---	-------------------	-------	---------	-----	--------------	----------

ACARBOSE

TABLET;ORAL

ACARBOSE

>D>	AB	ROXANE	25MG	A078470	001	May 07, 2008	Nov CAHN
>D>	AB		50MG	A078470	002	May 07, 2008	Nov CAHN
>D>	AB		100MG	A078470	003	May 07, 2008	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	25MG	A078470	001	May 07, 2008	Nov CAHN
>A>	AB		50MG	A078470	002	May 07, 2008	Nov CAHN
>A>	AB		100MG	A078470	003	May 07, 2008	Nov CAHN

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

ACETAMINOPHEN

AP		PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	May NEWA
AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar NEWA

OFIRMEV

AP	+	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Mar CFTG
----	---	-----------------	---------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		CNTY LINE PHARMS	325MG;50MG	A205120	001	Oct 30, 2015	Aug CAHN
AA		MIKART INC	300MG;50MG	A207386	001	Nov 15, 2016	Oct NEWA
AA	+	NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011	Oct CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	+	MAYNE PHARMA INC	325MG;50MG;40MG	A089007	001	Mar 17, 1986	Aug CAHN
	+	METRIC	325MG;50MG;40MG	A089007	001	Mar 17, 1986	Jun CAHN
AB	+	NEXGEN PHARMA	300MG;50MG;40MG	A040885	001	Nov 16, 2009	Oct CFTG
AB		NUVO PHARM INC	300MG;50MG;40MG	A207118	001	Oct 28, 2016	Oct NEWA

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	@	INGENUS PHARMS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Jan CAHN
	@	SUN PHARM INDS	325MG;50MG;40MG	A040601	001	Jul 29, 2005	Jan CAHN
		FIORICET					
AA		ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	May CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Jul CAHN
AB	+	ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Apr CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

LARKEN LABS INC

325MG; 30MG; 16MG

A204209 001 Sep 30, 2016 Sep NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ FRONTIDA BIOPHARM

300MG; 15MG

A089671 001 Feb 10, 1988 Sep CAHN

@

300MG; 30MG

A089672 001 Feb 10, 1988 Sep CAHN

@

300MG; 60MG

A089673 001 Feb 10, 1988 Jul CAHN

@ SUN PHARM INDS

300MG; 60MG

A089673 001 Feb 10, 1988 Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

ZYFREL

AA CYPRESS PHARM INC

325MG/15ML; 7.5MG/15ML

A090468 001 Apr 14, 2016 Apr NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ACTAVIS LABS FL INC

300MG; 5MG

A206470 001 Jun 02, 2016 May NEWA

AA

300MG; 7.5MG

A206470 002 Jun 02, 2016 May NEWA

AA

300MG; 10MG

A206470 003 Jun 02, 2016 May NEWA

>D> @ ALLERGAN SALES LLC

500MG; 10MG

A040148 002 Feb 14, 1997 Nov CAHN

@

500MG; 10MG

A040148 002 Feb 14, 1997 Jun CAHN

>A> AA AMNEAL PHARMS

300MG; 10MG

A207137 001 Nov 29, 2016 Nov NEWA

AA AMNEAL PHARMS NY

325MG; 7.5MG

A040746 002 May 10, 2016 Apr NEWA

>A> @ APIL

500MG; 10MG

A040148 002 Feb 14, 1997 Nov CAHN

AA LARKEN LABS INC

325MG; 5MG

A202935 002 Jun 15, 2016 Jun NEWA

AA

325MG; 7.5MG

A202935 003 Jun 15, 2016 Jun NEWA

AA

325MG; 10MG

A202935 004 Jun 15, 2016 Jun NEWA

>A> AA NOVEL LABS INC

300MG; 5MG

A206142 001 Nov 14, 2016 Nov NEWA

>A> AA

300MG; 7.5MG

A206142 002 Nov 14, 2016 Nov NEWA

>A> AA

300MG; 10MG

A206142 003 Nov 14, 2016 Nov NEWA

>A> AA

325MG; 5MG

A206245 001 Dec 01, 2016 Nov NEWA

>A> AA

325MG; 7.5MG

A206245 002 Dec 01, 2016 Nov NEWA

>A> AA

325MG; 10MG

A206245 003 Dec 01, 2016 Nov NEWA

AA PAR PHARM

300MG; 5MG

A205001 001 Jul 05, 2016 Jun NEWA

AA

300MG; 7.5MG

A205001 002 Jul 05, 2016 Jun NEWA

AA

300MG; 10MG

A205001 003 Jul 05, 2016 Jun NEWA

AA RHODES PHARMS

325MG; 5MG

A202991 001 Apr 12, 2016 Mar NEWA

AA

325MG; 7.5MG

A202991 002 Apr 12, 2016 Mar NEWA

AA

325MG; 10MG

A202991 003 Apr 12, 2016 Mar NEWA

AA TRIS PHARMA INC

300MG; 5MG

A202214 004 Mar 15, 2016 Jun NEWA

AA

300MG; 7.5MG

A202214 005 Mar 15, 2016 Jun NEWA

AA

300MG; 10MG

A202214 006 Mar 15, 2016 Jun NEWA

NORCO

>D> AA ALLERGAN SALES LLC

325MG; 2.5MG

A040148 004 Jul 07, 2014 Nov CAHN

AA

325MG; 2.5MG

A040148 004 Jul 07, 2014 Jun CAHN

>D> AA +

325MG; 5MG

A040099 001 Jun 25, 1997 Nov CAHN

AA +

325MG; 5MG

A040099 001 Jun 25, 1997 Jun CAHN

>D> AA

325MG; 5MG

A040148 005 Jul 07, 2014 Nov CAHN

AA

325MG; 5MG

A040148 005 Jul 07, 2014 Jun CAHN

>D> AA +

325MG; 7.5MG

A040148 003 Sep 12, 2000 Nov CAHN

AA +

325MG; 7.5MG

A040148 003 Sep 12, 2000 Jun CAHN

>D> AA +

325MG; 10MG

A040148 001 Feb 14, 1997 Nov CAHN

AA +

325MG; 10MG

A040148 001 Feb 14, 1997 Jun CAHN

>A> AA APIL

325MG; 2.5MG

A040148 004 Jul 07, 2014 Nov CAHN

>A> AA +

325MG; 5MG

A040099 001 Jun 25, 1997 Nov CAHN

>A> AA

325MG; 5MG

A040148 005 Jul 07, 2014 Nov CAHN

>A> AA +

325MG; 7.5MG

A040148 003 Sep 12, 2000 Nov CAHN

>A> AA +

325MG; 10MG

A040148 001 Feb 14, 1997 Nov CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

AA + MALLINCKRODT INC

325MG/5ML; 5MG/5ML

A040680 001 Sep 29, 2006 Aug CRLD

AA

325MG/5ML; 5MG/5ML

A040680 001 Sep 29, 2006 May CMFD

ROXICET

>D> @ ROXANE

325MG/5ML; 5MG/5ML

A089351 001 Dec 03, 1986 Nov CAHN

@

325MG/5ML; 5MG/5ML

A089351 001 Dec 03, 1986 Aug DISC

>A> @ WEST-WARD PHARMS INT

325MG/5ML; 5MG/5ML

A089351 001 Dec 03, 1986 Nov CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ALVOGEN MALTA	325MG;5MG	A202677	003	Mar 08, 2016	Feb NEWA
AA		325MG;7.5MG	A202677	001	Jul 26, 2012	Jan CAHN
AA		325MG;10MG	A202677	002	Jul 26, 2012	Jan CAHN
AA	AMNEAL PHARMS NY	325MG;7.5MG	A040778	002	Jun 27, 2014	Apr NEWA
>A> AA	CEROVENE INC	325MG;5MG	A207574	001	Dec 13, 2016	Nov NEWA
AA	MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20, 2008	Feb CAHN
AA		325MG;5MG	A090177	002	Oct 20, 2008	Feb CAHN
AA		325MG;7.5MG	A090177	003	Oct 20, 2008	Feb CAHN
AA		325MG;10MG	A090177	004	Oct 20, 2008	Feb CAHN
	@	500MG;7.5MG	A090177	005	Oct 20, 2008	Feb CAHN
	@	650MG;10MG	A090177	006	Oct 20, 2008	Feb CAHN
	ROXICET					
>D> AA	ROXANE	325MG;5MG	A087003	001		Nov CAHN
>A> AA	WEST-WARD PHARMS INT	325MG;5MG	A087003	001		Nov CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ATLAS PHARMS LLC	325MG;37.5MG	A202076	001	Mar 30, 2012	May CAHN
----	------------------	--------------	---------	-----	--------------	----------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar NEWA
AB	NOVAST LABS LTD	500MG	A203434	001	Sep 30, 2016	Sep NEWA

TABLET;ORAL

ACETAZOLAMIDE

AB	HERITAGE PHARMA	125MG	A205530	001	Oct 27, 2016	Oct NEWA
AB		250MG	A205530	002	Oct 27, 2016	Oct NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Sep CAHN
----	----------------------	--------------------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb NEWA
AP	FRESENIUS KABI USA	6GM/30ML (200MG/ML)	A200644	001	Nov 07, 2012	Sep CAHN

TABLET, EFFERVESCENT;ORAL

CETYLEV

	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Jan NEWA
+		2.5GM	N207916	002	Jan 29, 2016	Jan NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB	IMPAX LABS INC	10MG	A202552	001	Dec 23, 2015	Aug CAHN
AB		17.5MG	A202552	002	Dec 23, 2015	Aug CAHN
AB		22.5MG	A202552	003	Dec 23, 2015	Aug CAHN
AB		25MG	A202552	004	Dec 23, 2015	Aug CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+	AUXILIUM PHARMS INC	8MG;60MG	N019806	001	Mar 25, 1994	Mar CAHN
---	---------------------	----------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

	@ RANBAXY	200MG	A074975	001	Sep 30, 1998	Feb DISC
AB	ZYDUS PHARMS USA INC	200MG	A204313	001	Mar 25, 2016	Mar NEWA

OINTMENT;TOPICAL

ACYCLOVIR

AB	FOUGERA PHARMS INC	5%	A206633	001	May 11, 2016	Apr NEWA
----	--------------------	----	---------	-----	--------------	----------

TABLET;BUCCAL

SITAVIG

+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan CAHN
---	------------------	------	---------	-----	--------------	----------

TABLET;ORAL

ACYCLOVIR

@ SUN PHARM INDS LTD

400MG

A074980 001 Sep 30, 1998 Feb DISC

@

800MG

A074980 002 Sep 30, 1998 Feb DISC

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

@ AMPHASTAR PHARMS INC

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Jun CAHN

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Jun CAHN

@ BEDFORD

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Feb DISC

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Feb DISC

AP +

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Feb CTEC

@ EUROHLTH INTL SARL

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Apr CAHN

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Apr CAHN

AP

HIKMA PHARMS LLC

EQ 500MG BASE/VIAL

A205771 001 Feb 29, 2016 Feb NEWA

+

EQ 1GM BASE/VIAL

A205771 002 Feb 29, 2016 Feb CRLD

AP

EQ 1GM BASE/VIAL

A205771 002 Feb 29, 2016 Feb NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

AB

TARO

0.3%

A208322 001 Jun 23, 2016 Jun NEWA

SOLUTION;TOPICAL

ADAPALENE

AB

CALL INC

0.1%

A203981 001 Sep 23, 2016 Sep NEWA

AB +

0.1%

A204593 001 Jan 05, 2016 Sep CTEC

ADENOSINE

SOLUTION;IV (INFUSION)

ADENOSINE

AP +

TEVA PHARMS USA

60MG/20ML (3MG/ML)

A077425 001 Aug 29, 2013 Apr CRLD

AP +

90MG/30ML (3MG/ML)

A077425 002 Aug 29, 2013 Apr CRLD

ALBUTEROL SULFATE

SOLUTION;INHALATION

ALBUTEROL SULFATE

@ HI TECH PHARMA

EQ 0.083% BASE

A075063 001 Feb 09, 1999 Mar DISC

@ LANDELA PHARM

EQ 0.083% BASE

A077569 001 Apr 04, 2006 Mar DISC

AN +

NEPHRON

EQ 0.083% BASE

A074880 001 Sep 17, 1997 Mar CRLD

@ TEVA PHARMS

EQ 0.083% BASE

A075343 001 Nov 09, 1999 Mar DISC

@ WATSON LABS INC

EQ 0.083% BASE

A076370 001 Nov 24, 2003 Mar DISC

TABLET;ORAL

ALBUTEROL SULFATE

@ DAVA PHARMS INC

EQ 2MG BASE

A072860 002 Dec 20, 1989 Oct CMS1

AB

SUN PHARM INDS

EQ 2MG BASE

A072637 002 Dec 05, 1989 Mar CAHN

AB

EQ 4MG BASE

A072637 001 Dec 05, 1989 Mar CAHN

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

>D>

+

ROXANE

EQ 70MG BASE/75ML

A090520 001 Feb 25, 2013 Nov CAHN

+

EQ 70MG BASE/75ML

A090520 001 Feb 25, 2013 Aug CRLD

>A>

+

WEST-WARD PHARMS INT

EQ 70MG BASE/75ML

A090520 001 Feb 25, 2013 Nov CAHN

FOSAMAX

@ MERCK

EQ 70MG BASE/75ML

N021575 001 Sep 17, 2003 Aug DISC

TABLET;ORAL

ALENDRONATE SODIUM

AB

IMPAX LABS INC

EQ 5MG BASE

A075710 001 Feb 06, 2008 Aug CAHN

AB

EQ 10MG BASE

A075710 002 Feb 06, 2008 Aug CAHN

AB

EQ 35MG BASE

A075710 003 Feb 06, 2008 Aug CAHN

AB

EQ 40MG BASE

A075710 004 Feb 06, 2008 Aug CAHN

AB

EQ 70MG BASE

A075710 005 Feb 06, 2008 Aug CAHN

AB

JUBILANT CADISTA

EQ 5MG BASE

A090557 001 Feb 18, 2010 Jun CAHN

AB

EQ 10MG BASE

A090557 002 Feb 18, 2010 Jun CAHN

AB

EQ 35MG BASE

A090557 003 Feb 18, 2010 Jun CAHN

AB

EQ 70MG BASE

A090557 004 Feb 18, 2010 Jun CAHN

@ UPSHER-SMITH LABS

EQ 5MG BASE

A075871 001 Apr 22, 2009 Oct CAHN

@

EQ 10MG BASE

A075871 002 Apr 22, 2009 Oct CAHN

@

EQ 35MG BASE

A075871 004 Apr 22, 2009 Oct CAHN

@

EQ 40MG BASE

A075871 003 Apr 22, 2009 Oct CAHN

@

EQ 70MG BASE

A075871 005 Apr 22, 2009 Oct CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

EQ 70MG BASE; 2,800 IU

N021762 001 Apr 07, 2005 Aug CMFD

+

EQ 70MG BASE; 5,600 IU

N021762 002 Apr 26, 2007 Aug CMFD

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB

UNICHEM LABS LTD

10MG

A203192 001 Jan 28, 2016 Jan NEWA

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

NODEN PHARMA

EQ 150MG BASE

N021985 001 Mar 05, 2007 Oct CAHN

+

EQ 300MG BASE

N021985 002 Mar 05, 2007 Oct CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

NODEN PHARMA

EQ 150MG BASE; 12.5MG

N022107 001 Jan 18, 2008 Oct CAHN

EQ 150MG BASE; 25MG

N022107 002 Jan 18, 2008 Oct CAHN

+

EQ 300MG BASE; 12.5MG

N022107 003 Jan 18, 2008 Oct CAHN

+

EQ 300MG BASE; 25MG

N022107 004 Jan 18, 2008 Oct CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB

INDOCO REMEDIES

100MG

A204467 001 Jul 28, 2016 Jul NEWA

AB

300MG

A204467 002 Jul 28, 2016 Jul NEWA

AB

SUN PHARM INDS

300MG

A071450 001 Jan 09, 1987 Mar CAHN

ZYLOPRIM

AB

SEBELA IRELAND LTD

100MG

N016084 001 Jan CAHN

AB

+

300MG

N016084 002 Jan CAHN

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL

A076870 001 Aug 26, 2004 Oct CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB

AJANTA PHARMA LTD

EQ 6.25MG BASE

A205523 001 Mar 03, 2016 Feb NEWA

AB

EQ 12.5MG BASE

A205523 002 Mar 03, 2016 Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

>D> AB

ROXANE

EQ 0.5MG BASE

A200652 001 May 04, 2015 Nov CAHN

>D> AB

EQ 1MG BASE

A200652 002 May 04, 2015 Nov CAHN

>A> AB

WEST-WARD PHARMS INT

EQ 0.5MG BASE

A200652 001 May 04, 2015 Nov CAHN

>A> AB

EQ 1MG BASE

A200652 002 May 04, 2015 Nov CAHN

LOTRONEX

AB

SEBELA IRELAND LTD

EQ 0.5MG BASE

N021107 002 Dec 23, 2003 Feb CAHN

AB

+

EQ 1MG BASE

N021107 001 Feb 09, 2000 Feb CAHN

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

>D>

+

ROXANE

1MG/ML

A074312 001 Oct 31, 1993 Nov CAHN

>A>

+

WEST-WARD PHARMS INT

1MG/ML

A074312 001 Oct 31, 1993 Nov CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ ACTAVIS LABS FL INC

0.5MG

A077198 001 May 13, 2010 Jan DISC

@

1MG

A077198 002 May 13, 2010 Jan DISC

@

2MG

A077198 003 May 13, 2010 Jan DISC

@

3MG

A077198 004 May 13, 2010 Jan DISC

@ COREPHARMA

0.5MG

A077996 001 Jan 31, 2007 Mar DISC

@

1MG

A077996 002 Jan 31, 2007 Mar DISC

@

2MG

A077996 003 Jan 31, 2007 Mar DISC

TABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

@	3MG	A077996	004	Jan 31, 2007	Mar DISC
@ IMPAX LABS	0.5MG	A077968	004	May 24, 2007	Jan DISC
@	1MG	A077968	003	May 24, 2007	Jan DISC
@	2MG	A077968	002	May 24, 2007	Jan DISC
@	3MG	A077968	001	May 24, 2007	Jan DISC

ALPROSTADIL

INJECTABLE;INJECTION
ALPROSTADIL

AP	WEST-WARD PHARMS INT	0.5MG/ML	A074815	001	Jan 20, 1998	Sep CAHN
	EDEX					
	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN
	SUPPOSITORY;URETHRAL					
	MUSE					
+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
+		0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
+		0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL
AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
AB	NEWGEN PHARMS LLC	100MG	A207570	001	Sep 30, 2016	Sep NEWA
>A> AB	WATSON LABS INC	100MG	A208107	001	Dec 06, 2016	Nov NEWA
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA

AMIKACIN SULFATE

INJECTABLE;INJECTION
AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
AP		EUROHLTH INTL SARL	EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA
	@	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274	001	May 18, 1992	Oct CAHN
AP	+		EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Sep CAHN
	@		EQ 250MG BASE/ML	A063275	001	May 18, 1992	Oct CAHN
AP			EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Sep CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1	
	CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1	
	CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1	
	CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1	
	CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar CMS1	
	CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar CMS1	
	CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;	N020678	008	Mar 26, 1997	Mar CMS1	

INJECTABLE; INJECTION

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER		51MG/100ML; 261MG/100ML; 297MG/100ML ; 77MG/100ML				
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER		5%; 33MG/100ML; 10GM/100ML; 51MG/100M	N020678	016	Mar 26, 1997	Mar CMS1
+	BAXTER HLTHCARE	L; 261MG/100ML; 340MG/100ML; 59MG/100 ML				
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER		5%; 33MG/100ML; 15GM/100ML; 51MG/100M	N020678	017	Mar 26, 1997	Mar CMS1
+	BAXTER HLTHCARE	L; 261MG/100ML; 340MG/100ML; 59MG/100 ML				
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER		5%; 33MG/100ML; 20GM/100ML; 51MG/100M	N020678	018	Mar 26, 1997	Mar CMS1
+	BAXTER HLTHCARE	L; 261MG/100ML; 340MG/100ML; 59MG/100 ML				
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER		5%; 33MG/100ML; 25GM/100ML; 51MG/100M	N020678	019	Mar 26, 1997	Mar CMS1
+	BAXTER HLTHCARE	L; 261MG/100ML; 340MG/100ML; 59MG/100 ML				
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER		5%; 33MG/100ML; 35GM/100ML; 51MG/100M	N020678	021	Mar 26, 1997	Mar CMS1
+	BAXTER HLTHCARE	L; 261MG/100ML; 340MG/100ML; 59MG/100 ML				

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%	N208081	001	May 10, 2016	May NEWA
---	-------------	-----	---------	-----	--------------	----------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@	IDT AUSTRALIA LTD	100MG	A085261	003		May CAHN
@		100MG	A085262	002		May CAHN
@		200MG	A085261	002		May CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

>D>	AB	APOTEX CORP	200MG	A078578	001	Nov 06, 2008	Nov CAHN
>A>	AB	APOTEX INC	200MG	A078578	001	Nov 06, 2008	Nov CAHN
	AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	May NEWA
	AB	MURTY PHARMS	100MG	A077069	003	Oct 04, 2016	Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@	ANI PHARMS INC	10MG	A085031	002		Sep CMS1
	@		50MG	A085031	003		Sep CMS1
	@		75MG	A085031	004		Sep CMS1
	@	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar DISC
	@		10MG	A089399	002	Jul 14, 1987	Mar DISC
AB			10MG	A089399	002	Jul 14, 1987	Mar CAHN
	@		25MG	A040816	001	Jun 27, 2008	Mar DISC
	@		25MG	A089399	001	Jul 14, 1987	Mar DISC
AB			25MG	A089399	001	Jul 14, 1987	Mar CAHN
	@		50MG	A040816	003	Jun 27, 2008	Mar DISC
	@		50MG	A089399	003	Jul 14, 1987	Mar DISC
AB			50MG	A089399	003	Jul 14, 1987	Mar CAHN
	@		75MG	A040816	004	Jun 27, 2008	Mar DISC
	@		75MG	A089399	004	Jul 14, 1987	Mar DISC
AB			75MG	A089399	004	Jul 14, 1987	Mar CAHN
	@		100MG	A040816	005	Jun 27, 2008	Mar DISC
	@		100MG	A089399	005	Jul 14, 1987	Mar DISC
AB			100MG	A089399	005	Jul 14, 1987	Mar CAHN
	@		150MG	A040816	006	Jun 27, 2008	Mar DISC
	@		150MG	A089399	006	Jul 14, 1987	Mar DISC
AB			150MG	A089399	006	Jul 14, 1987	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@ FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Jul CAHN
@	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Jul CAHN
@ SUN PHARM INDS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Mar CAHN
@	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@ SUN PHARM INDS	10MG;2MG	A071077	001	Nov 12, 1986	Mar CAHN
@	10MG;4MG	A071078	001	Nov 12, 1986	Mar CAHN
@	25MG;2MG	A070297	001	Nov 12, 1986	Mar CAHN
@	25MG;4MG	A071079	001	Nov 12, 1986	Mar CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016	May NEWA
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb CAHN
AB		EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb CAHN
AB		EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb CAHN
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016	Jun NEWA
AB		EQ 5MG BASE	A207821	002	Jul 11, 2016	Jun NEWA
AB		EQ 10MG BASE	A207821	003	Jul 11, 2016	Jun NEWA
>D> AB	ROXANE	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Nov CAHN
>D> AB		EQ 5MG BASE	A077262	002	Jul 09, 2007	Nov CAHN
>D> AB		EQ 10MG BASE	A077262	003	Jul 09, 2007	Nov CAHN
	@ SUN PHARM INDS	EQ 2.5MG BASE	A078081	001	Jan 31, 2008	Mar CAHN
	@	EQ 5MG BASE	A078081	002	Jan 31, 2008	Mar CAHN
	@	EQ 10MG BASE	A078081	003	Jan 31, 2008	Mar CAHN
>A> AB	WEST-WARD PHARMS INT	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Nov CAHN
>A> AB		EQ 5MG BASE	A077262	002	Jul 09, 2007	Nov CAHN
>A> AB		EQ 10MG BASE	A077262	003	Jul 09, 2007	Nov CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	PAR PHARM INC	EQ 5MG BASE;12.5MG;20MG	A206137	001	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A206137	002	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;25MG;40MG	A206137	003	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A206137	004	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;25MG;40MG	A206137	005	Oct 26, 2016	Oct NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Oct NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Oct NEWA
AB		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Oct NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Oct NEWA
AB		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Oct NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A203580	002	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;25MG;40MG	A203580	003	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Oct NEWA
	TRIBENZOR					
AB	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010	Oct CFTG
AB		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010	Oct CFTG
AB		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010	Oct CFTG
AB		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010	Oct CFTG
AB	+	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010	Oct CFTG

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	AJANTA PHARMA LTD	EQ 5MG BASE;20MG	A207216	001	Oct 28, 2016	Oct NEWA
AB		EQ 5MG BASE;40MG	A207216	002	Oct 28, 2016	Oct NEWA
AB		EQ 10MG BASE;20MG	A207216	003	Oct 28, 2016	Oct NEWA
AB		EQ 10MG BASE;40MG	A207216	004	Oct 28, 2016	Oct NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE;20MG	A206884	001	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;40MG	A206884	003	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;20MG	A206884	002	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;40MG	A206884	004	Oct 26, 2016	Oct NEWA

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Oct	NEWA
AB		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Oct	NEWA
>A>	TORRENT PHARMS LLC	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Nov	NEWA
>A>		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Nov	NEWA
>A>		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Nov	NEWA
>A>		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Nov	NEWA
AZOR							
AB	DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007	Oct	CFTG
AB		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007	Oct	CFTG
AB		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007	Oct	CFTG
AB	+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007	Oct	CFTG

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

>A>	AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;40MG	A205234	001	Nov 17, 2016	Nov	NEWA
>A>	AB		EQ 5MG BASE;80MG	A205234	003	Nov 17, 2016	Nov	NEWA
>A>	AB		EQ 10MG BASE;40MG	A205234	002	Nov 17, 2016	Nov	NEWA
>A>	AB		EQ 10MG BASE;80MG	A205234	004	Nov 17, 2016	Nov	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A206512	001	Apr 22, 2016	Apr	NEWA
AB		EQ 5MG BASE;320MG	A206512	002	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;160MG	A206512	003	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;320MG	A206512	004	Apr 22, 2016	Apr	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Sep	NEWA
AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Sep	NEWA
AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Sep	NEWA
AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Sep	NEWA
AB	PAR PHARM INC	EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Oct	CMS1

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan	NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan	NEWA

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr	CRLD
----	---	------------------	-------------	---------	-----	--------------	-----	------

LOTION;TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr	CRLD
----	---	------------------	-------------	---------	-----	--------------	-----	------

AMOXAPINE

TABLET;ORAL

AMOXAPINE

>D>	@	SANDOZ	25MG	A072943	001	Jun 28, 1991	Nov	CAHN
>D>	@		50MG	A072944	001	Jun 28, 1991	Nov	CAHN
>D>	@		100MG	A072878	001	Jun 28, 1991	Nov	CAHN
>D>	@		150MG	A072879	001	Jun 28, 1991	Nov	CAHN
>A>	@	UPSHER-SMITH LABS	25MG	A072943	001	Jun 28, 1991	Nov	CAHN
>A>	@		50MG	A072944	001	Jun 28, 1991	Nov	CAHN
>A>	@		100MG	A072878	001	Jun 28, 1991	Nov	CAHN
>A>	@		150MG	A072879	001	Jun 28, 1991	Nov	CAHN

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 250MG
 @ 500MG

A065016 001 Apr 08, 1999 Feb DISC
 A065016 002 Apr 08, 1999 Feb DISC

TABLET;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 500MG
 @ 875MG

A065059 001 Nov 24, 2000 Feb DISC
 A065059 002 Nov 24, 2000 Feb DISC

TABLET, CHEWABLE;ORAL							
AMOXICILLIN							
	@ SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Feb	DISC
	@	250MG	A065021	002	Dec 23, 1999	Feb	DISC
TABLET, EXTENDED RELEASE;ORAL							
MOXATAG							
+	VERNALIS R AND D LTD	775MG	N050813	001	Jan 23, 2008	Jan	CAHN
<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE</u>							
CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL							
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN							
AB	CITRON PHARMA LLC	500MG,N/A,N/A,N/A,500MG,N/A,N/A,N/A,30MG	A206006	001	Oct 07, 2016	Sep	NEWA
<u>AMOXICILLIN; CLAVULANATE POTASSIUM</u>							
FOR SUSPENSION;ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb	CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb	CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb	CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb	DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb	DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb	DISC
TABLET;ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
AB	HIKMA PHARMS	875MG;EQ 125MG BASE	A203824	001	Aug 23, 2016	Aug	NEWA
	@ SUN PHARM INDS LTD	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Feb	DISC
TABLET, CHEWABLE;ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
	@ SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	DISC
	@	400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	DISC
	@ SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb	DISC
	@	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb	DISC
AUGMENTIN '125'							
	@ DR REDDYS LABS INC	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Jul	DISC
		125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Mar	CTEC
AUGMENTIN '250'							
	@ DR REDDYS LABS INC	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Jul	DISC
+		250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Mar	CRLD
<u>AMPHETAMINE</u>							
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL							
ADZENYS XR-ODT							
	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan	NEWA
		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan	NEWA
		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan	NEWA
		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan	NEWA
		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan	NEWA
+		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	May	CRLD
		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan	NEWA
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb	NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb	NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb	CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb	CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb	CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb	CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb	CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb	CTNA
TABLET;ORAL							
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan	NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan	NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG; 5MG; 5MG; 5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

@	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
@		100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug CAHN
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Aug CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Aug CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

@	UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Oct CAHN
@		EQ 1MG BASE	A076683	002	Apr 18, 2005	Oct CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

>D>	AB	ROXANE	1MG	A078485	001	Jun 28, 2010	Nov CAHN
		@ SANDOZ	1MG	A079007	001	Jun 28, 2010	Aug DISC
>A>	AB	WEST-WARD PHARMS INT	1MG	A078485	001	Jun 28, 2010	Nov CAHN

APRACLOINIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

IOPIDINE

>D>	AT	+ ALCON	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Nov CAHN
>D>			EQ 1% BASE	N019779	001	Dec 31, 1987	Nov CAHN
>A>	AT	+ NOVARTIS PHARMS CORP	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Nov CAHN
>A>			EQ 1% BASE	N019779	001	Dec 31, 1987	Nov CAHN

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	HOSPIRA INC	250MG/2.5ML (100MG/ML)	A204120	001	Sep 21, 2016	Sep NEWA
----	-------------	------------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

INJECTABLE; INTRAMUSCULAR

ABILIFY

@	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun DISC
---	--------	-------------------------	---------	-----	--------------	----------

SOLUTION; ORAL

ARIPIPRAZOLE

AA	+ AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
----	-----------------	--------	---------	-----	--------------	----------

TABLET; ORAL

ARIPIPRAZOLE

>A>	AB	ACCORD HLTHCARE	2MG	A206251	001	Dec 07, 2016	Nov NEWA
>A>	AB		5MG	A206251	002	Dec 07, 2016	Nov NEWA
>A>	AB		10MG	A206251	003	Dec 07, 2016	Nov NEWA
>A>	AB		15MG	A206251	004	Dec 07, 2016	Nov NEWA
>A>	AB		20MG	A206251	005	Dec 07, 2016	Nov NEWA
>A>	AB		30MG	A206251	006	Dec 07, 2016	Nov NEWA
	AB	AJANTA PHARMA LTD	2MG	A206174	001	Sep 12, 2016	Aug NEWA
	AB		5MG	A206174	002	Sep 12, 2016	Aug NEWA
	AB		10MG	A206174	003	Sep 12, 2016	Aug NEWA
	AB		15MG	A206174	004	Sep 12, 2016	Aug NEWA
	AB		20MG	A206174	005	Sep 12, 2016	Aug NEWA
	AB		30MG	A206174	006	Sep 12, 2016	Aug NEWA
	AB	AMNEAL PHARMS	2MG	A204838	001	Jun 17, 2016	Jun NEWA
	AB		5MG	A204838	002	Jun 17, 2016	Jun NEWA
	AB		10MG	A204838	003	Jun 17, 2016	Jun NEWA
	AB		15MG	A204838	004	Jun 17, 2016	Jun NEWA
	AB		20MG	A204838	005	Jun 17, 2016	Jun NEWA

TABLET;ORAL
ARIPIPIRAZOLE

AB		30MG	A204838	006	Jun 17, 2016	Jun NEWA
AB	MACLEODS PHARMS LTD	2MG	A204111	001	Oct 07, 2016	Sep NEWA
AB		5MG	A204111	002	Oct 07, 2016	Sep NEWA
AB		10MG	A204111	003	Oct 07, 2016	Sep NEWA
AB		15MG	A204111	004	Oct 07, 2016	Sep NEWA
AB		20MG	A204111	005	Oct 07, 2016	Sep NEWA
AB		30MG	A204111	006	Oct 07, 2016	Sep NEWA
AB	SCIEGEN PHARMS INC	2MG	A206383	001	Sep 29, 2016	Sep NEWA
AB		5MG	A206383	002	Sep 29, 2016	Sep NEWA
AB		10MG	A206383	003	Sep 29, 2016	Sep NEWA
AB		15MG	A206383	004	Sep 29, 2016	Sep NEWA
AB		20MG	A206383	005	Sep 29, 2016	Sep NEWA
AB		30MG	A206383	006	Sep 29, 2016	Sep NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

@ OTSUKA

10MG

N021729 002 Jun 07, 2006 May DISC

@

15MG

N021729 003 Jun 07, 2006 May DISC

ARIPIPIRAZOLE

+ ALEMBIC PHARMS LTD

10MG

A202102 001 Apr 28, 2015 May CRLD

15MG

A202102 002 Apr 28, 2015 May CTEC

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

>A>	AB	LUPIN LTD	50MG	A200751	001	Nov 28, 2016	Nov NEWA
>A>	AB		150MG	A200751	003	Nov 28, 2016	Nov NEWA
>A>	AB		200MG	A200751	004	Nov 28, 2016	Nov NEWA
>A>	AB		250MG	A200751	005	Nov 28, 2016	Nov NEWA
	AB	MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Apr CMFD
	AB		150MG	A200043	002	Jun 01, 2012	Apr CMFD
	AB		250MG	A200043	003	Jun 01, 2012	Apr CMFD
>A>	AB	NATCO PHARMA LTD	50MG	A202768	001	Nov 28, 2016	Nov NEWA
>A>	AB		150MG	A202768	002	Nov 28, 2016	Nov NEWA
>A>	AB		250MG	A202768	003	Nov 28, 2016	Nov NEWA
		NUVIGIL					
	AB	CEPHALON	50MG	N021875	001	Jun 15, 2007	Apr CTEC
	AB		150MG	N021875	003	Jun 15, 2007	Apr CTEC
>D>			200MG	N021875	005	Mar 26, 2009	Nov CTEC
>A>	AB		200MG	N021875	005	Mar 26, 2009	Nov CTEC
	AB	+	250MG	N021875	004	Jun 15, 2007	Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL

N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

FOREST LABS LLC

EQ 2.5 BASE

N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC

325MG;50MG;40MG

A078149 001 Jun 13, 2007 Jan CAHN

FIORINAL

AA + ALLERGAN SALES LLC

325MG;50MG;40MG

N017534 005 Apr 16, 1986 Apr CAHN

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA

PHARMACEUTICS INTL

325MG;50MG;40MG

A204195 001 Sep 22, 2016 Sep NEWA

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE

AB	MAYNE PHARMA INC	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Aug CAHN
	FIORINAL W/CODEINE					
AB	+ ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

AB	+ HERITAGE PHARMS INC	325MG;200MG	A089594	001	Mar 31, 1989	Jun CRLD
AB	INGENUS PHARMS NJ	325MG;200MG	A040832	001	Jan 07, 2010	Jan CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar CMFD
	@	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan CAHN
AB	+ SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Mar CTEC
	+	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan CRLD
	SOMA COMPOUND W/ CODEINE					
	@ MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB	AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	Oct CMFD
	@	25MG;200MG	A206392	001	Mar 08, 2016	Apr DISC
AB		25MG;200MG	A206392	001	Mar 08, 2016	Feb NEWA

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

	ARALEZ PHARMS	81MG;40MG	N205103	001	Sep 14, 2016	Sep NEWA
	+	325MG;40MG	N205103	002	Sep 14, 2016	Sep NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA	MAYNE PHARMA INC	325MG;4.8355MG	A091670	001	Mar 16, 2011	Aug CAHN
----	------------------	----------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

	@ SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998	Mar CAHN
	@	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982	Mar CAHN

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jan CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jan CAHN
	@ NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009	Aug DISC
	@	50MG	A078254	002	Sep 25, 2009	Aug DISC
	@	100MG	A078254	003	Sep 25, 2009	Aug DISC
	TENORMIN					
AB	ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan CAHN
AB		50MG	N018240	001		Jan CAHN
AB	+	100MG	N018240	002		Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan CAHN
AB		100MG;25MG	A072302	001	May 31, 1990	Jan CAHN
AB	SUN PHARM INDS	100MG;25MG	A073582	001	Apr 29, 1993	Mar CAHN
	TENORETIC 100					
AB	+ ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan CAHN

TABLET;ORAL

TENORETIC 50

AB	ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan CAHN
----	---------------	-----------	---------	-----	--------------	----------

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May NEWA
AB		EQ 20MG BASE	A205519	002	May 19, 2016	May NEWA
AB		EQ 40MG BASE	A205519	003	May 19, 2016	May NEWA
AB		EQ 80MG BASE	A205519	004	May 19, 2016	May NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP	NANJING KING-FRIEND	10MG/ML	A091489	001	Feb 17, 2012	Sep CAHN
AP	+ WEST-WARD PHARMS INT	10MG/ML	A074901	001	Jul 18, 1997	Oct CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	NANJING KING-FRIEND	10MG/ML	A091488	001	Feb 17, 2012	Sep CAHN
AP	+ WEST-WARD PHARMS INT	10MG/ML	A074900	001	Jul 18, 1997	Sep CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D> AA	+ ROXANE	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Nov CAHN
>A> AA	+ WEST-WARD PHARMS INT	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Nov CAHN

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ SUN PHARM INDS

0.025MG;2.5MG

A085506 001

Mar CAHN

LONOX

@ SANDOZ

0.025MG;2.5MG

A085311 002

Aug DISC

AURANOFIN

CAPSULE;ORAL

RIDAURA

	+ SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Jan CAHN
--	----------------------	-----	---------	-----	--------------	----------

AVANAFIL

TABLET;ORAL

STENDRA

METUCHEN PHARMS

50MG

N202276 001 Apr 27, 2012 Oct CAHN

100MG

N202276 002 Apr 27, 2012 Oct CAHN

+

200MG

N202276 003 Apr 27, 2012 Oct CAHN

AXITINIB

TABLET;ORAL

INLYTA

PF PRISM CV

1MG

N202324 001 Jan 27, 2012 Apr CAHN

+

5MG

N202324 002 Jan 27, 2012 Apr CAHN

AZACITIDINE

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Apr NEWA
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Sep NEWA

POWDER;IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

ACTAVIS LLC

100MG/VIAL

N208216 001 Apr 29, 2016 Apr NEWA

AZATHIOPRINE

TABLET;ORAL

IMURAN

@ SEBELA IRELAND LTD

25MG

N016324 002

Jan CAHN

AB

+

50MG

N016324 001

Jan CAHN

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

AZATHIOPRINE SODIUM

	+ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995	Sep CAHN
	IMURAN					

@ SEBELA IRELAND LTD

EQ 100MG BASE/VIAL

N017391 001

Jan CAHN

AZELASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
AZELASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A203660	001	Nov 08, 2016	Oct NEWA
	SPRAY, METERED;NASAL					
	AZELASTINE HYDROCHLORIDE					
>D> AB	ROXANE	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014	Nov CAHN

AZILSARTAN KAMEDOXOMILTABLET;ORAL
EDARBIARBOR PHARMS LLC EQ 40MG MEDOXOMIL
+ EQ 80MG MEDOXOMILN200796 001 Feb 25, 2011 Jan CAHN
N200796 002 Feb 25, 2011 Jan CAHNAZILSARTAN KAMEDOXOMIL; CHLORTHALIDONETABLET;ORAL
EDARBYCLORARBOR PHARMS LLC EQ 40MG MEDOXOMIL;12.5MG
+ EQ 40MG MEDOXOMIL;25MGN202331 001 Dec 20, 2011 Jan CAHN
N202331 002 Dec 20, 2011 Jan CAHNAZITHROMYCINFOR SUSPENSION;ORAL
AZITHROMYCINLUPIN LTD EQ 100MG BASE/5ML
BX EQ 200MG BASE/5MLA065488 001 May 15, 2015 Apr CTEC
A065488 002 May 15, 2015 Apr CTECAZTREONAMINJECTABLE;INJECTION
AZTREONAM@ EUROHLTH INTL SARL 1GM/VIAL
@ 2GM/VIAL
@ WEST-WARD PHARMS INT 1GM/VIAL
@ 2GM/VIALA065286 001 Mar 23, 2011 Mar DISC
A065286 002 Mar 23, 2011 Mar DISC
A065286 001 Mar 23, 2011 Sep CAHN
A065286 002 Mar 23, 2011 Sep CAHNBACLOFENINJECTABLE;INTRATHECAL
BACLOFENSINTETICA SA 0.05MG/ML
AP 0.5MG/ML
AP 2MG/MLA091193 001 May 03, 2016 Apr NEWA
A091193 002 May 03, 2016 Apr NEWA
A091193 003 May 03, 2016 Apr NEWA

LIORESAL

+ SAOL THERAPS RES LTD 0.05MG/ML
AP 0.5MG/ML
AP 2MG/MLN020075 003 Nov 07, 1996 May CAHN
N020075 001 Jun 17, 1992 May CAHN
N020075 002 Jun 17, 1992 May CAHNTABLET;ORAL
BACLOFEN

>A> AB	IMPAX LABS	10MG
AB	LANNETT	10MG
AB	NORTHSTAR HLTHCARE	10MG
>D> AB	WATSON LABS	10MG
>A> @		10MG
>D> AB		20MG
>A> @		20MG

A077971	001	Oct 26, 2007	Nov CMS1
A077241	002	Jul 06, 2007	Oct CMS1
A078401	002	Sep 18, 2009	Jan CMS1
A072824	001	Sep 18, 1991	Nov DISC
A072824	001	Sep 18, 1991	Nov DISC
A072825	001	Sep 18, 1991	Nov DISC
A072825	001	Sep 18, 1991	Nov DISC

BALSALAZIDE DISODIUMCAPSULE;ORAL
BALSALAZIDE DISODIUMROXANE 750MG
>A> AB WEST-WARD PHARMS INT 750MGA077806 001 Dec 28, 2007 Nov CAHN
A077806 001 Dec 28, 2007 Nov CAHNBARIUM SULFATEFOR SUSPENSION;ORAL
E-Z-HD

+ BRACCO 334GM/BOTTLE

N208036 001 Jan 11, 2016 Jan NEWA

PASTE;ORAL
VARIBAR

+ BRACCO 40% (92GM/230ML)

N208844 001 Oct 14, 2016 Oct NEWA

SUSPENSION; ORAL

READI-CAT 2

+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan NEWA
	READI-CAT 2 SMOOTHIES					
	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan DISC
@		10MG	A076267	002	Feb 11, 2004	Jan DISC
@		20MG	A076267	003	Feb 11, 2004	Jan DISC
@		40MG	A076267	004	Feb 11, 2004	Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	Jan DISC
@		10MG; 12.5MG	A076342	002	Feb 11, 2004	Jan DISC
@		20MG; 12.5MG	A076342	003	Feb 11, 2004	Jan DISC
@		20MG; 25MG	A076342	004	Feb 11, 2004	Jan DISC
@	IVAX SUB TEVA PHARMS	5MG; 6.25MG	A076348	001	Feb 11, 2004	Mar DISC
@		10MG; 12.5MG	A076348	002	Feb 11, 2004	Mar DISC
@		20MG; 12.5MG	A076348	003	Feb 11, 2004	Mar DISC
@		20MG; 25MG	A076348	004	Feb 11, 2004	Mar DISC
@	SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Mar DISC
@		10MG; 12.5MG	A077483	002	Sep 08, 2005	Mar DISC
@		20MG; 12.5MG	A077483	003	Sep 08, 2005	Mar DISC
@		20MG; 25MG	A077483	004	Sep 08, 2005	Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	May NEWA
AP		100MG/VIAL	A205574	002	May 19, 2016	May NEWA
AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar NEWA
AP	HOSPIRA INC	25MG/VIAL	A204086	001	May 20, 2016	May NEWA
AP		100MG/VIAL	A204086	002	May 20, 2016	May NEWA
AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar NEWA

TREANDA

AP	+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar CFTG
AP	+		100MG/VIAL	N022249	001	Mar 20, 2008	Mar CFTG

SOLUTION; IV (INFUSION)

BENDEKA

+	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015	Sep CRLD
---	--------------	---------------------	---------	-----	--------------	----------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	TOLMAR	5%; 1.2%	A203688	001	Aug 25, 2016	Aug NEWA
----	--------	----------	---------	-----	--------------	----------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

AKTIPAK

+	CUTANEA	5%; 3%	N050769	001	Nov 27, 2000	Sep CTNA
+		5%; 3%	N050769	001	Nov 27, 2000	Feb CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@	IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar DISC
---	------------	------	---------	-----	--------------	----------

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Jul CAHN
AA		1MG	A204713	002	Apr 14, 2015	Jul CAHN
AA		2MG	A204713	003	Apr 14, 2015	Jul CAHN
	@ FRONTIDA BIOPHARM	1MG	A081264	001	Jan 23, 1992	Sep CAHN
	@	2MG	A081265	001	Jan 23, 1992	Jul CAHN
AA	VINTAGE	0.5MG	A040715	001	Aug 27, 2007	Oct CMS1
AA		1MG	A040715	002	Aug 27, 2007	Oct CMS1

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb NEWA
---	--------------------	---------------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS	EQ 0.05% BASE; 1%	A202894	001	Oct 30, 2015	Mar CAHN
----	-----------------	-------------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan CAHN
----	---------------------	--------------	---------	-----	--------------	----------

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC S

>D>	+	ALCON	EQ 0.25% BASE	N019845	001	Dec 29, 1989	Nov CAHN
>A>	+	NOVARTIS PHARMS CORP	EQ 0.25% BASE	N019845	001	Dec 29, 1989	Nov CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

	@ IMPAX LABS	5MG	A040739	001	Nov 01, 2006	Mar DISC
	@	10MG	A040741	001	Nov 01, 2006	Mar DISC
	@	25MG	A040740	001	Nov 01, 2006	Mar DISC
	@	50MG	A040721	004	Nov 01, 2006	Mar DISC
	@ SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009	Oct DISC
	@	10MG	A040897	002	Apr 22, 2009	Oct DISC
	@	25MG	A040897	003	Apr 22, 2009	Oct DISC
	@	50MG	A040897	004	Apr 22, 2009	Oct DISC
	DUVOID					
AA	BI-COASTAL PHARMA	10MG	A086262	001		Jul CAHN
AA		25MG	A086263	001		Jul CAHN
AA		50MG	A085882	003		Jul CAHN

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016	Apr NEWA
----	------------	-------	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

@	SEBELA IRELAND LTD	262.4MG, N/A, N/A; N/A, 250MG, N/A, N/A, N/A, 500MG	N050719	001	Aug 15, 1996	Jan CAHN
---	--------------------	---	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

	@ FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jul CAHN
	@	10MG	A075474	002	Oct 25, 2002	Jul CAHN
AB	+	MYLAN	A075831	002	Dec 14, 2005	Aug CRLD
	@ SUN PHARM INDS	5MG	A075474	001	Oct 25, 2002	Mar CAHN
	@	10MG	A075474	002	Oct 25, 2002	Mar CAHN
	ZEBETA					
	@ TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Aug DISC
	@	10MG	N019982	001	Jul 31, 1992	Aug DISC

BIVALIRUDIN

INJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP	FRESENIUS KABI USA	250MG/VIAL	A090189	001	Oct 28, 2016	Oct NEWA
----	--------------------	------------	---------	-----	--------------	----------

BLEOMYCIN SULFATE

INJECTABLE;INJECTION
BLEOMYCIN SULFATE

AP	WEST-WARD PHARMS INT	EQ 15 UNITS BASE/VIAL	A065042	002	Oct 17, 2001	Sep CAHN
AP		EQ 30 UNITS BASE/VIAL	A065042	001	Oct 17, 2001	Sep CAHN

BOCEPREVIR

CAPSULE;ORAL
VICTRELIS

	@ MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Jun DISC
--	---------------------	-------	---------	-----	--------------	----------

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986	Sep DISC
	@	200MG/100ML	N019121	002	Apr 29, 1986	Sep DISC
	@	400MG/100ML	N019121	003	Apr 29, 1986	Sep DISC

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA

>D>	+	ALCON RES LTD	0.2%;1%	N204251	001	Apr 19, 2013	Nov CAHN
>A>	+	NOVARTIS PHARMS CORP	0.2%;1%	N204251	001	Apr 19, 2013	Nov CAHN

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC
AZOPT

>D>	+	ALCON PHARMS LTD	1%	N020816	001	Apr 01, 1998	Nov CAHN
>A>	+	NOVARTIS PHARMS CORP	1%	N020816	001	Apr 01, 1998	Nov CAHN

BRIVARACETAM

SOLUTION;INTRAVENOUS
BRIVIACT

+	UBC INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb NEWA
+	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	May CMS1

SOLUTION;ORAL
BRIVIACT

+	UCB INC	10MG/ML	N205838	001	May 12, 2016	May CMS1
+		10MG/ML	N205838	001	Feb 18, 2016	Feb NEWA

TABLET;ORAL
BRIVIACT

	UCB INC	10MG	N205836	001	May 12, 2016	May CMS1
		10MG	N205836	001	Feb 18, 2016	Feb NEWA
		25MG	N205836	002	May 12, 2016	May CMS1
		25MG	N205836	002	Feb 18, 2016	Feb NEWA
		50MG	N205836	003	May 12, 2016	May CMS1
		50MG	N205836	003	Feb 18, 2016	Feb NEWA
		75MG	N205836	004	May 12, 2016	May CMS1
		75MG	N205836	004	Feb 18, 2016	Feb NEWA
+		100MG	N205836	005	May 12, 2016	May CMS1
+		100MG	N205836	005	Feb 18, 2016	Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMSITE

+	INSITE VISION INC	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Apr NEWA
+	SUN PHARMA GLOBAL	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jul CAHN

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL
BROMOCRIPTINE MESYLATE

AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan CRLD
		PARLODEL					

>D>	@	US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Nov CMFD
>A>	AB		EQ 5MG BASE	N017962	002	Mar 01, 1982	Nov CMFD
	@		EQ 5MG BASE	N017962	002	Mar 01, 1982	Jan DISC

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN
PARLODEL							
AB		US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr CMFD
	@		EQ 2.5MG BASE	N017962	001		Jan DISC

BROMPHENIRAMINE MALEATE

TABLET;ORAL

BROMPHENIRAMINE MALEATE

@	UPSHER-SMITH LABS	4MG	A083215	001			Oct CAHN
---	-------------------	-----	---------	-----	--	--	----------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		ACELLA PHARMS LLC	2MG/5ML;10MG/5ML;30MG/5ML	A203375	001	Sep 20, 2016	Sep NEWA
----	--	-------------------	---------------------------	---------	-----	--------------	----------

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB		ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar NEWA
>A> AB		ALVOGEN MALTA	3MG	A206724	001	Nov 23, 2016	Nov NEWA
AB		MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Aug CAHN
ENTOCORT EC							
AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan CAHN
AB	+	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May CAHN

SUSPENSION;INHALATION

BUDESONIDE

AN		APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun CMFD
AN			0.5MG/2ML	A078202	002	Mar 30, 2009	Jun CMFD
AN		IMPAX LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Aug CAHN
AN			0.5MG/2ML	A078404	002	Jul 31, 2012	Aug CAHN
AN		TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb NEWA

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	+	AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun CAHN
AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr CAHN

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

EXPAREL

+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Sep CMFD
---	-------------------	------------------------	---------	-----	--------------	----------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May NEWA
AP			0.5%	A207183	002	May 13, 2016	May NEWA

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		CLARIS	0.75%	A207266	001	Jul 25, 2016	Jul NEWA
----	--	--------	-------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT;IMPLANTATION

PROBUPHINE

+	BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun CAHN
+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	May NEWA

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	EQ 0.3MG BASE/ML	A076931	001	Mar 02, 2005	Oct CAHN
----	--	----------------------	------------------	---------	-----	--------------	----------

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>D> AB		ROXANE	EQ 2MG BASE	A078633	001	Oct 08, 2009	Nov CAHN
>D> AB	+		EQ 8MG BASE	A078633	002	Oct 08, 2009	Nov CAHN
AB		SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan NEWA
AB			EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan NEWA
>A> AB		WEST-WARD PHARMS INT	EQ 2MG BASE	A078633	001	Oct 08, 2009	Nov CAHN
>A> AB	+		EQ 8MG BASE	A078633	002	Oct 08, 2009	Nov CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	KREMERS URBAN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205022	001	Sep 19, 2016	Sep NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205022	002	Sep 19, 2016	Sep NEWA
>D> AB	ROXANE	EQ 2MG BASE;EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Nov CAHN
>D> AB		EQ 8MG BASE;EQ 2MG BASE	A203326	002	Jun 27, 2014	Nov CAHN
AB	SUN PHARM INDS LTD	EQ 8MG BASE;EQ 2MG BASE	A201633	002	Aug 05, 2016	Jul NEWA
>A> AB	WEST-WARD PHARMS INT	EQ 2MG BASE;EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Nov CAHN
>A> AB		EQ 8MG BASE;EQ 2MG BASE	A203326	002	Jun 27, 2014	Nov CAHN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
AB	SUN PHARM INDS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A201633	001	Aug 05, 2016	Jul NEWA
ZUBSOLV						
	OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006	Oct 04, 2016	Oct NEWA
		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul CAHN
		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul CAHN
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul CAHN
		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul CAHN
		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	+	APOTEX INC	100MG	A076143	002	Jan 17, 2006	Sep CRLD
AB		HERITAGE PHARMA	75MG	A206975	001	Aug 19, 2016	Aug NEWA
AB			100MG	A206975	002	Aug 19, 2016	Aug NEWA
WELLBUTRIN							
	@	GLAXOSMITHKLINE	75MG	N018644	002	Dec 30, 1985	Sep DISC
	@		100MG	N018644	003	Dec 30, 1985	Sep DISC

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1		INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
AB3			150MG	A206556	001	Aug 26, 2016	Aug NEWA
AB1			150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1			200MG	A206674	003	Feb 09, 2016	Jan NEWA
AB3			300MG	A206556	002	Aug 26, 2016	Aug NEWA
AB1		SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1			150MG	A205794	002	Mar 01, 2016	Feb NEWA
AB2			150MG	A206122	001	Aug 17, 2016	Aug NEWA
AB1			200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014	Apr CAHN
---	----------	----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
AB			10MG	A204582	002	Sep 18, 2015	Jun CAHN
AB			15MG	A204582	003	Sep 18, 2015	Jun CAHN
AB			30MG	A204582	004	Sep 18, 2015	Jun CAHN
AB		IMPAX LABS INC	5MG	A074253	001	Mar 28, 2001	Aug CAHN
AB			10MG	A074253	002	Mar 28, 2001	Aug CAHN
AB			15MG	A074253	003	Mar 13, 2002	Aug CAHN
>A> AB		MYLAN	5MG	A076008	003	Mar 01, 2002	Nov CMS1
AB			7.5MG	A076008	002	Jul 08, 2013	Oct NEWA
>A> AB			10MG	A076008	004	Mar 01, 2002	Nov CMS1
>A> AB			15MG	A076008	005	Mar 28, 2001	Nov CMS1

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP		LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	--	---------------------	--------	---------	-----	--------------	----------

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

@ PERRIGO PHARMA INTL 2%

N019881 001 Feb 07, 1997 Jun CAHN

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

@ CLARIS 2MG/ML

A075697 001 Oct 23, 2001 Jan CAHN

BUTORPHANOL TARTRATE PRESERVATIVE FREE

@ CLARIS 1MG/ML

A075695 001 Oct 23, 2001 Mar CAHN

@ 2MG/ML

A075695 002 Oct 23, 2001 Mar CAHN

SPRAY, METERED;NASAL

BUTORPHANOL TARTRATE

AB APOTEX INC 1MG/SPRAY

A075499 001 Dec 04, 2002 Sep CAHN

>D> AB ROXANE 1MG/SPRAY

A075824 001 Mar 12, 2002 Nov CAHN

>A> AB WEST-WARD PHARMS INT 1MG/SPRAY

A075824 001 Mar 12, 2002 Nov CAHN

CABERGOLINE

TABLET;ORAL

CABERGOLINE

@ IMPAX LABS INC 0.5MG

A077843 001 Jul 03, 2007 Mar DISC

CABOZANTINIB S-MALATE

TABLET;ORAL

CABOMETYX

EXELIXIS INC EQ 20MG BASE

N208692 001 Apr 25, 2016 Apr NEWA

EQ 40MG BASE

N208692 002 Apr 25, 2016 Apr NEWA

+ EQ 60MG BASE

N208692 003 Apr 25, 2016 Apr NEWA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFCIT

AP + WEST-WARD PHARMS INT EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

N020793 001 Sep 21, 1999 Sep CAHN

SOLUTION;ORAL

CAFCIT

AA + WEST-WARD PHARMS INT EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

N020793 002 Apr 12, 2000 Sep CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

+ HORIZON PHARMA 100MG;2MG

A086557 001 Oct 04, 1983 Jan CAHN

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL

RAYALDEE

+ OPKO IRELAND GLOBAL 0.03MG

N208010 001 Jun 17, 2016 Jun NEWA

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

AB GLENMARK PHARMS 0.005%

A205772 001 Jun 09, 2015 Mar CAHN

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL

FORTICAL

@ UPSHER SMITH 200 IU/SPRAY

N021406 001 Aug 12, 2005 Sep DISC

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB BIONPHARMA INC 0.25MCG

A091174 001 May 24, 2013 Jan CAHN

AB 0.5MCG

A091174 002 May 24, 2013 Jan CAHN

>D> AB ROXANE 0.25MCG

A076917 001 Mar 27, 2006 Nov CAHN

>A> AB WEST-WARD PHARMS INT 0.25MCG

A076917 001 Mar 27, 2006 Nov CAHN

INJECTABLE;INJECTION

CALCITRIOL

AKORN 0.001MG/ML

A078066 001 Jan 29, 2008 Feb CTEC

@ ROCKWELL MEDCL 0.001MG/ML

A076206 001 Sep 17, 2003 Feb DISC

SOLUTION;ORAL
CALCITRIOL

>D> AA	ROXANE	1MCG/ML	A 076242	001	Jul 18, 2003	Nov CAHN
>A> AA	WEST-WARD PHARMS INT	1MCG/ML	A 076242	001	Jul 18, 2003	Nov CAHN

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

>D> AB	AMNEAL PHARMS	EQ 169MG CALCIUM	A 201658	001	Oct 06, 2014	Nov CPOT
>A> AB		667MG	A 201658	001	Oct 06, 2014	Nov CPOT
>D> AB	ECI PHARMS LLC	EQ 169MG CALCIUM	A 203298	001	Jul 26, 2016	Nov CPOT
AB		EQ 169MG CALCIUM	A 203298	001	Jul 26, 2016	Oct CAHN
>A> AB		667MG	A 203298	001	Jul 26, 2016	Nov CPOT
>D> AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A 202315	001	Jun 29, 2015	Nov CPOT
>A> AB		667MG	A 202315	001	Jun 29, 2015	Nov CPOT
>D> AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A 203135	001	Feb 07, 2013	Nov CPOT
>A> AB		667MG	A 203135	001	Feb 07, 2013	Nov CPOT
AB	LOTUS PHARM CO LTD	EQ 169MG CALCIUM	A 203298	001	Jul 26, 2016	Jul NEWA
>D> AB	LUPIN LTD	EQ 169MG CALCIUM	A 202127	001	Jul 09, 2015	Nov CPOT
>A> AB		667MG	A 202127	001	Jul 09, 2015	Nov CPOT
>D> AB	NOSTRUM LABS INC	EQ 169MG CALCIUM	A 203179	001	Oct 26, 2015	Nov CPOT
>A> AB		667MG	A 203179	001	Oct 26, 2015	Nov CPOT
>D> AB	PADDOCK LLC	EQ 169MG CALCIUM	A 091312	001	Jun 01, 2012	Nov CPOT
>A> AB		667MG	A 091312	001	Jun 01, 2012	Nov CPOT
>D> AB	ROXANE	EQ 169MG CALCIUM	A 077728	001	Feb 26, 2008	Nov CPOT
>A> AB		667MG	A 077728	001	Feb 26, 2008	Nov CPOT
>A> AB	WEST-WARD PHARMS INT	667MG	A 077728	001	Feb 26, 2008	Nov CAHN

PHOSLO

>D>	@ FRESENIUS MEDCL	EQ 84.5MG CALCIUM	N 021160	001	Apr 02, 2001	Nov CPOT
>D>	@	EQ 169MG CALCIUM	N 021160	002	Apr 02, 2001	Nov CPOT
>A>	@	333.5MG	N 021160	001	Apr 02, 2001	Nov CPOT
>A>	@	667MG	N 021160	002	Apr 02, 2001	Nov CPOT

PHOSLO GELCAPS

>D> AB	+ FRESENIUS MEDCL	EQ 169MG CALCIUM	N 021160	003	Apr 02, 2001	Nov CPOT
>A> AB	+	667MG	N 021160	003	Apr 02, 2001	Nov CPOT

SOLUTION;ORAL

PHOSLYRA

>D>	+ FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N 022581	001	Apr 18, 2011	Nov CPOT
>A>	+	667MG/5ML	N 022581	001	Apr 18, 2011	Nov CPOT

TABLET;ORAL

CALCIUM ACETATE

>D> AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A 202885	001	Jan 22, 2015	Nov CPOT
>A> AB		667MG	A 202885	001	Jan 22, 2015	Nov CPOT
>D> AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A 202420	001	Feb 05, 2013	Nov CPOT
>A> AB		667MG	A 202420	001	Feb 05, 2013	Nov CPOT
>D> AB	PADDOCK LLC	EQ 169MG CALCIUM	A 091561	001	Apr 13, 2011	Nov CPOT
>A> AB		667MG	A 091561	001	Apr 13, 2011	Nov CPOT
>D>	@ ROXANE	EQ 169MG CALCIUM	A 077693	001	Jan 30, 2008	Nov CPOT
>A>	@	667MG	A 077693	001	Jan 30, 2008	Nov CPOT
>A>	@ WEST-WARD PHARMS INT	667MG	A 077693	001	Jan 30, 2008	Nov CAHN
ELIPHOS						
>D> AB	+ CYPRESS PHARM	EQ 169MG CALCIUM	A 078502	001	Nov 25, 2008	Nov CPOT
>A> AB	+	667MG	A 078502	001	Nov 25, 2008	Nov CPOT
PHOSLO						
>D>	@ FRESENIUS MEDCL	EQ 169MG CALCIUM	N 019976	001	Dec 10, 1990	Nov CPOT
>A>	@	667MG	N 019976	001	Dec 10, 1990	Nov CPOT

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

@ B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML	N 018807	001	Aug 26, 1983	Oct DISC
	; 9.2GM/100ML;9.6GM/100ML				

@	510MG/100ML;30GM/100ML;200MG/100ML	N 018807	003	Aug 26, 1983	Oct DISC
	; 9.4GM/100ML;11GM/100ML				

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

@ B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML	N 018807	002	Aug 26, 1983	Oct DISC
	; 9.2GM/100ML;9.6GM/100ML				

@	510MG/100ML;50GM/100ML;200MG/100ML	N 018807	004	Aug 26, 1983	Oct DISC
	; 9.4GM/100ML;11GM/100ML				

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002		Feb	DISC
-------------------	---	---------	-----	--	-----	------

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003		Feb	DISC
-------------------	---	---------	-----	--	-----	------

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988	Feb	DISC
-------------------	---	---------	-----	--------------	-----	------

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001		Feb	DISC
-------------------	--	---------	-----	--	-----	------

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982	Feb	DISC
-------------------	---	---------	-----	--------------	-----	------

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982	Feb	DISC
-------------------	---	---------	-----	--------------	-----	------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988	Feb	DISC
-------------------	---	---------	-----	--------------	-----	------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESenius MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982	Feb	DISC
-------------------	--	---------	-----	--------------	-----	------

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ B BRAUN	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 30MG/100ML; 450MG/100ML	N018460	007	Jan 29, 1986	Oct	DISC
-----------	---	---------	-----	--------------	-----	------

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ B BRAUN	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 30MG/100ML; 450MG/100ML	N018460	005	Nov 02, 1983	Oct	DISC
-----------	---	---------	-----	--------------	-----	------

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ B BRAUN	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	009	Jan 29, 1986	Oct	DISC
-----------	---	---------	-----	--------------	-----	------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	010	Nov 18, 1985	Feb	CTEC
-----------------	---	---------	-----	--------------	-----	------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985	Feb	CTEC
-----------------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP +	BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N016682	001		Aug	CRLD
------	-----------------	--	---------	-----	--	-----	------

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

INVOKAMET XR

JANSSEN PHARMS

50MG; 500MG

N205879	001	Sep 20, 2016	Sep	NEWA
---------	-----	--------------	-----	------

50MG; 1GM

N205879	002	Sep 20, 2016	Sep	NEWA
---------	-----	--------------	-----	------

150MG; 500MG

N205879	003	Sep 20, 2016	Sep	NEWA
---------	-----	--------------	-----	------

+

150MG; 1GM

N205879	004	Sep 20, 2016	Oct	CRLD
---------	-----	--------------	-----	------

150MG; 1GM

N205879	004	Sep 20, 2016	Sep	NEWA
---------	-----	--------------	-----	------

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

MACLEODS PHARMS LTD

4MG

A203813	001	Dec 05, 2016	Nov	NEWA
---------	-----	--------------	-----	------

>A> AB

8MG

A203813	002	Dec 05, 2016	Nov	NEWA
---------	-----	--------------	-----	------

>A> AB

16MG

A203813	003	Dec 05, 2016	Nov	NEWA
---------	-----	--------------	-----	------

>A> AB

32MG

A203813	004	Dec 05, 2016	Nov	NEWA
---------	-----	--------------	-----	------

CANGRELOR

POWDER; IV (INFUSION)

KENGREAL

+ CHIESI USA INC

50MG/VIAL

N204958	001	Jun 22, 2015	Jul	CAHN
---------	-----	--------------	-----	------

CAPECITABINE

TABLET; ORAL

CAPECITABINE

>D>	AB	ROXANE	150MG	A200483	001	Jul 14, 2016	Nov CAHN
	AB		150MG	A200483	001	Jul 14, 2016	Jul NEWA
>D>	AB		500MG	A200483	002	Jul 14, 2016	Nov CAHN
	AB		500MG	A200483	002	Jul 14, 2016	Jul NEWA
>A>	AB	SHILPA MEDICARE LTD	150MG	A207456	001	Dec 12, 2016	Nov NEWA
>A>	AB		500MG	A207456	002	Dec 12, 2016	Nov NEWA
>A>	AB	WEST-WARD PHARMS INT	150MG	A200483	001	Jul 14, 2016	Nov CAHN
>A>	AB		500MG	A200483	002	Jul 14, 2016	Nov CAHN

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

		@ APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar DISC
		@	25MG	A074737	002	Oct 28, 1998	Mar DISC
		@	50MG	A074737	003	Oct 28, 1998	Mar DISC
		@	100MG	A074737	004	Oct 28, 1998	Mar DISC
AB		HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun CAHN
AB			25MG	A074505	002	Feb 13, 1996	Jun CAHN
AB			50MG	A074505	003	Feb 13, 1996	Jun CAHN
AB			100MG	A074505	004	Feb 13, 1996	Jun CAHN
AB		PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jul CMFD
AB			25MG	A074477	002	Feb 13, 1996	Jul CMFD
AB			50MG	A074477	003	Feb 13, 1996	Jul CMFD
AB			100MG	A074477	004	Feb 13, 1996	Jul CMFD
		@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan DISC
		@	25MG	A074363	002	Nov 09, 1995	Jan DISC
		@	50MG	A074363	003	Nov 09, 1995	Jan DISC
		@	100MG	A074363	004	Nov 09, 1995	Jan DISC
		@ STASON	12.5MG	A074677	004	May 30, 1997	Mar DISC
		@	25MG	A074677	002	May 30, 1997	Mar DISC
		@	50MG	A074677	001	May 30, 1997	Mar DISC
		@	100MG	A074677	003	May 30, 1997	Mar DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan CAHN
AB			200MG	A076697	002	May 20, 2011	Jan CAHN
AB			300MG	A076697	003	May 20, 2011	Jan CAHN
		SOLUTION; IV (INFUSION)					
		CARNEXIV					
	+	LUNDBECK LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Oct NEWA

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB		EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb NEWA
----	--	-------------------	------	---------	-----	--------------	----------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

		@ IDT AUSTRALIA LTD	10MG; 100MG	A073586	001	Jun 29, 1995	May CAHN
		@	25MG; 100MG	A073587	001	Jun 29, 1995	May CAHN
		@	25MG; 250MG	A073620	001	Jun 29, 1995	May CAHN
AB		MAYNE PHARMA	10MG; 100MG	A073618	001	Aug 28, 1992	Aug CAHN
AB			25MG; 100MG	A073589	001	Aug 28, 1992	Aug CAHN
AB			25MG; 250MG	A073607	001	Aug 28, 1992	Aug CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

		MIKART INC	6MG	A207484	001	May 31, 2016	May NEWA
--	--	------------	-----	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

@ WEST-WARD PHARMS INT	50MG/VIAL	A076099	001	Oct 14, 2004	Oct CAHN
@	150MG/VIAL	A076099	002	Oct 14, 2004	Oct CAHN
@	450MG/VIAL	A076099	003	Oct 14, 2004	Oct CAHN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr DISC
	@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr DISC
	@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr DISC
	@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr DISC
AP	NANJING KING-FRIEND	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Oct CAHN
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Oct CAHN
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Oct CAHN
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Oct CAHN
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb CAHN
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb CAHN
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb CAHN
AP	SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar NEWA
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar NEWA
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar NEWA
AP	WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	Oct CAHN
AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	Oct CAHN
AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	Oct CAHN
AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	Oct CAHN

CARFILZOMIB

POWDER; INTRAVENOUS
KYPROLIS

ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Jun NEWA
+	60MG/VIAL	N202714	001	Jul 20, 2012	Feb CAHN

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AB	AUROBINDO PHARMA	250MG	A040792	002	Nov 08, 2016	Oct NEWA
AA	INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan CAHN
AB	STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	May CAHN
AA		350MG	A205513	002	Nov 12, 2015	May CAHN

CARVEDILOL

TABLET; ORAL
COREG

AB	SMITHKLINE BEECHAM	3.125MG	N020297	004	May 29, 1997	May CAHN
AB		6.25MG	N020297	003	Sep 14, 1995	May CAHN
AB	+	12.5MG	N020297	002	Sep 14, 1995	May CAHN
AB		25MG	N020297	001	Sep 14, 1995	May CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
COREG CR

SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	May CAHN
	20MG	N022012	002	Oct 20, 2006	May CAHN
+	40MG	N022012	003	Oct 20, 2006	May CAHN
	80MG	N022012	004	Oct 20, 2006	May CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb DISC
@	EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb DISC
@	EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan NEWA
	@ WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807	001	Jan 12, 1988	Oct CAHN
	@	EQ 500MG BASE/VIAL	A062807	002	Jan 12, 1988	Oct CAHN
	@	EQ 1GM BASE/VIAL	A062807	003	Jan 12, 1988	Oct CAHN

INJECTABLE; INJECTION							
CEFAZOLIN SODIUM							
	@	EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988	Oct	CAHN
	@	EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988	Oct	CAHN
	@	EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988	Oct	CAHN
<u>CEFDITOREN PIVOXIL</u>							
TABLET; ORAL							
SPECTRACEF							
	@ VANSER PHARMA	200MG	N021222	001	Aug 29, 2001	Apr	DISC
	@	400MG	N021222	002	Jul 21, 2008	Apr	DISC
<u>CEFEPIME HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
CEFEPIME HYDROCHLORIDE							
AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	NEWA
<u>CEFOTAXIME SODIUM</u>							
INJECTABLE; INJECTION							
CEFOTAXIME SODIUM							
AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb	NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb	NEWA
CLAFORAN							
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun	DISC
	@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun	DISC
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
	@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN
<u>CEFOTETAN DISODIUM</u>							
INJECTABLE; INJECTION							
CEFOTAN							
	@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan	CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan	CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan	CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan	CAHN
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER							
	+ B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun	CMS2
	+	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun	CMS2
<u>CEFOXITIN SODIUM</u>							
INJECTABLE; INJECTION							
CEFOXITIN							
AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May	CAHN
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May	CAHN
AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May	CAHN
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER							
AP	+ B BRAUN	EQ 1GM BASE/VIAL	N065214	001	Mar 10, 2006	Aug	CRLD
AP	+	EQ 2GM BASE/VIAL	N065214	002	Mar 10, 2006	Aug	CRLD
<u>CEFPODOXIME PROXETIL</u>							
FOR SUSPENSION; ORAL							
CEFPODOXIME PROXETIL							
	@ SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb	DISC
	@	EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb	DISC
TABLET; ORAL							
CEFPODOXIME PROXETIL							
	@ SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb	DISC
	@	EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb	DISC

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL

CEDAX

@ PERNIX THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995 Jun DISC

FOR SUSPENSION;ORAL

CEDAX

@ PERNIX THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995 Jun DISC

@

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995 Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

@ HOSPIRA INC

EQ 1GM BASE/VIAL

A065231 001 Aug 02, 2005 Apr DISC

@

EQ 1GM BASE/VIAL

A202563 001 Aug 20, 2012 Apr DISC

@

EQ 2GM BASE/VIAL

A065231 002 Aug 02, 2005 Apr DISC

@

EQ 2GM BASE/VIAL

A202563 002 Aug 20, 2012 Apr DISC

ROCEPHIN

@ HOFFMANN LA ROCHE

EQ 500MG BASE/VIAL

A063239 002 Aug 13, 1993 Apr DISC

@

EQ 1GM BASE/VIAL

A063239 003 Aug 13, 1993 Apr DISC

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

@ BEDFORD

EQ 250MG BASE/VIAL

A065465 001 Aug 18, 2008 Jun DISC

@

EQ 500MG BASE/VIAL

A065465 002 Aug 18, 2008 Jun DISC

@

EQ 1GM BASE/VIAL

A065465 003 Aug 18, 2008 Jun DISC

@

EQ 2GM BASE/VIAL

A065465 004 Aug 18, 2008 Jun DISC

AP QILU PHARM CO LTD

EQ 250MG BASE/VIAL

A203702 001 Jun 29, 2016 Jun NEWA

AP

EQ 500MG BASE/VIAL

A203702 002 Jun 29, 2016 Jun NEWA

AP

EQ 1GM BASE/VIAL

A203702 003 Jun 29, 2016 Jun NEWA

AP

EQ 2GM BASE/VIAL

A203702 004 Jun 29, 2016 Jun NEWA

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFTIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

N050672 001 Jun 30, 1994 Feb CTEC

+

EQ 250MG BASE/5ML

N050672 002 Apr 29, 1997 Feb CTEC

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD

EQ 125MG BASE/5ML

A065323 001 Feb 05, 2008 Feb DISC

@

EQ 250MG BASE/5ML

A065323 002 Feb 05, 2008 Feb DISC

TABLET;ORAL

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD

EQ 125MG BASE

A065118 001 Apr 25, 2003 Feb DISC

@

EQ 250MG BASE

A065118 002 Apr 25, 2003 Feb DISC

@

EQ 500MG BASE

A065118 003 Apr 25, 2003 Feb DISC

CEFUROXIME SODIUM

INJECTABLE;INJECTION

ZINACEF

AP + IGI LABS INC

EQ 1.5GM BASE/VIAL

N050558 003 Oct 19, 1983 Jan CAHN

AP

+

EQ 7.5GM BASE/VIAL

N050558 004 Oct 23, 1986 Jan CAHN

ZINACEF IN PLASTIC CONTAINER

@ IGI LABS INC

EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Jan CAHN

+

EQ 30MG BASE/ML

N050643 002 Apr 28, 1989 Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB + IGI LABS INC

EQ 750MG BASE/VIAL

N050558 002 Oct 19, 1983 Jan CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB AUROBINDO PHARMA LTD

50MG

A206827 001 Feb 01, 2016 Jan NEWA

AB

100MG

A206827 002 Feb 01, 2016 Jan NEWA

AB

200MG

A206827 003 Feb 01, 2016 Jan NEWA

AB

400MG

A206827 004 Feb 01, 2016 Jan NEWA

AB

MACLEODS PHARMS LTD

50MG

A204590 001 Mar 16, 2016 Feb NEWA

AB

100MG

A204590 002 Mar 16, 2016 Feb NEWA

AB

200MG

A204590 003 Mar 16, 2016 Feb NEWA

AB

400MG

A204590 004 Mar 16, 2016 Feb NEWA

CEPHALEXIN

CAPSULE;ORAL						
CEPHALEXIN						
	@ SUN PHARM INDS LTD	EQ 250MG BASE	A 065007	001	Sep 16, 1999	Feb DISC
	@	EQ 500MG BASE	A 065007	002	Sep 16, 1999	Feb DISC
KEFLEX						
AB	PRAGMA PHARMS LLC	EQ 250MG BASE	N 050405	002		Jul CAHN
	@	EQ 333MG BASE	N 050405	004	May 12, 2006	Jul CAHN
AB		EQ 500MG BASE	N 050405	003		Jul CAHN
AB	+	EQ 750MG BASE	N 050405	005	May 12, 2006	Jul CAHN
FOR SUSPENSION;ORAL						
KEFLEX						
	@ PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N 050406	003		Mar CAHN
	@	EQ 125MG BASE/5ML	N 050406	001		Mar CAHN
	@	EQ 250MG BASE/5ML	N 050406	002		Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL						
CETIRIZINE HYDROCHLORIDE						
AA	NOSTRUM LABS INC	5MG/5ML	A 090191	001	Nov 12, 2009	Mar CAHN
AA	+ PERRIGO R AND D	5MG/5ML	A 078398	001	Jun 17, 2008	Aug CRLD
	@ WOCKHARDT	5MG/5ML	A 078757	001	Aug 28, 2009	Apr DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL						
CEVIMELINE HYDROCHLORIDE						
>D> AB	ROXANE	30MG	A 091591	001	Jul 08, 2013	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	30MG	A 091591	001	Jul 08, 2013	Nov CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL						
CHLORDIAZEPOXIDE HYDROCHLORIDE						
>D>	@ SANDOZ	25MG	A 084679	002		Nov CAHN
	@ UPSHER-SMITH LABS	5MG	A 084678	001		Oct CAHN
	@	10MG	A 084041	001		Oct CAHN
>A>	@	25MG	A 084679	002		Nov CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL						
LIBRAX						
	+ VALEANT PHARMS	5MG;2.5MG	N 012750	001		Jul NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL						
PERIOGARD						
AT	COLGATE-PALMOLIVE CO	0.12%	A 203212	001	Jan 28, 2016	Jan NEWA

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION						
CHLOROPROCAINE HYDROCHLORIDE						
AP	WEST-WARD PHARMS INT	2%	A 040273	001	Sep 09, 1998	Sep CAHN
AP		3%	A 040273	002	Sep 09, 1998	Sep CAHN

CHLOROQUINE PHOSPHATE

TABLET;ORAL						
CHLOROQUINE PHOSPHATE						
	@ IMPAX LABS	EQ 150MG BASE	A 080880	001		Mar DISC
	@	EQ 300MG BASE	A 040516	001	Aug 29, 2003	Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL						
CHLORPHENIRAMINE MALEATE						
	@ AUROLIFE PHARMA LLC	4MG	A 080961	001		Mar CAHN
	@ SUN PHARM INDS	4MG	A 080700	001		Jun CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

@ SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun DISC
---------------	------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Feb CAHN
----	------------------	--------------------------	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC	100MG	A088725	001	Aug 31, 1984	Mar CAHN
@	250MG	A088726	001	Aug 31, 1984	Mar CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	MYLAN	25MG	A086831	002		Jan CTEC
AB	SUN PHARM INDS	25MG	A089286	002	Jul 21, 1986	Jan CMS1

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC	250MG	A089852	001	May 04, 1988	Feb CAHN
@	500MG	A089853	001	May 04, 1988	Feb CAHN
+ MIKART	750MG	A040861	002	Jun 01, 2010	Apr CRLD
+ MIKART INC	250MG	A207483	001	Jun 24, 2016	Jun NEWA
@ SUN PHARM INDS	500MG	A089970	001	Sep 27, 1990	Mar CAHN
AA + WATSON LABS	500MG	A089859	001	May 04, 1988	Jul CRLD

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB	IMPAX LABS INC	EQ 45MG FENOFIBRIC ACID	A200264	001	Sep 07, 2016	Aug NEWA
AB		EQ 135MG FENOFIBRIC ACID	A200264	002	Sep 07, 2016	Aug NEWA

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

+ TAKEDA GMBH	0.08MG/INH	N021658	002	Jan 10, 2008	Jan CRLD
---------------	------------	---------	-----	--------------	----------

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

@ FRONTIDA BIOPHARM	50MG	A077208	002	Mar 29, 2006	Jul CAHN	
@	100MG	A077208	001	Mar 29, 2006	Jul CAHN	
>D> AB	ROXANE	50MG	A077024	001	May 17, 2005	Nov CAHN
>D> AB		100MG	A077024	002	May 17, 2005	Nov CAHN
@ SUN PHARM INDS	50MG	A077208	002	Mar 29, 2006	Jun CAHN	
@	100MG	A077208	001	Mar 29, 2006	Jun CAHN	
AB + TEVA	50MG	A077027	001	Nov 24, 2004	Jun CRLD	
AB +	100MG	A077027	002	Nov 24, 2004	Jun CRLD	
>A> AB	WEST-WARD PHARMS INT	50MG	A077024	001	May 17, 2005	Nov CAHN
>A> AB		100MG	A077024	002	May 17, 2005	Nov CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Oct CAHN
@	300MG	A074506	002	Jan 24, 1996	Oct CAHN
@	400MG	A074506	003	Jan 24, 1996	Oct CAHN
@	800MG	A074506	004	Jan 24, 1996	Oct CAHN

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC

CILOXAN

>D> + ALCON PHARMS LTD	EQ 0.3% BASE	N020369	001	Mar 30, 1998	Nov CAHN
>A> + NOVARTIS PHARMS CORP	EQ 0.3% BASE	N020369	001	Mar 30, 1998	Nov CAHN

SOLUTION/DROPS;OPHTHALMIC									
CILOXAN									
>D>	AT	+	ALCON PHARMS LTD	EQ 0.3% BASE	N019992	001	Dec 31, 1990	Nov	CAHN
>A>	AT	+	NOVARTIS PHARMS CORP	EQ 0.3% BASE	N019992	001	Dec 31, 1990	Nov	CAHN
CIPROFLOXACIN HYDROCHLORIDE									
	AT		TELIGENT PHARMA INC	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jul	CAHN
TABLET;ORAL									
CIPROFLOXACIN HYDROCHLORIDE									
		@	IDT AUSTRALIA LTD	EQ 100MG BASE	A075939	001	Mar 03, 2005	May	CAHN
		@		EQ 250MG BASE	A075939	002	Jun 09, 2004	May	CAHN
		@		EQ 500MG BASE	A075939	003	Jun 09, 2004	May	CAHN
		@		EQ 750MG BASE	A075939	004	Jun 09, 2004	May	CAHN
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE</u>									
SOLUTION/DROPS;OTIC									
OTOVEL									
		+	LABORATORIOS SALVAT	EQ 0.3% BASE;0.025%	N208251	001	Apr 29, 2016	Apr	NEWA
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE</u>									
SUSPENSION/DROPS;OTIC									
CIPRO HC									
>D>		+	ALCON PHARMS LTD	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998	Nov	CAHN
>A>		+	NOVARTIS PHARMS CORP	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998	Nov	CAHN
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE;ORAL									
CIPROFLOXACIN EXTENDED RELEASE									
		@	ACTAVIS LABS FL INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	Jan	DISC
		@		425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	Jan	DISC
<u>CIPROFLOXACIN; DEXAMETHASONE</u>									
SUSPENSION/DROPS;OTIC									
CIPRODEX									
>D>		+	ALCON PHARMS LTD	0.3%;0.1%	N021537	001	Jul 18, 2003	Nov	CAHN
>A>		+	NOVARTIS PHARMS CORP	0.3%;0.1%	N021537	001	Jul 18, 2003	Nov	CAHN
<u>CISPLATIN</u>									
INJECTABLE;INJECTION									
CISPLATIN									
AP			WEST-WARD PHARMS INT	1MG/ML	A075036	001	Nov 07, 2000	Oct	CAHN
<u>CITALOPRAM HYDROBROMIDE</u>									
SOLUTION;ORAL									
CITALOPRAM HYDROBROMIDE									
>D>	AA	+	ROXANE	EQ 10MG BASE/5ML	A077043	001	Dec 13, 2004	Nov	CAHN
>A>	AA	+	WEST-WARD PHARMS INT	EQ 10MG BASE/5ML	A077043	001	Dec 13, 2004	Nov	CAHN
TABLET;ORAL									
CITALOPRAM HYDROBROMIDE									
		@	SUN PHARM INDS	EQ 10MG BASE	A077052	001	Jul 03, 2006	Mar	CAHN
		@		EQ 20MG BASE	A077052	002	Jul 03, 2006	Mar	CAHN
		@		EQ 40MG BASE	A077052	003	Jul 03, 2006	Mar	CAHN
<u>CLADRIBINE</u>									
INJECTABLE;INJECTION									
CLADRIBINE									
AP			WEST-WARD PHARMS INT	1MG/ML	A075405	001	Feb 28, 2000	Oct	CAHN
<u>CLARITHROMYCIN</u>									
TABLET;ORAL									
CLARITHROMYCIN									
>D>	AB		ROXANE	250MG	A065178	002	May 25, 2004	Nov	CAHN
>D>	AB			500MG	A065178	001	May 25, 2004	Nov	CAHN
>A>	AB		WEST-WARD PHARMS INT	250MG	A065178	002	May 25, 2004	Nov	CAHN
>A>	AB			500MG	A065178	001	May 25, 2004	Nov	CAHN
TABLET, EXTENDED RELEASE;ORAL									
CLARITHROMYCIN									
AB			ALLIED PHARMA INC	500MG	A203243	001	Feb 29, 2016	Feb	NEWA
		@	IDT AUSTRALIA LTD	500MG	A065250	001	Aug 25, 2005	May	CAHN
AB	+		MAYNE PHARMA	500MG	A065154	001	May 18, 2005	Aug	CAHN

CLEVIDIPINE

EMULSION;INTRAVENOUS
CLEVIPREX

+	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008	Aug CAHN
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008	Aug CAHN
+		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013	Aug CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	May NEWA
----	------------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL
CLINDESSE

+	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004	Jun CAHN
---	---------------------	------------	---------	-----	--------------	----------

INJECTABLE;INJECTION
CLINDAMYCIN PHOSPHATE

AP	@ WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987	Oct CAHN
		EQ 150MG BASE/ML	A062889	001	Apr 25, 1988	Oct CAHN
	@	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988	Oct CAHN
	@	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989	Oct CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@	INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Oct CAHN
---	--------------------	------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL
VELTIN

BX	+	AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010	Jan CAHN
----	---	-----------------	-------------	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

CREAM;TOPICAL
CLOBETASOL PROPIONATE (EMOLLIENT)
@ INGENUS PHARMS LLC 0.05%

A075733	001	Aug 22, 2001	Oct CAHN
---------	-----	--------------	----------

LOTION;TOPICAL

CLOBETASOL PROPIONATE

>A> AB	TELIGENT PHARMA INC	0.05%	A208667	001	Nov 29, 2016	Nov NEWA
--------	---------------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar CRLD
----	---	----------------	-------	---------	-----	--------------	----------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL
ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan CRLD

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL
CLONIDINE

AB	MAYNE PHARMA	0.1MG/24HR	A079090	001	Aug 20, 2010	Aug CAHN
AB		0.2MG/24HR	A079090	002	Aug 20, 2010	Aug CAHN
AB		0.3MG/24HR	A079090	003	Aug 20, 2010	Aug CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL
CLONIDINE HYDROCHLORIDE

@	AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb CAHN
@		0.2MG	A070886	001	Aug 31, 1988	Feb CAHN
@		0.3MG	A071294	001	Aug 31, 1988	Feb CAHN
AB	FRONTIDA BIOPHARM	0.1MG	A070925	001	Sep 04, 1987	Jul CAHN
AB		0.2MG	A070924	001	Sep 04, 1987	Jul CAHN
AB		0.3MG	A070923	001	Sep 04, 1987	Jul CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

	@ ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Jun DISC
AB	SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG
@	7.5MG
@	15MG

A072219	001	Aug 26, 1988	Apr CAHN
A072220	001	Aug 26, 1988	Feb CAHN
A072112	001	Aug 26, 1988	Feb CAHN

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG
@	7.5MG
@	15MG

A072512	001	May 11, 1990	Mar CAHN
A072513	001	May 11, 1990	Mar CAHN
A072514	001	May 11, 1990	Feb CAHN

TRANXENE

@ RECORDATI RARE	3.75MG
------------------	--------

N017105	006		Jun DISC
---------	-----	--	----------

CLOTTRIMAZOLE

TROCHE/LOZENGE; ORAL

CLOTTRIMAZOLE

>D> AB	+	ROXANE	10MG
>A> AB	+	WEST-WARD PHARMS INT	10MG

A076387	001	Jul 29, 2004	Nov CAHN
A076387	001	Jul 29, 2004	Nov CAHN

CLOZAPINE

TABLET; ORAL

CLOZAPINE

>A> AB	AUROBINDO PHARMA LTD	25MG
>A> AB		50MG
>A> AB		100MG
>A> AB		200MG
AB	MAYNE PHARMA	25MG
AB		100MG

A206433	001	Nov 29, 2016	Nov NEWA
A206433	002	Nov 29, 2016	Nov NEWA
A206433	003	Nov 29, 2016	Nov NEWA
A206433	004	Nov 29, 2016	Nov NEWA
A203807	001	Sep 17, 2015	Aug CAHN
A203807	002	Sep 17, 2015	Aug CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	NOSTRUM LABS INC	10MG/5ML; 6.25MG/5ML
----	------------------	----------------------

A090180	001	Mar 17, 2010	Feb CAHN
---------	-----	--------------	----------

COLCHICINE

CAPSULE; ORAL

MITIGARE

+	HIKMA INTL PHARMS	0.6MG
---	-------------------	-------

N204820	001	Sep 26, 2014	Mar CRLD
---------	-----	--------------	----------

TABLET; ORAL

COLCRYS

AB	+	TAKEDA PHARMS USA	0.6MG
	+		0.6MG

N022352	001	Jul 29, 2009	Oct CTEC
N022352	001	Jul 29, 2009	Sep CFTG

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB	INGENUS PHARMS NJ	0.5MG; 500MG
----	-------------------	--------------

A040618	001	May 13, 2008	Jan CAHN
---------	-----	--------------	----------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	ENDO PHARMS INC	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML
---	-----------------	---

N050356	001		Feb CAHN
---------	-----	--	----------

CORTICOTROPIN

INJECTABLE; INJECTION

PURIFIED CORTROPHIN GEL

@ ANI PHARMS	40 UNITS/ML
@	80 UNITS/ML

N008975	001		Feb CAHN
N008975	002		Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDEINJECTABLE; INJECTION
CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML N009854 001 Feb CAHN

CROFELEMERTABLET, DELAYED RELEASE; ORAL
FULYZAQ

+ NAPO PHARMS INC 125MG N202292 001 Dec 31, 2012 Jun CAHN

CROTAMITONLOTION; TOPICAL
CROTAN

AT MARNEL PHARMS 10% A087204 001 Aug CAHN

CYANOCOBALAMININJECTABLE; INJECTION
CYANOCOBALAMIN

AP SOMERSET THERAPS LLC 1MG/ML A206503 001 Dec 11, 2015 Mar CAHN

AP WEST-WARD PHARMS INT 1MG/ML A080515 002 Oct CMFD

SPRAY, METERED; NASAL
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY N021642 001 Jan 31, 2005 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
AMRIX

>D> AB TEVA PHARMS INTL 15MG N021777 001 Feb 01, 2007 Nov CTEC

>A> 15MG N021777 001 Feb 01, 2007 Nov CTEC

AB 15MG N021777 001 Feb 01, 2007 Oct CAHN

>D> AB + 30MG N021777 002 Feb 01, 2007 Nov CTEC

>A> + 30MG N021777 002 Feb 01, 2007 Nov CTEC

AB + 30MG N021777 002 Feb 01, 2007 Oct CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

@ TWI PHARMS INC 15MG A091281 001 Jan 31, 2013 Oct DISC

@ 30MG A091281 002 Jan 31, 2013 Oct DISC

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB FRONTIDA BIOPHARM 5MG A073541 002 Apr 06, 2006 Jul CAHN

AB 10MG A073541 001 May 23, 1995 Jul CAHN

@ UPSHER-SMITH LABS 5MG A072854 002 Feb 03, 2006 Oct CAHN

@ 10MG A072854 001 Nov 19, 1991 Oct CAHN

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL N012142 003 Mar DISC

@ 1GM/VIAL N012142 004 Aug 30, 1982 Mar DISC

@ 2GM/VIAL N012142 005 Aug 30, 1982 Mar DISC

TABLET; ORAL

CYCLOPHOSPHAMIDE

@ ROXANE 25MG A040032 001 Aug 17, 1999 Oct DISC

@ 50MG A040032 002 Aug 17, 1999 Oct DISC

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1 MAYNE PHARMA 25MG A065044 002 Dec 20, 2000 Aug CAHN

AB1 100MG A065044 001 Dec 20, 2000 Aug CAHN

EMULSION; OPHTHALMIC

>A> RESTASIS MULTIDOSE

>A> + ALLERGAN 0.05% N050790 002 Oct 27, 2016 Nov NEWA

INJECTABLE; INJECTION

CYCLOSPORINE

AP WEST-WARD PHARMS INT 50MG/ML A065004 001 Oct 29, 1999 Sep CAHN

SOLUTION; ORAL

CYCLOSPORINE

AB1 MAYNE PHARMA 100MG/ML A065054 001 Dec 18, 2001 Aug CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	APPCO PHARMA LLC	4MG	A206553	001	Nov 29, 2016	Nov NEWA
	AA	INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	Mar CAHN
AP		20MG/ML	A200916	001	Dec 13, 2011	Mar CAHN
AP	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Sep CAHN
AP		500MG/VIAL	A071472	001	Aug 02, 1989	Sep CAHN
AP		1GM/VIAL	A074245	001	Aug 31, 1994	Sep CAHN
AP		2GM/VIAL	A074245	002	Aug 31, 1994	Sep CAHN

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP	WEST-WARD PHARMS INT	200MG/VIAL	A075812	001	Jun 15, 2001	Oct CAHN
AP		500MG/VIAL	A075812	002	Oct 31, 2002	Oct CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

BRISTOL-MYERS SQUIBB EQ 90MG BASE

N206843 003 Apr 13, 2016 Apr NEWA

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL

A090304 001 Mar 16, 2010 Feb DISC

@ WEST-WARD PHARMS INT 0.5MG/VIAL

A090304 001 Mar 16, 2010 Oct CAHN

DALBAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL

N021883 001 May 23, 2014 Jan CDFR

DANAZOL

CAPSULE; ORAL

DANAZOL

AB	LANNETT	50MG
AB		100MG

A077246	002	Apr 19, 2007	Sep NEWA
A077246	003	Apr 19, 2007	Sep NEWA

DANTROLENE SODIUM

FOR SUSPENSION; INTRAVENOUS

RYANODEX

+ EAGLE PHARMS 250MG/VIAL

N205579 001 Jul 22, 2014 Jun CRLD

INJECTABLE; INJECTION

DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL

A205239 001 Feb 18, 2016 Feb NEWA

DAPSONE

GEL; TOPICAL

ACZONE

+ ALLERGAN INC 7.5%

N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL

DAPSONE

AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Mar CAHN	
AB		100MG	A205429	002	Jan 07, 2016	Mar CAHN	
AB	NORTH CREEK PHARMS	25MG	A204074	001	May 10, 2016	Apr NEWA	
AB		100MG	A204074	002	May 10, 2016	Apr NEWA	
AB	NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016	Apr NEWA	
AB		100MG	A203887	002	May 06, 2016	Apr NEWA	
>A>	AB	PAR PHARM INC	25MG	A206505	001	Dec 01, 2016	Nov NEWA
>A>	AB		100MG	A206505	002	Dec 01, 2016	Nov NEWA

DAPTOMYCINPOWDER; INTRAVENOUS
CUBICIN

AP	+	CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan CDFR
AP	+	CUBIST PHARMS LLC	500MG/VIAL	N021572	002	Sep 12, 2003	Aug CAHN
		CUBICIN RF					
	+	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016	Aug NEWA
		DAPTOMYCIN					
AP		CRANE PHARMS LLC	500MG/VIAL	A206005	001	Jun 15, 2016	Jun NEWA
AP		HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan CDFR
AP		TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016	Mar NEWA
		POWDER; IV (INFUSION)					
		CUBICIN					
	@	CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan CDFR
	@	CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003	Aug CAHN

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	EQ 7.5MG BASE	A206743	001	Sep 19, 2016	Sep NEWA
AB			EQ 15MG BASE	A206743	002	Sep 19, 2016	Sep NEWA
AB		CIPLA LTD	EQ 7.5MG BASE	A207664	001	Sep 01, 2016	Aug NEWA
AB			EQ 15MG BASE	A207664	002	Sep 01, 2016	Aug NEWA
AB		JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Oct NEWA
AB			EQ 15MG BASE	A205550	002	Oct 12, 2016	Oct NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 7.5MG BASE	A205209	001	Nov 17, 2016	Nov NEWA
>A>	AB		EQ 15MG BASE	A205209	002	Nov 17, 2016	Nov NEWA
		ENABLEX					
AB		APIL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan CAHN
AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET, EXTENDED RELEASE; ORAL
VIEKIRA XR

+	ABBVIE INC	EQ 200MG BASE; 8.33MG; 50MG; 33.33MG	N208624	001	Jul 22, 2016	Jul NEWA
---	------------	--------------------------------------	---------	-----	--------------	----------

DASATINIBTABLET; ORAL
DASATINIB

AB		APOTEX INC	20MG	A202103	001	Jun 10, 2016	May NEWA
AB			50MG	A202103	002	Jun 10, 2016	May NEWA
AB			70MG	A202103	003	Jun 10, 2016	May NEWA
AB			100MG	A202103	004	Jun 10, 2016	May NEWA
		SPRYCEL					
AB		BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May CFTG
AB			50MG	N021986	002	Jun 28, 2006	May CFTG
AB			70MG	N021986	003	Jun 28, 2006	May CFTG
AB	+		100MG	N021986	004	May 30, 2008	May CFTG

DAUNORUBICIN CITRATEINJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

@	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	May DISC
---	------------	----------------	---------	-----	--------------	----------

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
CERUBIDINE

AP	+	WEST-WARD PHARMS INT	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Sep CAHN
		DAUNORUBICIN HYDROCHLORIDE					
AP	+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Sep CAHN

DEFERASIROXTABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB		ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB			250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB			500MG	A203560	003	Jan 26, 2016	Jan NEWA
		EXJADE					
AB		NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB			250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+		500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

AP	WEST-WARD PHARMS INT	500MG/VIAL	A078086	001	May 30, 2007	Oct	CAHN
AP		2GM/VIAL	A078086	002	May 30, 2007	Oct	CAHN

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)
DEFITELIO

+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar	NEWA
+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Aug	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DEMECLOCYCLINE HYDROCHLORIDE

@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar	DISC
@		300MG	A065094	002	Mar 22, 2004	Mar	DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar	NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar	NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar	NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar	NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar	NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar	NEWA
AB	COREPHARMA	10MG	A205153	001	Oct 28, 2016	Oct	NEWA
AB		25MG	A205153	002	Oct 28, 2016	Oct	NEWA
AB		50MG	A205153	003	Oct 28, 2016	Oct	NEWA
AB		75MG	A205153	004	Oct 28, 2016	Oct	NEWA
AB		100MG	A205153	005	Oct 28, 2016	Oct	NEWA
AB		150MG	A205153	006	Oct 28, 2016	Oct	NEWA
AB	HERITAGE PHARMS INC	10MG	A207433	001	May 05, 2016	Jun	CAHN
AB		25MG	A207433	002	May 05, 2016	Jun	CAHN
AB		50MG	A207433	003	May 05, 2016	Jun	CAHN
AB		75MG	A207433	004	May 05, 2016	Jun	CAHN
AB		100MG	A207433	005	May 05, 2016	Jun	CAHN
AB		150MG	A207433	006	May 05, 2016	Jun	CAHN
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr	NEWA
AB		25MG	A207433	002	May 05, 2016	Apr	NEWA
AB		50MG	A207433	003	May 05, 2016	Apr	NEWA
AB		75MG	A207433	004	May 05, 2016	Apr	NEWA
AB		100MG	A207433	005	May 05, 2016	Apr	NEWA
AB		150MG	A207433	006	May 05, 2016	Apr	NEWA
	NORPRAMIN						
AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan	CAHN
AB		25MG	N014399	001		Jan	CAHN
AB		50MG	N014399	003		Jan	CAHN
AB		75MG	N014399	004		Jan	CAHN
AB	+	100MG	N014399	005		Jan	CAHN
AB		150MG	N014399	006		Jan	CAHN

DESLOMATADINE

SOLUTION; ORAL
DESLOMATADINE

AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May	NEWA
----	------	----------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE (NEEDS NO REFRIGERATION)

+	CSL BEHRING	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Aug	CPOT
---	-------------	--------------	---------	-----	--------------	-----	------

TABLET; ORAL
DESMOPRESSIN ACETATE

@	FERRING	0.1MG	N021795	001	May 08, 2008	Jun	DISC
@		0.2MG	N021795	002	May 08, 2008	Jun	DISC
AB	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006	Aug	CAHN
AB		0.2MG	A077122	002	Jan 25, 2006	Aug	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	+	DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	002	Aug 12, 1999	Sep CRLD
AB		MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Aug CAHN
AB			0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Aug CAHN

ORTHO-CEPT

@ JANSSSEN PHARMS

VOLNEA

AB		SANDOZ INC	0.15MG;0.03MG	N020301	002	Dec 14, 1992	Sep DISC
			0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug NEWA

DESONIDE

CREAM; TOPICAL

DESONIDE

AB		G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan CAHN
----	--	------------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB		GROUPE PARIMA INC	0.05%	A204675	001	Aug 12, 2016	Aug NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

OINTMENT; TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	0.25%	A204965	001	Nov 07, 2016	Oct NEWA
>A>	AB	GROUPE PARIMA INC	0.25%	A204272	001	Nov 30, 2016	Nov NEWA
>A>	AB	LUPIN ATLANTIS	0.05%	A208044	001	Dec 12, 2016	Nov NEWA
>A>	AB		0.25%	A208104	001	Dec 01, 2016	Nov NEWA
AB		NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr NEWA
AB		PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May CAHN
AB		TELLIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb NEWA

TOPICORT

>D>	+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	Nov CFTG
>A>	AB	+	0.05%	N018594	001	Jan 17, 1985	Nov CFTG

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB		ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	Jul NEWA
AB			EQ 50MG BASE	A204065	002	Jul 29, 2016	Jul NEWA
AB			EQ 100MG BASE	A204065	003	Jul 29, 2016	Jul NEWA
>D>	AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Nov CAHN
AB			EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb NEWA
>D>	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Nov CAHN
AB			EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb NEWA
>A>	AB	WEST-WARD PHARMS INT	EQ 50MG BASE	A204082	001	Feb 16, 2016	Nov CAHN
>A>	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Nov CAHN
		PRISTIQ					
AB		WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul CFTG

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

>D>	+	ROXANE	1MG/ML	A088252	001	Sep 01, 1983	Nov CAHN
>A>	+	WEST-WARD PHARMS INT	1MG/ML	A088252	001	Sep 01, 1983	Nov CAHN

SOLUTION; ORAL

DEXAMETHASONE

>D>	+	ROXANE	0.5MG/5ML	A088248	001	Sep 01, 1983	Nov CAHN
>A>	+	WEST-WARD PHARMS INT	0.5MG/5ML	A088248	001	Sep 01, 1983	Nov CAHN

SUSPENSION/DROPS; OPHTHALMIC

MAXIDEX

>D>	+	ALCON	0.1%	N013422	001		Nov CAHN
>A>	+	NOVARTIS PHARMS CORP	0.1%	N013422	001		Nov CAHN

TABLET; ORAL

DEXAMETHASONE

		@ IDT AUSTRALIA LTD	0.75MG	A080399	001		May CAHN
>D>	BP	ROXANE	0.5MG	A084611	001		Nov CAHN
>D>	BP		0.75MG	A084613	001		Nov CAHN
>D>	BP		1MG	A088306	001	Sep 15, 1983	Nov CAHN
>D>	AB		1.5MG	A084610	001		Nov CAHN
>D>	BP		2MG	A087916	001	Aug 26, 1982	Nov CAHN
>D>	BP		4MG	A084612	001		Nov CAHN

TABLET; ORAL

DEXAMETHASONE

>D>	BP	+	6MG	A088316	001	Sep 15, 1983	Nov CAHN
		@ SUN PHARM INDS	0.25MG	A084013	001		Mar CAHN
		@	0.25MG	A084764	001		Mar CAHN
		@	0.5MG	A084084	001		Mar CAHN
		@	0.5MG	A084766	001		Mar CAHN
		@	0.75MG	A084081	001		Mar CAHN
		@	0.75MG	A084765	001		Mar CAHN
		@	1.5MG	A084086	001		Mar CAHN
		@	1.5MG	A084763	001		Mar CAHN
>A>	BP	WEST-WARD PHARMS INT	0.5MG	A084611	001		Nov CAHN
>A>	BP		0.75MG	A084613	001		Nov CAHN
>A>	BP		1MG	A088306	001	Sep 15, 1983	Nov CAHN
>A>	AB		1.5MG	A084610	001		Nov CAHN
>A>	BP		2MG	A087916	001	Aug 26, 1982	Nov CAHN
>A>	BP		4MG	A084612	001		Nov CAHN
>A>	BP	+	6MG	A088316	001	Sep 15, 1983	Nov CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar CTNA
----	---	--------------------	----------------------	---------	-----	--------------	----------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

>D>	AT	+	ALCON LABS INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050023	002	Nov CAHN
>A>	AT	+	NOVARTIS PHARMS CORP	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050023	002	Nov CAHN

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

DEXILANT SOLUTAB

	+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan NEWA
--	---	-------------------	------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan NEWA
AP		ACTAVIS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204686	001	Oct 17, 2016	Oct NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar NEWA
AP		SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May NEWA
		PRECEDEX					
	+	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		IMPAX LABS INC	5MG	A079108	001	Aug 05, 2015	Aug CAHN
AB			10MG	A079108	002	Aug 05, 2015	Aug CAHN
AB			15MG	A079108	003	May 19, 2014	Aug CAHN
AB			20MG	A079108	004	Dec 21, 2015	Aug CAHN
AB			30MG	A079108	005	Nov 21, 2013	Aug CAHN
>A>	AB	PAR PHARM INC	5MG	A202842	001	Nov 30, 2016	Nov NEWA
>A>	AB		10MG	A202842	002	Nov 30, 2016	Nov NEWA
>A>	AB		15MG	A202842	003	Nov 30, 2016	Nov NEWA
>A>	AB		20MG	A202842	004	Nov 30, 2016	Nov NEWA
>A>	AB		25MG	A202842	005	Nov 30, 2016	Nov NEWA
>A>	AB		30MG	A202842	006	Nov 30, 2016	Nov NEWA
>A>	AB		35MG	A202842	007	Nov 30, 2016	Nov NEWA
>A>	AB		40MG	A202842	008	Nov 30, 2016	Nov NEWA
		FOCALIN XR					
>D>		NOVARTIS	25MG	N021802	008	Apr 21, 2011	Nov CFTG
>A>	AB		25MG	N021802	008	Apr 21, 2011	Nov CFTG
>D>			35MG	N021802	007	Apr 21, 2011	Nov CFTG
>A>	AB		35MG	N021802	007	Apr 21, 2011	Nov CFTG

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb CAHN
AB		5MG	A201231	002	Sep 24, 2015	Feb CAHN
AB		10MG	A201231	003	Sep 24, 2015	Feb CAHN
AB	TRIS PHARMA INC	2.5MG	A207901	001	Aug 26, 2016	Aug NEWA
AB		5MG	A207901	002	Aug 26, 2016	Aug NEWA
AB		10MG	A207901	003	Aug 26, 2016	Aug NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

>A>	AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A207321	001	Nov 28, 2016	Nov NEWA
	AP	WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Oct CAHN
	AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Oct CAHN
		TOTECT					
	+	CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Mar CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

AB	MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002	Aug CAHN
AB		10MG	A076137	002	Jan 18, 2002	Aug CAHN
AB		15MG	A076137	003	Jan 18, 2002	Aug CAHN
AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan NEWA
AB		10MG	A206735	002	Jan 27, 2016	Jan NEWA
AB		15MG	A206735	003	Jan 27, 2016	Jan NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

	@	COREPHARMA	5MG	A090652	001	Mar 07, 2014	Sep DISC
	@		10MG	A090652	002	Mar 07, 2014	Sep DISC
	@	IDT AUSTRALIA LTD	5MG	A085370	001		Aug CAHN
AA		NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA			10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA		NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA			10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@	ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984	Feb CMS1
---	------------	----------------------	---------	-----	--------------	----------

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	50MG/ML	A207449	001	Oct 21, 2016	Oct NEWA
----	--------------------	---------	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML	N019515	001	May 08, 1986	Sep DISC
---	---------	---	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML	N017484	001		Feb CMS1
--	-----------------	---	---------	-----	--	----------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	N018840	001	Jun 29, 1983	Feb CMS1
---	-----------------	---	---------	-----	--------------	----------

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	2.5GM/100ML; 450MG/100ML	N016697	001			Oct	CRLD
		DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER							
	+	HOSPIRA	5GM/100ML; 225MG/100ML	N017606	001			Oct	CRLD
		DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	+	HOSPIRA	5GM/100ML; 300MG/100ML	N017799	001			Oct	CRLD

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM INTENSOL

>D>	AA	+	ROXANE	5MG/ML	A071415	001	Apr 03, 1987	Nov	CAHN
>A>	AA	+	WEST-WARD PHARMS INT	5MG/ML	A071415	001	Apr 03, 1987	Nov	CAHN

INJECTABLE; INJECTION

DIAZEPAM

		@	EUROHLTH INTL SARL	5MG/ML	A070313	001	Dec 16, 1985	Jan	CAHN
>D>	AP	+	HOSPIRA	5MG/ML	A071583	001	Oct 13, 1987	Nov	CPOT
>D>	AP			5MG/ML	A072079	001	Dec 20, 1988	Nov	CPOT
>A>		+		10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Nov	CPOT
>A>		+		50MG/10ML (5MG/ML)	A071583	001	Oct 13, 1987	Nov	CPOT
		@	WEST-WARD PHARMS INT	5MG/ML	A070311	001	Dec 16, 1985	Oct	CAHN
		@		5MG/ML	A070312	001	Dec 16, 1985	Oct	CAHN
		@		5MG/ML	A070313	001	Dec 16, 1985	Oct	CAHN
		@		5MG/ML	A071308	001	Jul 17, 1987	Oct	CAHN
		@		5MG/ML	A071309	001	Jul 17, 1987	Oct	CAHN
		@		5MG/ML	A071310	001	Jul 17, 1987	Oct	CAHN

SOLUTION; ORAL

DIAZEPAM

	AA		LANNETT HOLDINGS INC	5MG/5ML	A206477	001	Jun 24, 2016	Jun	NEWA
>D>	AA	+	ROXANE	5MG/5ML	A070928	001	Apr 03, 1987	Nov	CAHN
	AA	+		5MG/5ML	A070928	001	Apr 03, 1987	Jun	CFTG
>A>	AA	+	WEST-WARD PHARMS INT	5MG/5ML	A070928	001	Apr 03, 1987	Nov	CAHN

TABLET; ORAL

DIAZEPAM

			DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan	CMS1
				5MG	A070228	003	Sep 26, 1985	Jan	CMS1
AB			MAYNE PHARMA	2MG	A071134	001	Feb 03, 1987	Aug	CAHN
AB				5MG	A071135	001	Feb 03, 1987	Aug	CAHN
AB				10MG	A071136	001	Feb 03, 1987	Aug	CAHN
		@	UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Oct	CAHN
		@		5MG	A070303	001	Dec 20, 1985	Oct	CAHN
		@		10MG	A070304	001	Dec 20, 1985	Oct	CAHN

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

>D>		@	TARO	50MG	N011366	001		Nov	CAHN
>A>		@	TARO PHARMS NORTH	50MG	N011366	001		Nov	CAHN
			KEYEYIS						
>D>			TARO	50MG	N011366	002	Aug 07, 2015	Nov	CAHN
>A>			TARO PHARMS NORTH	50MG	N011366	002	Aug 07, 2015	Nov	CAHN

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

AB			BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb	NEWA
			ZIPSOR						
AB	+		DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb	CFTG
			FOR SOLUTION; ORAL						
			CAMBIA						
AB	+		DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr	CFTG
			DICLOFENAC POTASSIUM						
AB			PAR FORM	50MG	A202964	001	May 02, 2016	Apr	NEWA

TABLET; ORAL

CATAFLAM

		@	NOVARTIS	50MG	N020142	002	Nov 24, 1993	Mar	DISC
			DICLOFENAC POTASSIUM						
AB	+		MYLAN	50MG	A075463	001	Jul 26, 1999	Mar	CRLD
		@	SUN PHARM INDS	50MG	A075470	001	Feb 21, 2002	Jun	CAHN

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar NEWA
AB	GLENMARK PHARMS LTD	3%	A208301	001	Sep 13, 2016	Aug NEWA
AB	TARO	3%	A206298	001	Apr 28, 2016	Apr NEWA

VOLTAREN

AB	+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar CFTG
----	------------------------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT	AMNEAL PHARMS	1.5%	A206116	001	Sep 02, 2016	Aug NEWA
AT	TELIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015	May CAHN

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT	RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan CAHN
----	-------------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB	+ ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb CRLD
	VOLTAREN-XR					
	@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

>A>	AB	AMNEAL PHARMS	50MG; 0.2MG	A203995	001	Nov 25, 2016	Nov NEWA
>A>	AB		75MG; 0.2MG	A203995	002	Nov 25, 2016	Nov NEWA
	AB	EXELA PHARMA SCS LLC	50MG; 0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
	AB		75MG; 0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

@ SUN PHARM INDS 10MG

A084505	001	Oct 21, 1986	Mar CAHN
---------	-----	--------------	----------

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

AP	EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Mar CMS1
AP	WEST-WARD PHARMS INT	10MG/ML	A040465	001	Jun 30, 2003	Sep CAHN

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

+ MIKART 10MG/5ML

A040169	001	Mar 24, 2005	Jan CRLD
---------	-----	--------------	----------

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

@ SUN PHARM INDS 20MG

A084600	001	Jul 29, 1985	Mar CAHN
---------	-----	--------------	----------

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

ESTRADIOL VALERATE AND DIENOGEST

AB	WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A	A202349	001	May 06, 2016	Apr NEWA
----	-----------------	--	---------	-----	--------------	----------

NATAZIA

AB	+ BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A	N022252	001	May 06, 2010	Apr CFTG
----	------------------	--	---------	-----	--------------	----------

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

@ COREPHARMA 25MG

A040828	001	Nov 05, 2008	Mar DISC
---------	-----	--------------	----------

TENUATE

AA	+ ACTAVIS LABS UT INC	25MG	N011722	002		Apr CAHN
AA	+ ALLERGAN SALES LLC	25MG	N011722	002		Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

AB	+ ACTAVIS LABS UT INC	75MG	N012546	001		Apr CAHN
AB	+ ALLERGAN SALES LLC	75MG	N012546	001		Mar CAHN

DIFLUNISALTABLET; ORAL
DIFLUNISAL

@	IDT AUSTRALIA LTD	500MG	A074604	001	Jun 10, 1996	May CAHN
---	-------------------	-------	---------	-----	--------------	----------

DIFLUPREDNATEEMULSION; OPHTHALMIC
DUREZOL

>D>	+	ALCON PHARMS LTD	0.05%	N022212	001	Jun 23, 2008	Nov CAHN
>A>	+	NOVARTIS PHARMS CORP	0.05%	N022212	001	Jun 23, 2008	Nov CAHN

DIGOXININJECTABLE; INJECTION
LANOXIN

AP	+	COVIS PHARMA SARL	0.25MG/ML	N009330	002		Jun CAHN
		LANOXIN PEDIATRIC					
	+	COVIS PHARMA SARL	0.1MG/ML	N009330	004		Jun CAHN

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DILACOR XR

@	ALLERGAN SALES LLC	120MG	N020092	001	May 29, 1992	Jul CAHN
@		180MG	N020092	002	May 29, 1992	Jul CAHN
@		240MG	N020092	003	May 29, 1992	Jul CAHN

DILTIAZEM HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan DISC
	@		180MG	A074852	002	Oct 10, 1997	Jan DISC
	@		240MG	A074852	003	Oct 10, 1997	Jan DISC
AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan CAHN

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074617	001	Feb 28, 1996	Jun CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996	Apr CAHN

DINOPROSTONEINSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan CAHN
---	--------------------	------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

@	HIKMA INTL PHARMS	50MG	A083567	001		Jul CAHN
@	HIKMA PHARMS	50MG	A083567	001		Feb CAHN
@	SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987	Mar CAHN
@		50MG	A089489	001	Jan 02, 1987	Jun CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074939	001	Apr 13, 1998	Jun CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074939	001	Apr 13, 1998	Apr CAHN
AP		WEST-WARD PHARMS INT	5MG/ML	A074521	001	Oct 18, 1996	Oct CAHN

TABLET; ORAL

DIPYRIDAMOLE

@	IDT AUSTRALIA LTD	25MG	A086944	002	Apr 16, 1991	May CAHN
@		50MG	A087562	001	Feb 25, 1992	May CAHN
@		75MG	A087561	001	Feb 25, 1992	May CAHN
@	LANNETT	25MG	A040898	001	Apr 23, 2008	Aug DISC
@		50MG	A040898	002	Apr 23, 2008	Aug DISC
@		75MG	A040898	003	Apr 23, 2008	Aug DISC
@	PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990	Jul DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

		@ AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb CAHN
		@	EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb CAHN
AB		MAYNE PHARMA	EQ 100MG BASE	A070173	001	May 31, 1985	Aug CAHN
AB			EQ 150MG BASE	A070174	001	May 31, 1985	Aug CAHN
		@ SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985	Mar CAHN
		@	EQ 150MG BASE	A070352	001	Dec 17, 1985	Mar CAHN

DISULFIRAM

TABLET; ORAL

DISULFIRAM

>D>	AB	ROXANE	250MG	A202652	001	Feb 05, 2014	Nov CAHN
>D>	AB		500MG	A202652	002	Feb 05, 2014	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	250MG	A202652	001	Feb 05, 2014	Nov CAHN
>A>	AB		500MG	A202652	002	Feb 05, 2014	Nov CAHN
		DISULFIRAM					
AB		ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

>D>		@ IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Nov CMFD
>A>	AB		EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Nov CMFD
		@	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb DISC
>D>		@	EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Nov CMFD
>A>	AB		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Nov CMFD
		@	EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

		@ TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Jan CAHN
AP		WEST-WARD PHARMS INT	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994	Sep CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

HOSPIRA INC

20MG/ML (20MG/ML)
80MG/4ML (20MG/ML)
120MG/6ML (20MG/ML)

N022234 004 Jun 23, 2016 Jun NEWA
N022234 005 Jun 23, 2016 Jun NEWA
N022234 006 Jun 23, 2016 Jun NEWA

SOLUTION; IV (INFUSION)

DOCETAXEL

EAGLE PHARMS

20MG/ML (20MG/ML)
80MG/4ML (20MG/ML)
160MG/8ML (20MG/ML)

N205934 001 Dec 22, 2015 Jan CAHN
N205934 002 Dec 22, 2015 Jan CAHN
N205934 003 Dec 22, 2015 Jan CAHN

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

AB		TIGER PHARMS LLC	0.125MG	A207058	001	Jun 06, 2016	May NEWA
AB			0.25MG	A207058	002	Jun 06, 2016	May NEWA
AB			0.5MG	A207058	003	Jun 06, 2016	May NEWA
		TIKOSYN					
AB		PFIZER	0.125MG	N020931	001	Oct 01, 1999	May CFTG
AB			0.25MG	N020931	002	Oct 01, 1999	May CFTG
AB	+		0.5MG	N020931	003	Oct 01, 1999	May CFTG

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+ US PHARM HOLDINGS
+
+
+
@
+

12.5MG/0.625ML (20MG/ML)
12.5MG/0.625ML (20MG/ML)
100MG/5ML (20MG/ML)
500MG/25ML (20MG/ML)
500MG/25ML (20MG/ML)

N020624 002 Sep 11, 1997 Jan CAHN
N020624 002 Sep 11, 1997 Jan CAHN
N020624 001 Sep 11, 1997 Jan CAHN
N020624 003 Dec 11, 2001 Jun DISC
N020624 003 Dec 11, 2001 Jan CAHN

TABLET; ORAL

ANZEMET

US PHARM HOLDINGS

50MG
100MG

N020623 001 Sep 11, 1997 Jan CAHN
N020623 002 Sep 11, 1997 Jan CAHN

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

VIIV HLTHCARE

EQ 10MG BASE

N204790 002 Jun 09, 2016 Jun NEWA

EQ 25MG BASE

N204790 003 Jun 09, 2016 Jun NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB DEXCEL PHARMA 23MG

A203713 001 Feb 19, 2016 Feb NEWA

AB INDICUS PHARMA 23MG

A203419 001 Apr 12, 2016 Mar NEWA

AB OSMOTICA PHARM CORP 23MG

A203114 001 Jan 26, 2016 Jan NEWA

AB OSMOTICA PHARM US 23MG

A203114 001 Jan 26, 2016 Jun CAHN

AB UNICHEM LABS LTD 5MG

A203656 001 Jun 23, 2016 Jun NEWA

AB 10MG

A203656 002 Jun 23, 2016 Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

@ SUN PHARM INDS 5MG

A077975 002 Dec 11, 2009 Mar CAHN

@ 10MG

A077975 001 Dec 11, 2009 Mar CAHN

AB UNICHEM LABS LTD 5MG

A204831 001 Nov 10, 2016 Oct NEWA

AB 10MG

A204831 002 Nov 10, 2016 Oct NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

FOREST LABS LLC

10MG; 7MG

N206439 003 Jul 18, 2016 Aug NEWA

10MG; 21MG

N206439 004 Jul 18, 2016 Aug NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ LANNETT HOLDINGS INC EQ 2% BASE; EQ 0.5% BASE

A201998 001 Dec 17, 2014 Aug DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP + WEST-WARD PHARMS INT 20MG/ML

N014879 001 Oct CAHN

DOXAPRAM HYDROCHLORIDE

AP AMPHASTAR PHARMS INC 20MG/ML

A076266 001 Jan 10, 2003 Jun CAHN

AP EUROHLTH INTL SARL 20MG/ML

A076266 001 Jan 10, 2003 Apr CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ IDT AUSTRALIA LTD EQ 1MG BASE

A075432 001 Oct 18, 2000 Mar CAHN

@ EQ 2MG BASE

A075432 002 Oct 18, 2000 Mar CAHN

@ EQ 4MG BASE

A075432 003 Oct 18, 2000 Mar CAHN

@ EQ 8MG BASE

A075432 004 Oct 18, 2000 Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

@ SUN PHARM INDS EQ 25MG BASE

A071502 001 Feb 18, 1988 Mar CAHN

@ EQ 50MG BASE

A071653 001 Feb 18, 1988 Mar CAHN

@ EQ 75MG BASE

A071654 001 Feb 18, 1988 Mar CAHN

@ EQ 100MG BASE

A071521 001 Feb 18, 1988 Mar CAHN

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

AB MYLAN PHARMS INC EQ 3MG BASE

A202337 001 Jan 20, 2016 Jan NEWA

AB EQ 6MG BASE

A202337 002 Jan 20, 2016 Jan NEWA

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

AB RISING PHARMS INC 0.5MCG

A201518 001 Sep 09, 2016 Aug NEWA

AB 1MCG

A201518 002 Sep 09, 2016 Aug NEWA

AB 2.5MCG

A201518 003 Sep 09, 2016 Aug NEWA

>D> AB ROXANE 0.5MCG

A091433 001 Sep 23, 2011 Nov CAHN

>D> AB 1MCG

A091433 002 Jan 14, 2014 Nov CAHN

>D> AB 2.5MCG

A091433 003 Jan 14, 2014 Nov CAHN

>A> AB WEST-WARD PHARMS INT 0.5MCG

A091433 001 Sep 23, 2011 Nov CAHN

		CAPSULE;ORAL					
		DOXERCALCIFEROL					
>A>	AB	1MCG		A091433	002	Jan 14, 2014	Nov CAHN
>A>	AB	2.5MCG		A091433	003	Jan 14, 2014	Nov CAHN
		INJECTABLE;INJECTION					
		DOXERCALCIFEROL					
AP	AKORN INC	2MCG/ML (2MCG/ML)		A203929	002	Mar 28, 2016	Mar NEWA
		HECTOROL					
AP	GENZYME CORP	2MCG/ML (2MCG/ML)		N021027	002	Apr 06, 2000	Mar CFTG
<u>DOXORUBICIN HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION					
		DOXORUBICIN HYDROCHLORIDE					
AP	ACTAVIS INC	2MG/ML		A203622	001	Jun 27, 2014	May CRLD
AP		200MG/100ML		A203622	002	Jun 27, 2014	May CRLD
AP	+ PHARMACIA AND UPJOHN	2MG/ML		N050629	001	Dec 23, 1987	May CRLD
AP	+	200MG/100ML		N050629	002	May 03, 1988	May CRLD
>D>	AP	SANDOZ INC	2MG/ML	A200146	001	Jul 18, 2012	Nov DISC
>A>	@	2MG/ML		A200146	001	Jul 18, 2012	Nov DISC
AP	WEST-WARD PHARMS INT	2MG/ML		A062975	001	Mar 17, 1989	Sep CAHN
AP	+	10MG/VIAL		A062921	001	Mar 17, 1989	Sep CAHN
AP	+	20MG/VIAL		A062921	002	Mar 17, 1989	Sep CAHN
AP	+	50MG/VIAL		A062921	003	Mar 17, 1989	Sep CAHN
AP		200MG/100ML		A064097	001	Sep 13, 1994	Sep CAHN
<u>DOXYCYCLINE</u>							
		CAPSULE;ORAL					
		DOXYCYCLINE					
AB	G AND W LABS INC	EQ 50MG BASE		A204446	001	May 28, 2015	Mar CAHN
AB		EQ 75MG BASE		A204446	002	May 28, 2015	Mar CAHN
AB		EQ 100MG BASE		A204446	003	May 28, 2015	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE		A205115	001	Feb 18, 2016	Feb NEWA
AB		EQ 75MG BASE		A205115	002	Feb 18, 2016	Feb NEWA
AB		EQ 100MG BASE		A205115	003	Feb 18, 2016	Feb NEWA
		TABLET;ORAL					
		DOXYCYCLINE					
	@ SUN PHARM INDS	EQ 50MG BASE		A065471	001	Apr 17, 2009	Jun CAHN
	@	EQ 75MG BASE		A065471	002	Apr 17, 2009	Jun CAHN
	@	EQ 100MG BASE		A065471	003	Apr 17, 2009	Jun CAHN
<u>DOXYCYCLINE HYCLATE</u>							
		CAPSULE;ORAL					
		ACTICLATE CAP					
+	AQUA PHARMS	EQ 75MG BASE		N208253	001	Apr 26, 2016	Apr NEWA
		DOXYCYCLINE HYCLATE					
AB	AMNEAL PHARMS	EQ 100MG BASE		A207289	001	Jun 27, 2016	Jun NEWA
AB	SUN PHARM INDS	EQ 100MG BASE		A062676	001	Jul 10, 1986	Mar CAHN
		INJECTABLE;INJECTION					
		DOXYCYCLINE					
	@ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL		A062450	001	Oct 27, 1983	Oct CAHN
AP	+	EQ 100MG BASE/VIAL		A062569	001	Mar 09, 1988	Sep CAHN
	@	EQ 200MG BASE/VIAL		A062450	002	Oct 27, 1983	Oct CAHN
	@	EQ 200MG BASE/VIAL		A062569	002	Mar 09, 1988	Sep CAHN
		DOXYCYCLINE HYCLATE					
	@ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL		A062992	001	Feb 16, 1989	Oct CAHN
	@	EQ 200MG BASE/VIAL		A062992	002	Feb 16, 1989	Oct CAHN
		TABLET;ORAL					
		DOXYCYCLINE HYCLATE					
	@ COREPHARMA	EQ 20MG BASE		A065182	001	May 13, 2005	Mar DISC
AB	SUN PHARM INDS	EQ 20MG BASE		A065134	001	May 13, 2005	Mar CAHN
AB		EQ 100MG BASE		A062677	001	Jul 10, 1986	Mar CAHN
	@ VINTAGE PHARMS	EQ 100MG BASE		A062538	001	Apr 07, 1986	Mar DISC
		TABLET, DELAYED RELEASE;ORAL					
		DORYX					
AB	MAYNE PHARMA	EQ 50MG BASE		N050795	006	Dec 19, 2014	Jul CTNA
AB		EQ 50MG BASE		N050795	006	Dec 19, 2014	May CFTG
AB		EQ 80MG BASE		N050795	004	Apr 11, 2013	Apr CFTG
AB	+	EQ 200MG BASE		N050795	005	Apr 11, 2013	May CFTG
		DORYX MPC					
	MAYNE PHARMA	EQ 60MG BASE		N050795	007	May 20, 2016	Jul CTNA
		EQ 60MG BASE		N050795	007	May 20, 2016	May NEWA
>D>		EQ 120MG BASE		N050795	008	May 20, 2016	Nov CRLD

TABLET, DELAYED RELEASE;ORAL
DORYX MPC

>A>	+	EQ 120MG BASE	N050795	008	May 20, 2016	Nov CRLD
		EQ 120MG BASE	N050795	008	May 20, 2016	Jul CTNA
		EQ 120MG BASE	N050795	008	May 20, 2016	May NEWA
		DOXYCYCLINE HYCLATE				
	@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar DISC
	@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar DISC
AB	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May NEWA
AB		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr NEWA
AB		EQ 200MG BASE	A090431	005	May 19, 2016	May NEWA
AB	PRINSTON INC	EQ 150MG BASE	A207494	001	Nov 15, 2016	Oct NEWA
AB		EQ 200MG BASE	A207494	002	Nov 15, 2016	Oct NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL
DICLEGIS

AB	+	10MG;10MG	N021876	001	Apr 08, 2013	Aug CFTG
		DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE				
AB	ACTAVIS LABS FL INC	10MG;10MG	A205811	001	Aug 19, 2016	Aug NEWA
		TABLET, EXTENDED RELEASE;ORAL				
>A>		BONJESTA				
>A>	+	20MG;20MG	N209661	001	Nov 07, 2016	Nov NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL
MELAMISA

AB	NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan NEWA
		TABLET;ORAL-28				
		DROSPIRENONE AND ETHINYL ESTRADIOL				
>A>	AB	ACCORD HLTHCARE	A207245	001	Nov 22, 2016	Nov NEWA
AB	APOTEX INC	3MG;0.03MG	A205876	001	Sep 21, 2016	Sep NEWA
AB	GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar NEWA
AB	MAYNE PHARMA	3MG;0.03MG	A090081	001	Sep 07, 2010	Aug CAHN

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL
BEYAZ

AB	BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep CFTG
		DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM				
AB	WATSON LABS INC	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	A203593	001	Oct 11, 2016	Sep NEWA
AB		3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	A203594	001	Oct 11, 2016	Sep NEWA
		SAFYRAL				
AB	+	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Sep CFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB	HETERO LABS LTD III	EQ 20MG BASE	A204343	001	Aug 03, 2016	Jul NEWA
AB		EQ 30MG BASE	A204343	002	Aug 03, 2016	Jul NEWA
AB		EQ 60MG BASE	A204343	003	Aug 03, 2016	Jul NEWA

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

AB	ASCENT PHARMS INC	0.5MG	A206574	001	Oct 21, 2016	Oct NEWA
AB	AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr CAHN
AB	BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan CAHN
AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb NEWA
AB	MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May NEWA
>D>	AB	ROXANE	A202204	001	Nov 23, 2015	Nov CAHN
AB	STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar CAHN
>A>	AB	WEST-WARD PHARMS INT	A202204	001	Nov 23, 2015	Nov CAHN

DYPHYLLINE

TABLET;ORAL
LUFYLLIN

@	MEDA PHARMS	200MG	A084566	001		Jun DISC
@		400MG	A084566	002		Jun DISC

ECONAZOLE NITRATE

	AEROSOL, FOAM;TOPICAL								
	ECOZA								
	+ EXELTIS SUISSE	1%		N205175	001	Oct 24, 2013	Jul	CAHN	
	CREAM;TOPICAL								
	ECONAZOLE NITRATE								
AB	TELIGENT PHARMA INC	1%		A076574	001	Dec 17, 2004	May	CAHN	
	SPECTAZOLE								
	@ ALVOGEN MALTA	1%		N018751	001	Dec 23, 1982	Jul	CAHN	

EDROPHONIUM CHLORIDE

	INJECTABLE;INJECTION								
	TENSILON PRESERVATIVE FREE								
	@ TELIGENT PHARMA INC	10MG/ML		N007959	002		Jan	CAHN	

EFAVIRENZ

	TABLET;ORAL								
	EFAVIRENZ								
AB	MYLAN LABS LTD	600MG		A091471	001	Feb 17, 2016	Feb	NEWA	
AB	MYLAN PHARMS INC	600MG		A091471	001	Feb 17, 2016	Jun	CAHN	
	SUSTIVA								
AB	+ BRISTOL MYERS SQUIBB	600MG		N021360	002	Feb 01, 2002	Feb	CFTG	

ELBASVIR; GRAZOPREVR

	TABLET;ORAL								
	ZEPATIER								
	+ MERCK SHARP DOHME	50MG;100MG		N208261	001	Jan 28, 2016	Jan	NEWA	

ELUXADOLINE

	TABLET;ORAL								
	VIBERZI								
	ALLERGAN HOLDINGS	75MG		N206940	001	May 27, 2015	May	CAHN	
	+	100MG		N206940	002	May 27, 2015	May	CAHN	

EMEDASTINE DIFUMARATE

	SOLUTION/DROPS;OPHTHALMIC								
	EMADINE								
>D>	+ ALCON	0.05%		N020706	001	Dec 29, 1997	Nov	CAHN	
>A>	+ NOVARTIS PHARMS CORP	0.05%		N020706	001	Dec 29, 1997	Nov	CAHN	

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

	TABLET;ORAL								
	ODEFSEY								
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE		N208351	001	Mar 01, 2016	Apr	CAIN	

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET;ORAL								
	ODEFSEY								
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE		N208351	001	Mar 01, 2016	Mar	NEWA	

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

	TABLET;ORAL								
	DESCOVY								
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE		N208215	001	Apr 04, 2016	Apr	NEWA	

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET;ORAL								
	TRUVADA								
	GILEAD	100MG;150MG		N021752	002	Mar 10, 2016	Mar	NEWA	
		133MG;200MG		N021752	003	Mar 10, 2016	Mar	NEWA	
		167MG;250MG		N021752	004	Mar 10, 2016	Mar	NEWA	

ENALAPRIL MALEATE

	SOLUTION;ORAL								
	EPANED								
	SILVERGATE PHARMS	1MG/ML		N208686	001	Sep 20, 2016	Sep	NEWA	

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ UPSHER-SMITH LABS 5MG; 12.5MG

A076116 001 Sep 19, 2001 Oct CAHN

@ 10MG; 25MG

A076116 002 Sep 19, 2001 Oct CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP + AMPHASTAR PHARMS INC 1.25MG/ML

A075634 001 Aug 22, 2000 Jun CAHN

AP + EUROHLTH INTL SARL 1.25MG/ML

A075634 001 Aug 22, 2000 Apr CAHN

ENFLURANE

LIQUID; INHALATION

ENFLURANE

@ PIRAMAL CRITICAL 99.9%

A074396 001 Jul 29, 1994 Aug DISC

ENTECAVIR

TABLET; ORAL

ENTECAVIR

>A> AB CIPLA LTD 0.5MG

A206872 001 Dec 06, 2016 Nov NEWA

>A> AB 1MG

A206872 002 Dec 06, 2016 Nov NEWA

>A> AB PAR PHARM INC 0.5MG

A206294 001 Nov 23, 2016 Nov NEWA

>A> AB 1MG

A206294 002 Nov 23, 2016 Nov NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOAZ

+ FLAMEL IRELAND LTD 50MG/ML

N208289 001 Apr 29, 2016 Apr NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

>A> AT ALCON RES LTD 0.05%

A203384 001 Dec 07, 2016 Nov NEWA

AT SOMERSET THERAPS LLC 0.05%

A090951 001 Oct 31, 2011 Mar CAHN

EPINEPHRINE

INJECTABLE; INJECTION

SUS-PHRINE SULFITE FREE

@ FOREST LABS 1.5MG/AMP

N007942 003 Feb 05, 1999 Mar CMS1

@ 5MG/ML

N007942 001 Mar CMS1

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

AUVI-Q

BX + KALEO INC EQ 0.15MG/DELIVERY

N201739 002 Aug 10, 2012 Mar CAHN

BX EQ 0.3MG/DELIVERY

N201739 001 Aug 10, 2012 Mar CAHN

TWINJECT 0.15

@ AMEDRA PHARMS EQ 0.15MG/DELIVERY

N020800 002 May 28, 2004 May DISC

TWINJECT 0.3

@ AMEDRA PHARMS EQ 0.3MG/DELIVERY

N020800 001 May 30, 2003 May DISC

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014 Jul CAIN

EPINEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014 Feb CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP IMPAX LABS INC 50MG/25ML (2MG/ML)

A065331 001 Aug 09, 2007 Aug CAHN

AP 200MG/100ML (2MG/ML)

A065331 002 Aug 09, 2007 Aug CAHN

AP WEST-WARD PHARMS INT 50MG/25ML (2MG/ML)

A065289 001 Jun 27, 2007 Sep CAHN

AP 200MG/100ML (2MG/ML)

A065289 002 Jun 27, 2007 Sep CAHN

EPTIFIBATIDE

INJECTABLE; INJECTION
EPTIFIBATIDE

>A>	AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	Nov NEWA
>A>	AP		75MG/100ML	A205581	002	Dec 08, 2016	Nov NEWA
		@ TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015	Aug DISC

ERGOALCIFEROL

CAPSULE; ORAL
DRISDOL

AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001		Jan CAHN
		VITAMIN D					
AA		BIONPHARMA INC	50,000 IU	A080704	001		Jan CAHN

ERGOLOID MESYLATES

TABLET; ORAL
ERGOLOID MESYLATES

AB		SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar CAHN
		TABLET; SUBLINGUAL					
		ERGOLOID MESYLATES					
		@ SUN PHARM INDS	0.5MG	A087407	001		Jun CAHN
		@	1MG	A087552	001		Jun CAHN

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR

+	TERSERA THERAP	2MG	A087693	001	Feb 24, 1983	Aug CAHN
---	----------------	-----	---------	-----	--------------	----------

ERYTHROMYCIN

SOLUTION; TOPICAL
C-SOLVE-2

		@ FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb DISC
		ERYTHRO-STATIN					
		@ HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb DISC
		ERYTHROMYCIN					
AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan CRLD
AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan CRLD

ESCITALOPRAM OXALATE

SOLUTION; ORAL
ESCITALOPRAM OXALATE

AA		MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754	001	Mar 31, 2016	Mar NEWA
----	--	---------------------	-----------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
ESMOLOL HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	10MG/ML	A076323	001	Aug 10, 2004	Oct CAHN
		SOLUTION; INTRAVENOUS					
		ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER					
	+	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016	Apr NEWA
		ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER					
	+	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun CRLD
			2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr NEWA
AB			EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr NEWA
BX		HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr CTEC
BX			EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP		AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Jul NEWA
AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul NEWA

ESTAZOLAM

TABLET; ORAL						
ESTAZOLAM						
AB	MAYNE PHARMA	1MG	A074921	001	Jul 10, 1997	Aug CAHN
AB	+	2MG	A074921	002	Jul 10, 1997	Aug CAHN

ESTRADIOL

CREAM; VAGINAL						
ESTRACE						
	+ ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr CAHN
FILM, EXTENDED RELEASE; TRANSDERMAL						
ALORA						
BX	ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN
TABLET; ORAL						
ESTRADIOL						
AB	EPIC PHARMA INC	0.5MG	A040275	001	Dec 29, 1998	Oct CMFD
AB		1MG	A040275	002	Dec 29, 1998	Oct CMFD
AB		2MG	A040275	003	Dec 29, 1998	Oct CMFD
AB	MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Aug CAHN
AB		1MG	A040114	001	Mar 14, 1996	Aug CAHN
AB		2MG	A040114	002	Mar 14, 1996	Aug CAHN
TABLET; VAGINAL						
ESTRADIOL						
AB	AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	Aug CMFD
VAGIFEM						
AB	+ NOVO NORDISK INC	10MCG	N020908	002	Nov 25, 2009	Aug CTEC

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL						
FEMRING						
	APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan CAHN
	+	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan CAHN
TABLET; ORAL						
FEMTRACE						
	APIL	0.45MG	N021633	001	Aug 20, 2004	Jan CAHN
		0.9MG	N021633	002	Aug 20, 2004	Jan CAHN
	+	1.8MG	N021633	003	Aug 20, 2004	Jan CAHN

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL						
ESTRASORB						
	+ EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL						
AMABELZ						
AB	LUPIN LTD	0.5MG; 0.1MG	A203339	001	Jun 20, 2016	Jun NEWA
AB		1MG; 0.5MG	A203339	002	Jun 20, 2016	Jun NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL						
CENESTIN						
@	TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun DISC
@		0.45MG	N020992	005	Feb 05, 2004	Jun DISC
@		0.625MG	N020992	002	Mar 24, 1999	Jun DISC
@		0.9MG	N020992	003	Mar 24, 1999	Jun DISC
@		1.25MG	N020992	004	Mar 13, 2000	Jun DISC

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL						
ENJUVIA						
@	TEVA WOMENS	0.625MG	N021443	003	May 10, 2004	Jun DISC
@		1.25MG	N021443	004	May 10, 2004	Sep DISC

ESZOPICLONETABLET; ORAL
ESZOPICLONE

AB	AUROBINDO PHARMA LTD	1MG	A208451	001	Sep 15, 2016	Sep NEWA
AB		2MG	A208451	002	Sep 15, 2016	Sep NEWA
AB		3MG	A208451	003	Sep 15, 2016	Sep NEWA
>D> AB	ROXANE	1MG	A091153	001	Apr 15, 2014	Nov CAHN
>D> AB		2MG	A091153	002	Apr 15, 2014	Nov CAHN
>D> AB		3MG	A091153	003	Apr 15, 2014	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	1MG	A091153	001	Apr 15, 2014	Nov CAHN
>A> AB		2MG	A091153	002	Apr 15, 2014	Nov CAHN
>A> AB		3MG	A091153	003	Apr 15, 2014	Nov CAHN

ETEPLIRSENSOLUTION; IV (INFUSION)
EXONDYS 51

+	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016	Sep NEWA
+		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016	Sep NEWA

ETHACRYNATE SODIUMINJECTABLE; INJECTION
ETHACRYNATE SODIUM

AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A204634	001	Aug 23, 2016	Aug NEWA
----	---------------------	-------------------	---------	-----	--------------	----------

ETHACRYNIC ACIDTABLET; ORAL
EDECRIN

AB	+ ATON	25MG	N016092	001		Jun CFTG
AB	EDENBRIDGE PHARMS	25MG	A205609	001	Jun 30, 2016	Jun NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATETABLET; ORAL-28
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	0.05MG; 1MG	A204704	001	Feb 09, 2016	Jan NEWA
AB	ZOVIA 1/35E-28					
AB	MAYNE PHARMA	0.035MG; 1MG	A072721	001	Dec 30, 1991	Aug CAHN
AB	ZOVIA 1/50E-28					
AB	+ WATSON LABS	0.05MG; 1MG	A072723	001	Dec 30, 1991	Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
FAYOSIM

AB	LUPIN LTD	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	A205943	001	Mar 29, 2016	Mar NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB	AMNEAL PHARMS	0.03MG; 0.15MG	A203871	001	Nov 13, 2015	Jul CAHN
>A> AB		0.03MG, 0.01MG; 0.15MG, N/A	A203872	001	Dec 22, 2015	Nov CAHN
>D> AB	HAUPT PHARMA	0.03MG, 0.01MG; 0.15MG, N/A	A203872	001	Dec 22, 2015	Nov CAHN
AB		0.03MG, 0.01MG; 0.15MG, N/A	A203872	001	Dec 22, 2015	Jul CMS1
AB	MAYNE PHARMA	0.02MG, 0.01MG; 0.1MG, N/A	A200407	001	Oct 25, 2011	Aug CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
AB	MAYNE PHARMA	0.03MG, 0.01MG; 0.15MG, N/A	A078834	001	May 31, 2011	Aug CAHN
	QUARTETTE					
AB	+ TEVA BRANDED PHARM	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	N204061	001	Mar 28, 2013	Mar CFTG

TABLET; ORAL-21

TRIVORA-21

@	MAYNE PHARMA	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A074538	001	Dec 18, 1997	Aug CAHN
---	--------------	--	---------	-----	--------------	----------

TABLET; ORAL-28

AFIRMELLE

AB1	AUROBINDO PHARMA LTD	0.02MG; 0.1MG	A206886	001	Nov 14, 2016	Oct NEWA
	AYUNA					
AB	AUROBINDO PHARMA LTD	0.03MG; 0.15MG	A206866	001	Sep 23, 2016	Sep NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	AMNEAL PHARMS	0.02MG; 0.1MG	A201108	001	Feb 05, 2014	May CAHN
AB		0.03MG; 0.15MG	A201095	001	Dec 08, 2014	Jul CAHN
AB1	+ MAYNE PHARMA	0.02MG; 0.1MG	A076625	001	Nov 18, 2004	Aug CAHN
AB2	+	0.02MG; 0.1MG	A077681	001	May 31, 2006	Aug CAHN

TABLET;ORAL-28							
LEVORA 0.15/30-28							
AB	+	MAYNE PHARMA	0.03MG;0.15MG	A073594	001	Dec 13, 1993	Aug CAHN
TRIVORA-28							
AB	+	MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	002	Dec 18, 1997	Aug CAHN
<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>							
TABLET;ORAL-21							
BREVICON 21-DAY							
@ ALLERGAN SALES LLC		0.035MG;0.5MG	N017566	001			Apr CAHN
NORINYL 1+35 21-DAY							
AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565	001		Mar CAHN
TRI-NORINYL 21-DAY							
@ MAYNE PHARMA		0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984		Aug CAHN
TABLET;ORAL-28							
BREVICON 28-DAY							
AB		ALLERGAN SALES LLC	0.035MG;0.5MG	N017743	001		Mar CAHN
CYONANZ							
AB		AUROBINDO PHARMA LTD	0.035MG;0.5MG	A207055	001	Oct 21, 2016	Oct NEWA
NORETHINDRONE AND ETHINYL ESTRADIOL							
AB		MAYNE PHARMA	0.035MG;0.5MG	A070686	001	Jan 29, 1987	Aug CAHN
NORINYL 1+35 28-DAY							
AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565	002		Mar CAHN
NYLIA 1/35							
AB		AUROBINDO PHARMA LTD	0.035MG;1MG	A207056	001	Oct 21, 2016	Oct NEWA
NYLIA 7/7/7							
AB		AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A207054	001	Oct 21, 2016	Oct NEWA
TRI-NORINYL 28-DAY							
AB	+	MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Aug CAHN
TABLET, CHEWABLE;ORAL							
FEMCON FE							
AB	+	APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+	APIL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan CAHN
AB		LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Mar NEWA
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>							
CAPSULE;ORAL							
TAYTULLA							
+ APIL		0.02MG;1MG	N204426	001	Apr 19, 2013		Aug CTNA
@		0.02MG;1MG	N204426	001	Apr 19, 2013		Apr CAHN
TABLET;ORAL							
FEMHRT							
AB		APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan CAHN
@		0.005MG;1MG	N021065	002	Oct 15, 1999		Jan CAHN
LERIBANE							
AB		NOVAST LABS LTD	0.0025MG;0.5MG	A203435	002	Jun 03, 2016	May NEWA
AB			0.005MG;1MG	A203435	001	Jun 03, 2016	May NEWA
LO LOESTRIN FE							
AB	+	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May CFTG
AB	+		0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan CAHN
LOESTRIN 24 FE							
AB		APIL	0.02MG;1MG	N021871	001	Feb 17, 2006	Aug CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB		JAI PHARMA LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May NEWA
TABLET;ORAL-21							
ESTROSTEP 21							
@ APIL		0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996		Jan CAHN
LOESTRIN 21 1.5/30							
AB		APIL	0.03MG;1.5MG	N017875	001		Apr CAHN
LOESTRIN 21 1/20							
AB		APIL	0.02MG;1MG	N017876	001		Apr CAHN
MICROGESTIN 1.5/30							
AB		MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Aug CAHN
MICROGESTIN 1/20							
AB		MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Aug CAHN

ETHOSUXIMIDE

	CAPSULE; ORAL						
	ETHOSUXIMIDE						
AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan	CAHN

ETIDRONATE DISODIUM

	TABLET; ORAL						
	DIDRONEL						
AB	APIL	200MG	N017831	001		Apr	CAHN
AB	+	400MG	N017831	002		Apr	CAHN

ETODOLAC

	CAPSULE; ORAL						
	ETODOLAC						
	@ IDT AUSTRALIA LTD	200MG	A074840	001	Aug 29, 1997	May	CAHN
	@	300MG	A074840	002	Aug 29, 1997	May	CAHN
	@ LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	ETODOLAC						
	@ IDT AUSTRALIA LTD	400MG	A075943	001	Jul 26, 2002	Aug	CAHN
	@	500MG	A075943	002	Jul 26, 2002	Aug	CAHN
	@	600MG	A075943	003	Jul 26, 2002	Aug	CAHN

ETOMIDATE

	INJECTABLE; INJECTION						
	ETOMIDATE						
AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb	NEWA

ETOPOSIDE

	INJECTABLE; INJECTION						
	ETOPOSIDE						
AP	WEST-WARD PHARMS INT	20MG/ML	A074290	001	Jul 17, 1995	Sep	CAHN

EXEMESTANE

	TABLET; ORAL						
	EXEMESTANE						
AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan	CAHN
>D> AB	ROXANE	25MG	A077431	001	Apr 01, 2011	Nov	CAHN
>A> AB	WEST-WARD PHARMS INT	25MG	A077431	001	Apr 01, 2011	Nov	CAHN

EXENATIDE SYNTHETIC

	FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS							
	BYDUREON PEN							
	+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb	NEWA

EZETIMIBE

	TABLET; ORAL							
	EZETIMIBE							
AB	GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Oct	CMFD	
	ZETIA							
AB	+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Oct	CTEC

FAMCICLOVIR

	TABLET; ORAL						
	FAMCICLOVIR						
>D> AB	ROXANE	125MG	A090128	001	Mar 21, 2011	Nov	CAHN
>D> AB		250MG	A090128	002	Mar 21, 2011	Nov	CAHN
>D> AB		500MG	A090128	003	Mar 21, 2011	Nov	CAHN
>A> AB	WEST-WARD PHARMS INT	125MG	A090128	001	Mar 21, 2011	Nov	CAHN
>A> AB		250MG	A090128	002	Mar 21, 2011	Nov	CAHN
>A> AB		500MG	A090128	003	Mar 21, 2011	Nov	CAHN

FAMOTIDINE

	INJECTABLE; INJECTION						
	FAMOTIDINE						
AP	AMPHASTAR PHARMS INC	10MG/ML	A075651	001	Apr 16, 2001	Jun	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Jun	CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Apr	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Apr	CAHN

INJECTABLE;INJECTION

FAMOTIDINE PRESERVATIVE FREE

AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN

TABLET;ORAL

FAMOTIDINE

@	SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar CAHN
@		40MG	A075639	001	Dec 12, 2001	Mar CAHN

FELBAMATE

TABLET;ORAL

FELBAMATE

AB	ALVOGEN MALTA	400MG	A204595	001	Jan 11, 2016	Aug CAHN
AB		600MG	A204595	002	Jan 11, 2016	Aug CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB	JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Aug NEWA
AB		5MG	A203983	002	Aug 19, 2016	Aug NEWA
AB		10MG	A203983	003	Aug 19, 2016	Aug NEWA
AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

>A>	AB	RHODES PHARMS	67MG	A075753	001	Sep 03, 2002	Nov CAHN
>A>	AB		134MG	A075753	002	Apr 09, 2002	Nov CAHN
>A>	AB	+	200MG	A075753	003	Apr 09, 2002	Nov CAHN
>D>	AB	TEVA	67MG	A075753	001	Sep 03, 2002	Nov CAHN
>D>	AB		134MG	A075753	002	Apr 09, 2002	Nov CAHN
>D>	AB	+	200MG	A075753	003	Apr 09, 2002	Nov CAHN

TABLET;ORAL

FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA	
AB		145MG	A205118	002	May 05, 2016	Apr NEWA	
AB	HETERO LABS LTD III	48MG	A204598	001	Jul 12, 2016	Jun NEWA	
AB		145MG	A204598	002	Jul 12, 2016	Jun NEWA	
AB	MYLAN	40MG	A204475	001	Jun 23, 2016	Jun NEWA	
AB		120MG	A204475	002	Jun 23, 2016	Jun NEWA	
>A>	AB	RHODES PHARMS	54MG	A076433	001	May 13, 2005	Nov CAHN
>A>	AB	+	160MG	A076433	002	May 13, 2005	Nov CAHN
>D>	AB	TEVA	54MG	A076433	001	May 13, 2005	Nov CAHN
>D>	AB	+	160MG	A076433	002	May 13, 2005	Nov CAHN

FENOGLIDE

AB	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Jun CFTG
AB	+	120MG	N022118	002	Aug 10, 2007	Jun CFTG

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

	ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Apr CAHN
+		105MG	N022418	002	Aug 14, 2009	Apr CAHN
	ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009	Jun CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Oct CAHN
----	----------------------	-----------------	---------	-----	--------------	----------

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar CAHN
@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN

TABLET; ORAL

FENOPROFEN CALCIUM

@ AUROLIFE PHARMA LLC EQ 600MG BASE
 @ SUN PHARM INDS EQ 600MG BASE

A072396 001 Oct 17, 1988 Feb CAHN
 A072902 001 Dec 21, 1990 Mar CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB 3M DRUG DELIVERY 100MCG/HR

A202097 005 Nov 04, 2016 Oct NEWA

FENTANYL-12

AB 3M DRUG DELIVERY 12.5MCG/HR

A202097 001 Nov 04, 2016 Oct NEWA

AB AVEVA 12.5MCG/HR

A077449 005 Sep 11, 2015 Jan NEWA

FENTANYL-25

AB 3M DRUG DELIVERY 25MCG/HR

A202097 002 Nov 04, 2016 Oct NEWA

FENTANYL-50

AB 3M DRUG DELIVERY 50MCG/HR

A202097 003 Nov 04, 2016 Oct NEWA

FENTANYL-75

AB 3M DRUG DELIVERY 75MCG/HR

A202097 004 Nov 04, 2016 Oct NEWA

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP + WEST-WARD PHARMS INT EQ 0.05MG BASE/ML

N019101 001 Jul 11, 1984 Oct CAHN

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION; INTRAVENOUS

TRIFERIC

+ ROCKWELL MEDICAL INC 272MG IRON/PACKET

N208551 001 Apr 25, 2016 Apr NEWA

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

@ ALKEM LABS LTD 4MG
 @ 8MG

A204827 001 Dec 10, 2015 Jan DISC
 A204827 002 Dec 10, 2015 Jan DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ BARR 60MG; 120MG
 @ IMPAX PHARMS 60MG; 120MG

A076236 001 Apr 14, 2005 Mar DISC
 A076298 001 Nov 12, 2010 Mar DISC

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

>D> + ALCON RES LTD 0.3%
 >A> + NOVARTIS PHARMS CORP 0.3%

N206307 001 Dec 17, 2014 Nov CAHN
 N206307 001 Dec 17, 2014 Nov CAHN

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

SMOFLIPID 20%

+ FRESENIUS KABI USA 3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (100ML) N207648 001 Jul 13, 2016 Jul NEWA
 + 3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (250ML) N207648 002 Jul 13, 2016 Jul NEWA
 + 3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (500ML) N207648 003 Jul 13, 2016 Jul NEWA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS 100MG

A076234 001 Aug 28, 2003 Mar DISC

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

@ IDT AUSTRALIA LTD 50MG
 @ 100MG
 @ 150MG

A076030 001 Oct 28, 2002 May CAHN
 A076030 002 Oct 28, 2002 May CAHN
 A076030 003 Oct 28, 2002 May CAHN

>D> AB ROXANE 50MG

A076278 001 Jan 14, 2003 Nov CAHN

>D> AB 100MG

A076278 002 Jan 14, 2003 Nov CAHN

>D> AB + 150MG

A076278 003 Jan 14, 2003 Nov CAHN

>A> AB WEST-WARD PHARMS INT 50MG

A076278 001 Jan 14, 2003 Nov CAHN

		TABLET;ORAL					
		FLECAINIDE ACETATE					
>A>	AB	100MG	A076278	002	Jan 14, 2003	Nov	CAHN
>A>	AB	150MG	A076278	003	Jan 14, 2003	Nov	CAHN
		TAMBOCOR					
	AB	50MG	N018830	004	Aug 23, 1988	Oct	CMFD
	AB	100MG	N018830	001	Oct 31, 1985	Oct	CMFD
	AB	150MG	N018830	003	Jun 03, 1988	Oct	CMFD
<u>FLORBETAPIR F-18</u>							
		SOLUTION;INTRAVENOUS					
		AMYVID					
	@ AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012	Sep	DISC
<u>FLOXURIDINE</u>							
		INJECTABLE;INJECTION					
		FLOXURIDINE					
AP	+ WEST-WARD PHARMS INT	500MG/VIAL	A075387	001	Apr 16, 2000	Oct	CAHN
<u>FLUCICLOVINE F-18</u>							
		SOLUTION;INTRAVENOUS					
		AXUMIN					
	+ BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May	NEWA
<u>FLUCONAZOLE</u>							
		FOR SUSPENSION;ORAL					
		FLUCONAZOLE					
>D>	AB	50MG/5ML	A076246	001	Jul 29, 2004	Nov	CAHN
>D>	AB	200MG/5ML	A076246	002	Jul 29, 2004	Nov	CAHN
	@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb	DISC
	@	200MG/5ML	A076332	002	Jul 29, 2004	Feb	DISC
>A>	AB	50MG/5ML	A076246	001	Jul 29, 2004	Nov	CAHN
>A>	AB	200MG/5ML	A076246	002	Jul 29, 2004	Nov	CAHN
		INJECTABLE;INJECTION					
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9%					
	@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan	DISC
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan	DISC
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CMS1
AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CMS1
		TABLET;ORAL					
		FLUCONAZOLE					
	@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May	CAHN
	@	100MG	A076086	002	Jul 29, 2004	May	CAHN
	@	150MG	A076086	003	Jul 29, 2004	May	CAHN
	@	200MG	A076086	004	Jul 29, 2004	May	CAHN
<u>FLUDARABINE PHOSPHATE</u>							
		INJECTABLE;INJECTION					
		FLUDARABINE PHOSPHATE					
AP	SAGENT PHARMS	50MG/VIAL	A076349	001	Aug 28, 2003	Aug	CAHN
AP		50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Aug	CAHN
<u>FLUDEOXYGLUCOSE F-18</u>							
		INJECTABLE;INTRAVENOUS					
		FLUDEOXYGLUCOSE F18					
AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar	NEWA
>A>	AP	MEM SLOAN-KETTERING	A208679	001	Dec 08, 2016	Nov	NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar	CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb	CAHN
<u>FLUOCINOLONE ACETONIDE</u>							
		OIL;TOPICAL					
		FLUOCINOLONE ACETONIDE					
AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr	NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr	NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May	NEWA
AT		0.01%	A209336	001	May 19, 2016	May	NEWA
		OIL/DROPS;OTIC					
		FLUOCINOLONE ACETONIDE					
AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr	NEWA

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Oct NEWA
AT		G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Sep NEWA

FLUOCINONIDE

OINTMENT;TOPICAL

LIDEX

AB		CNTY LINE PHARMS	0.05%	N016909	002		Sep CMFD
----	--	------------------	-------	---------	-----	--	----------

FLUORESCCEIN SODIUM

INJECTABLE;INTRAVENOUS

FLUORESCITE

>D>	AP	+	ALCON PHARMS LTD	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Nov CAHN
>A>	AP	+	NOVARTIS PHARMS CORP	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Nov CAHN

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

FLAREX

>D>		+	ALCON	0.1%	N019079	001	Feb 11, 1986	Nov CAHN
>A>		+	NOVARTIS PHARMS CORP	0.1%	N019079	001	Feb 11, 1986	Nov CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP			SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP				5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
>A>		+	SPECTRUM PHARMS	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016	Nov NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

@ SUN PHARM INDS

EQ 10MG BASE

A075787 001 Jan 29, 2002 Mar CAHN

@

EQ 20MG BASE

A075787 002 Jan 29, 2002 Mar CAHN

FLUOXETINE HYDROCHLORIDE

MYLAN

EQ 10MG BASE

A078045 001 Nov 17, 2008 Sep CTEC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

@ LANNETT

EQ 20MG BASE/5ML

A076458 001 May 14, 2004 Aug DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

		+	EDGE MONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar CRLD
AB		+	MYLAN	EQ 20MG BASE	A075755	002	Aug 02, 2001	Aug CTEC
AB			PAR FORM	EQ 10MG BASE	A203836	001	Aug 19, 2016	Aug NEWA
AB				EQ 20MG BASE	A203836	002	Aug 19, 2016	Aug NEWA
AB1			TORRENT PHARMS LTD	EQ 10MG BASE	A206937	001	Oct 21, 2016	Oct NEWA
AB1				EQ 20MG BASE	A206937	002	Oct 21, 2016	Oct NEWA
			SARAFEM					
AB1			APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
AB1				EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN
AB1		+		EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO			WEST-WARD PHARMS INT	25MG/ML	A074531	001	Aug 30, 1996	Sep CAHN
----	--	--	----------------------	---------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB			LANNETT	1MG	A089743	002	Aug 25, 1988	Sep NEWA
AB				2.5MG	A089743	003	Aug 25, 1988	Sep NEWA
AB				5MG	A089743	004	Aug 25, 1988	Sep NEWA
AB			SANDOZ	1MG	A089586	002	Oct 16, 1987	Oct CMS1
AB				2.5MG	A089586	003	Oct 16, 1987	Oct CMS1
AB				5MG	A089586	004	Oct 16, 1987	Oct CMS1

FLURANDRENOLIDE

CREAM; TOPICAL						
CORDRAN SP						
AT	+ AQUA PHARMS	0.05%	N012806	002		Mar CFTG
FLURANDRENOLIDE						
AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar NEWA
LOTION; TOPICAL						
CORDRAN						
AT	+ AQUA PHARMS	0.05%	N013790	001		Aug CTEC
FLURANDRENOLIDE						
AT	PERRIGO UK FINCO	0.05%	A207133	001	Aug 30, 2016	Aug NEWA
TAPE; TOPICAL						
CORDRAN						
	+ ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001		Apr CAHN

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL						
CORDRAN N						
	@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001		Mar CMS1
OINTMENT; TOPICAL						
CORDRAN N						
	@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001		Mar CMS1

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL						
FLURAZEPAM HYDROCHLORIDE						
	@ AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb CAHN
	@	30MG	A071717	001	Jul 31, 1991	Feb CAHN
	@ HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986	May CAHN
	@ SUN PHARM INDS	15MG	A070454	001	Aug 04, 1986	Mar CAHN
	@	30MG	A070455	001	Aug 04, 1986	Mar CAHN

FLURBIPROFEN

TABLET; ORAL						
FLURBIPROFEN						
	@ AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995	Feb CAHN
	@	100MG	A074448	002	Jul 28, 1995	Feb CAHN

FLUTAMIDE

CAPSULE; ORAL						
FLUTAMIDE						
AB	+ CIPLA LTD	125MG	A075780	001	Sep 19, 2001	Sep CAHN

FLUTICASONE FUROATE

POWDER; INHALATION						
ARNUITY ELLIPTA						
	+ GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Mar CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION						
BREO ELLIPTA						
	+ GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Mar CRLD

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL						
FLONASE						
	@ GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jun DISC
FLUTICASONE PROPIONATE						
>D> AB	ROXANE	0.05MG/SPRAY	A076504	001	Feb 22, 2006	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	0.05MG/SPRAY	A076504	001	Feb 22, 2006	Nov CAHN

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL						
FLUVASTATIN SODIUM						
AB	MYLAN PHARMS INC	EQ 80MG BASE	A202458	001	Sep 11, 2015	May CPOT
AB	TEVA PHARMS USA	EQ 80MG BASE	A079011	001	Jan 27, 2016	May CPOT
AB		80MG	A079011	001	Jan 27, 2016	Jan NEWA
LESCOL XL						
AB	+ NOVARTIS	EQ 80MG BASE	N021192	001	Oct 06, 2000	May CPOT

FLUVOXAMINE MALEATE

TABLET; ORAL							
FLUVOXAMINE MALEATE							
	@ NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb	CAHN
	@	50MG	A075900	002	Feb 23, 2006	Feb	CAHN
	@	100MG	A075900	003	Feb 23, 2006	Feb	CAHN
	@ SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002	Mar	CAHN
	@	50MG	A076125	002	Apr 29, 2002	Mar	CAHN
	@	100MG	A076125	003	Apr 29, 2002	Mar	CAHN
	@ UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001	Oct	CAHN
AB		25MG	A075888	001	Nov 29, 2000	Oct	CAHN
	@	50MG	A075887	002	Jan 05, 2001	Oct	CAHN
AB		50MG	A075888	002	Nov 29, 2000	Oct	CAHN
	@	100MG	A075887	003	Jan 05, 2001	Oct	CAHN
AB	+	100MG	A075888	003	Nov 29, 2000	Oct	CAHN

FOLIC ACID

INJECTABLE; INJECTION							
FOLVITE							
	@ WYETH PHARMS INC	5MG/ML	N005897	008		May	CAHN
TABLET; ORAL							
FOLIC ACID							
	@ SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005	Mar	CAHN
FOLVITE							
	@ WYETH PHARMS INC	1MG	N005897	004		May	CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS							
FOLLISTIM AQ							
	@ ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005	Jun	DISC
	@	150 IU/0.5ML	N021273	002	Aug 26, 2005	Jun	DISC

FOMEPIZOLE

INJECTABLE; INJECTION									
ANTIZOL									
AP	+	PAR PHARM INC	1.5GM/1.5ML (1GM/ML)	N020696	001	Dec 04, 1997	Oct	CAHN	

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION							
BEVESPI AEROSPHERE							
+	PEARL THERAPS INC	0.0048MG/INH; 0.0090MG/INH	N208294	001	Apr 25, 2016	Apr	NEWA

FOSAMPRENAVIR CALCIUM

TABLET; ORAL							
FOSAMPRENAVIR CALCIUM							
AB	MYLAN PHARMS INC	EQ 700MG BASE	A204060	001	Apr 15, 2016	Apr	NEWA
LEXIVA							
AB	+ VIIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr	CFTG

FOSAPREPITANT DIMEGLUMINE

	POWDER; INTRAVENOUS							
	EMEND							
AP	+	MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010	May	CFTG
	FOSAPREPITANT DIMEGLUMINE							
AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016	May	NEWA

FOSINOPRIL SODIUM

TABLET; ORAL								
FOSINOPRIL SODIUM								
	@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan	DISC
	@		20MG	A076620	002	Oct 15, 2004	Jan	DISC
	@		40MG	A076620	003	Oct 15, 2004	Jan	DISC
AB		PRINSTON INC	10MG	A205670	001	Aug 29, 2016	Aug	NEWA
AB			20MG	A205670	002	Aug 29, 2016	Aug	NEWA
AB			40MG	A205670	003	Aug 29, 2016	Aug	NEWA
>D>	@	SANDOZ	10MG	A076188	001	Oct 08, 2004	Nov	CAHN
>D>	@		20MG	A076188	002	Oct 08, 2004	Nov	CAHN
>D>	@		40MG	A076188	003	Oct 08, 2004	Nov	CAHN
>A>	@	UPSHER-SMITH LABS	10MG	A076188	001	Oct 08, 2004	Nov	CAHN
AB			10MG	A076483	001	Apr 23, 2004	Oct	CAHN
>A>	@		20MG	A076188	002	Oct 08, 2004	Nov	CAHN

TABLET;ORAL

FOSINOPRIL SODIUM

AB		20MG	A076483	002	Apr 23, 2004	Oct CAHN
>A>	@	40MG	A076188	003	Oct 08, 2004	Nov CAHN
AB		40MG	A076483	003	Apr 23, 2004	Oct CAHN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan DISC
@		20MG;12.5MG	A076608	002	Dec 03, 2004	Jan DISC
@	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb DISC
@		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

CEREBYX

AP	+	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Aug CRLD
		FOSPHENYTOIN SODIUM					
		@ FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Aug DISC

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb NEWA
----	--	---------------------	---------------	---------	-----	--------------	----------

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul NEWA
AP		CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May CAHN
	@	EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN
	@	WEST-WARD PHARMS INT	10MG/ML	A071439	001	Sep 14, 1990	Oct CAHN
	@		10MG/ML	N018267	001		Oct CAHN

SOLUTION;ORAL

FUROSEMIDE

>D>	AA	+	ROXANE	10MG/ML	A070434	001	Apr 22, 1987	Nov CAHN
>D>				40MG/5ML	A070433	001	Apr 22, 1987	Nov CAHN
>A>	AA	+	WEST-WARD PHARMS INT	10MG/ML	A070434	001	Apr 22, 1987	Nov CAHN
>A>				40MG/5ML	A070433	001	Apr 22, 1987	Nov CAHN

TABLET;ORAL

FUROSEMIDE

>D>	AB		ROXANE	80MG	A070086	001	Jan 24, 1986	Nov CAHN
		@	SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar CAHN
		@		80MG	A070100	001	Jan 26, 1988	Mar CAHN
>A>	AB		WEST-WARD PHARMS INT	80MG	A070086	001	Jan 24, 1986	Nov CAHN
			LASIX					
	AB		US PHARM HOLDINGS	20MG	N016273	002		Jan CAHN
	AB			40MG	N016273	001		Jan CAHN
	AB	+		80MG	N016273	003		Jan CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb NEWA
AB			300MG	A204989	002	Feb 18, 2016	Feb NEWA
AB			400MG	A204989	003	Feb 18, 2016	Feb NEWA
	@	SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar CAHN
	@		300MG	A076537	002	Jun 30, 2005	Mar CAHN
	@		400MG	A076537	003	Jun 30, 2005	Mar CAHN
	@	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Sep DISC
	@		300MG	A076606	002	Oct 07, 2005	Sep DISC
	@		400MG	A076606	003	Oct 07, 2005	Sep DISC

SOLUTION;ORAL

GABAPENTIN

AA		TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb NEWA
----	--	-----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

GABAPENTIN

AB		SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan NEWA
AB			800MG	A205101	002	Feb 04, 2016	Jan NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL
HORIZANT

ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011	Jul CAHN
+	600MG	N022399	001	Apr 06, 2011	Jul CAHN

GADOFOSVESET TRISODIUM

SOLUTION;INTRAVENOUS
ABLAVAR

@ LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008	Sep DISC
@	3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008	Sep DISC

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL
GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895	001	Aug 05, 2016	Jul NEWA
AB		EQ 16MG BASE	A204895	002	Aug 05, 2016	Jul NEWA
AB		EQ 24MG BASE	A204895	003	Aug 05, 2016	Jul NEWA
	@ IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb DISC
	@	EQ 16MG BASE	A078484	002	May 27, 2009	Feb DISC
	@	EQ 24MG BASE	A078484	003	May 27, 2009	Feb DISC

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

>D>	+	ROXANE	4MG/ML	A078185	001	Jan 30, 2009	Nov CAHN
	+		4MG/ML	A078185	001	Jan 30, 2009	May CRLD
>A>	+	WEST-WARD PHARMS INT	4MG/ML	A078185	001	Jan 30, 2009	Nov CAHN
		RAZADYNE					
	@	JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May DISC

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB	ROXANE	EQ 4MG BASE	A077608	001	Feb 11, 2009	Nov CAHN
>D>	AB		EQ 8MG BASE	A077608	002	Feb 11, 2009	Nov CAHN
>D>	AB		EQ 12MG BASE	A077608	003	Feb 11, 2009	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 4MG BASE	A077608	001	Feb 11, 2009	Nov CAHN
>A>	AB		EQ 8MG BASE	A077608	002	Feb 11, 2009	Nov CAHN
>A>	AB		EQ 12MG BASE	A077608	003	Feb 11, 2009	Nov CAHN

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS
NETSPOT

+	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016	Aug NEWA
---	-------------	---------------	---------	-----	--------------	----------

GANCICLOVIR SODIUM

INJECTABLE;INJECTION
GANCICLOVIR

>A>	AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	Nov NEWA
		GANCICLOVIR SODIUM					
		@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Oct CAHN

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun NEWA
----	---------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar NEWA	
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar NEWA	
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar NEWA	
AP	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar CFTG
AP	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar CFTG
AP	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar CFTG

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB	CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun NEWA
----	-------------------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATEINJECTABLE; INJECTION
GENTAMICIN SULFATE@ WEST-WARD PHARMS INT EQ 10MG BASE/ML
@ EQ 40MG BASE/MLA062251 002
A062251 001Oct CAHN
Oct CAHNGLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE@ ACTAVIS LABS FL INC 1MG
@ 2MG
@ 4MGA076995 001 Apr 27, 2010 Jan DISC
A076995 002 Apr 27, 2010 Jan DISC
A076995 003 Apr 27, 2010 Jan DISCGLIMEPIRIDE; ROSIGLITAZONE MALEATETABLET; ORAL
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE+ TEVA PHARMS USA 1MG; 4MG
2MG; 4MG
2MG; 8MG
4MG; 4MG
4MG; 8MGA078709 001 Apr 01, 2016 Mar NEWA
A078709 002 Apr 01, 2016 Mar NEWA
A078709 004 Apr 01, 2016 Mar NEWA
A078709 003 Apr 01, 2016 Mar NEWA
A078709 005 Apr 01, 2016 Mar NEWAGLUTETHIMIDETABLET; ORAL
GLUTETHIMIDE>D> @ SANDOZ 500MG
>A> @ UPSHER-SMITH LABS 500MGA083234 002 Nov CAHN
A083234 002 Nov CAHNGLYBURIDETABLET; ORAL
GLYBURIDEAB1 PHARMADAX INC 1.25MG
AB1 2.5MG
AB1 5MG
AB1 ZYDUS PHARMS USA INC 1.25mg
AB1 2.5mg
AB1 5MGA203581 001 Apr 14, 2016 Apr NEWA
A203581 002 Apr 14, 2016 Apr NEWA
A203581 003 Apr 14, 2016 Apr NEWA
A206749 001 May 10, 2016 Apr NEWA
A206749 002 May 10, 2016 Apr NEWA
A206749 003 May 10, 2016 Apr NEWAGLYBURIDE; METFORMIN HYDROCHLORIDETABLET; ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE@ COREPHARMA 1.25MG; 250MG
@ 2.5MG; 500MG
@ 5MG; 500MG
AB IMPAX LABS INC 1.25MG; 250MG
AB 2.5MG; 500MG
AB 5MG; 500MG
AB ZYDUS PHARMS USA INC 1.25MG; 250MG
AB 2.5MG; 500MG
AB 5MG; 500MGA076731 001 Nov 19, 2004 Jan DISC
A076731 002 Nov 19, 2004 Jan DISC
A076731 003 Nov 19, 2004 Jan DISC
A076345 001 Feb 18, 2004 Aug CAHN
A076345 002 Feb 18, 2004 Aug CAHN
A076345 003 Feb 18, 2004 Aug CAHN
A206748 001 Feb 29, 2016 Feb NEWA
A206748 002 Feb 29, 2016 Feb NEWA
A206748 003 Feb 29, 2016 Feb NEWAGLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATEAP + HIKMA FARMACEUTICA 0.2MG/ML
ROBINUL
@ EUROHLTH INTL SARL 0.2MG/ML
@ WEST-WARD PHARMS INT 0.2MG/MLA090963 001 Sep 21, 2011 Feb CRLD
N017558 001 Feb DISC
N017558 001 Oct CAHN

TABLET; ORAL

GLYCOPYRROLATE

@ HIKMA INTL PHARMS 1MG
@ 2MG
AA NATCO PHARMA LTD 1MG
AA 2MG
AA RISING PHARMS INC 1MG
AA 2MGA040836 001 Mar 05, 2009 May CAHN
A040836 002 Mar 05, 2009 May CAHN
A091413 001 Jun 20, 2016 Jun NEWA
A091413 002 Jun 20, 2016 Jun NEWA
A040821 001 Dec 29, 2008 Jan CAHN
A040821 002 Dec 29, 2008 Jan CAHN

ROBINUL

AA + CASPER PHARMA LLC 1MG
ROBINUL FORTE
AA + CASPER PHARMA LLC 2MGN012827 001 Jan CAHN
N012827 002 Jan CAHN

GRANISETRONFILM, EXTENDED RELEASE;TRANSDERMAL
SANCUSO

+	KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008	Aug CAHN
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS						
SUSTOL						
+	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug NEWA

GRANISETRON HYDROCHLORIDEINJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun NEWA
AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG	A078863	001	Jun 30, 2008	Jan CAHN
		BASE/ML)				
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@ CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG	A078197	001	Dec 31, 2007	May CAHN
		BASE/ML)				
AP	HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN
TABLET;ORAL						
GRANISETRON HYDROCHLORIDE						
	@ COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
>D> AB	ROXANE	EQ 1MG BASE	A077842	001	Dec 31, 2007	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	EQ 1MG BASE	A077842	001	Dec 31, 2007	Nov CAHN

GRISEOFULVIN, MICROSIZESUSPENSION;ORAL
GRISEOFULVIN

AB	CIPLA LTD	125MG/5ML	A065354	001	Sep 10, 2007	Sep CAHN
----	-----------	-----------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION;ORAL
HYCOFENIX

+	MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
---	----------------------	------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

	@ IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
	@	EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
	@	EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
	@	EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC

HALOBETASOL PROPIONATELOTION;TOPICAL
ULTRAVATE

+	SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

HALOPERIDOLTABLET;ORAL
HALOPERIDOL

	@ CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
	@ FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Jul CAHN
	@	1MG	A071157	001	Jan 02, 1987	Jul CAHN
	@	2MG	A071172	001	Jan 02, 1987	Jul CAHN
	@	5MG	A071212	001	Jan 07, 1988	Jul CAHN
	@	10MG	A071173	001	Jan 07, 1988	Jul CAHN
	@ SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
	@	1MG	A071157	001	Jan 02, 1987	Jun CAHN
	@	2MG	A071172	001	Jan 02, 1987	Mar CAHN
	@	5MG	A071212	001	Jan 07, 1988	Mar CAHN
	@	10MG	A071173	001	Jan 07, 1988	Mar CAHN
	@	20MG	A071177	001	Jan 07, 1988	Mar CAHN
	@ VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
	@	1MG	A071235	003	Nov 03, 1986	Jan CMS1
	@	5MG	A071235	004	Nov 03, 1986	Jan CMS1
	@	10MG	A071235	005	Jul 20, 1987	Jan CMS1

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Sep CAHN
AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Oct CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Oct CAHN
----	----------------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

AP	FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May NEWA
AP	+ WEST-WARD PHARMS INT	1,000 UNITS/ML	N017037	001		Oct CAHN
AP	+	5,000 UNITS/ML	N017037	002		Oct CAHN
	@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Oct CAHN
AP	+	10,000 UNITS/ML	N017037	003		Oct CAHN

HEXACHLOROPHENE

EMULSION; TOPICAL
PHISOHEX

@	SANOFI AVENTIS US	3%	N006882	001		May DISC
---	-------------------	----	---------	-----	--	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
@ ACTAVIS ELIZABETH 1.5MG; 5MG

A040295	001	Dec 01, 2000	Jan CMS1
---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
----	---------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	@ ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC
	@	25MG	A091679	002	Mar 04, 2013	Apr DISC
	@	50MG	A091679	003	Mar 04, 2013	Apr DISC
	@	100MG	A091679	004	Mar 04, 2013	Apr DISC
	@ FRONTIDA BIOPHARM	10MG	A089359	001	Jul 25, 1986	Jul CAHN
	@	25MG	A089258	001	May 05, 1986	Jul CAHN
	@	50MG	A089259	001	May 05, 1986	Jul CAHN
	@	100MG	A088729	001	Apr 11, 1985	Jul CAHN
>D>	@ SANDOZ	10MG	A083241	001		Nov CAHN
>D>	@	25MG	A083560	001		Nov CAHN
>D>	@	50MG	A083561	001		Nov CAHN
	@ SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar CAHN
	@	25MG	A089258	001	May 05, 1986	Mar CAHN
	@	50MG	A089259	001	May 05, 1986	Mar CAHN
	@	100MG	A088729	001	Apr 11, 1985	Jun CAHN
>A>	@ UPSHER-SMITH LABS	10MG	A083241	001		Nov CAHN
>A>	@	25MG	A083560	001		Nov CAHN
>A>	@	50MG	A083561	001		Nov CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDRALAZINE AND HYDROCHLOROTHIAZIDE
@ WATSON LABS 25MG; 15MG

A085827	001		Feb CMS1
---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
@ SUN PHARM INDS 25MG; 15MG; 0.1MG

A088570	001	Apr 10, 1984	Mar CAHN
---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

	@ LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Aug DISC
AB	+ ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	@ AUROLIFE PHARMA LLC	25MG	A083899	001		Feb CAHN
	@	50MG	A085219	001		Feb CAHN
	@ HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006	May CAHN
AB		50MG	A084878	001		May CAHN
	@ LANNETT	25MG	A084325	001		Aug DISC
	@	50MG	A084324	001		Aug DISC
	@ SUN PHARM INDS	25MG	A083972	001		Mar CAHN
	@	50MG	A083972	002		Mar CAHN
	@	100MG	A083972	003		Mar CAHN
	ORETIC					
	@ ABBVIE	50MG	N011971	002		Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;150MG	A091370	001	Oct 15, 2012	Sep CAHN
AB		12.5MG;300MG	A091370	002	Oct 15, 2012	Sep CAHN
AB		25MG;300MG	A091370	003	Oct 12, 2016	Sep NEWA
AB		25MG;300MG	A091370	003	Oct 12, 2016	Sep CAHN
AB	AUROBINDO PHARMA LTD	25MG;300MG	A203630	003	Mar 31, 2016	Mar NEWA
AB	HISUN PHARM HANGZHOU	12.5MG;150MG	A207896	001	Oct 14, 2016	Oct NEWA
AB		12.5MG;300MG	A207896	002	Oct 14, 2016	Oct NEWA
AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016	Jan NEWA
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Jan NEWA
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar CTEC
		25MG;300MG	A203036	003	Jan 15, 2016	Jan NEWA
AB	MYLAN PHARMS INC	25MG;300MG	A077969	003	Jul 20, 2016	Jul NEWA
>D> AB	ROXANE	12.5MG;150MG	A090351	001	Oct 15, 2012	Nov CAHN
>D> AB		12.5MG;300MG	A090351	002	Oct 15, 2012	Nov CAHN
>D> AB	WATSON LABS INC	12.5MG;150MG	A091539	001	Oct 22, 2012	Nov DISC
>A>	@	12.5MG;150MG	A091539	001	Oct 22, 2012	Nov DISC
>D> AB		12.5MG;300MG	A091539	002	Oct 22, 2012	Nov DISC
>A>	@	12.5MG;300MG	A091539	002	Oct 22, 2012	Nov DISC
>A> AB	WEST-WARD PHARMS INT	12.5MG;150MG	A090351	001	Oct 15, 2012	Nov CAHN
>A> AB		12.5MG;300MG	A090351	002	Oct 15, 2012	Nov CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

ZESTORETIC

AB	ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan CAHN
AB	+	12.5MG;20MG	N019888	001	Sep 20, 1990	Jan CAHN
AB	+	25MG;20MG	N019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D> AB	ROXANE	12.5MG;50MG	A077732	002	Oct 06, 2010	Nov CAHN
>D> AB		12.5MG;100MG	A077732	001	Apr 06, 2010	Nov CAHN
>D> AB		25MG;100MG	A077732	003	Oct 06, 2010	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	12.5MG;50MG	A077732	002	Oct 06, 2010	Nov CAHN
>A> AB		12.5MG;100MG	A077732	001	Apr 06, 2010	Nov CAHN
>A> AB		25MG;100MG	A077732	003	Oct 06, 2010	Nov CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	+	TEVA	25MG;15MG	A076980	002	Mar 07, 2007	Aug CRLD
----	---	------	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

AB	DAIICHI SANKYO	12.5MG;20MG	N021532	002	Jun 05, 2003	Oct CFTG
AB		12.5MG;40MG	N021532	003	Jun 05, 2003	Oct CFTG
AB	+	25MG;40MG	N021532	005	Jun 05, 2003	Oct CFTG
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE					
AB	MYLAN PHARMS INC	12.5MG;20MG	A078827	001	Oct 26, 2016	Oct NEWA
AB		12.5MG;40MG	A078827	002	Oct 26, 2016	Oct NEWA
AB		25MG;40MG	A078827	003	Oct 26, 2016	Oct NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS	25MG; 25MG	A089534	001	Jul 02, 1987	Mar CAHN
----	----------------	------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG; 80MG	A206083	001	Feb 08, 2016	Jan NEWA
AB		12.5MG; 160MG	A206083	002	Feb 08, 2016	Jan NEWA
AB		12.5MG; 320MG	A206083	003	Feb 08, 2016	Jan NEWA
AB		25MG; 160MG	A206083	004	Feb 08, 2016	Jan NEWA
AB		25MG; 320MG	A206083	005	Feb 08, 2016	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

	@ ACTAVIS LABS FL INC	5MG; 200MG	A077454	001	Jun 23, 2010	Jan DISC
AB	AUROLIFE PHARMA LLC	7.5MG; 200MG	A204575	001	Jun 02, 2016	May NEWA

HYDROCORTISONE

LOTION; TOPICAL

NUTRACORT

>D>						
>D>	AT	DOW PHARM	2.5%	A087644	001	Aug 24, 1982
>A>		@	2.5%	A087644	001	Aug 24, 1982

TABLET; ORAL

HYDROCORTISONE

>D>	AB	AMEDRA PHARMS	5MG	A040646	001	Mar 30, 2007	Nov CAHN
>D>	AB		10MG	A040646	002	Mar 30, 2007	Nov CAHN
>D>	AB		20MG	A040646	003	Mar 30, 2007	Nov CAHN
>A>	AB	IMPAX LABS INC	5MG	A040646	001	Mar 30, 2007	Nov CAHN
>A>	AB		10MG	A040646	002	Mar 30, 2007	Nov CAHN
>A>	AB		20MG	A040646	003	Mar 30, 2007	Nov CAHN
	AB	PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr NEWA
	AB		10MG	A207029	002	Apr 26, 2016	Apr NEWA
	AB		20MG	A207029	003	Apr 26, 2016	Apr NEWA

HYDROCORTISONE VALERATE

CREAM; TOPICAL

WESTCORT

	@ RANBAXY LABS LTD	0.2%	N017950	001		Jul CAHN
	@ SUN PHARM INDS LTD	0.2%	N017950	001		Jun CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

PEDIOTIC

	@ MONARCH PHARMS	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062822	001	Sep 29, 1987	Jan DISC
--	------------------	---------------------------------------	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

>D>	AA	ROXANE	5MG/5ML	A074653	001	Jul 29, 1998	Nov CAHN
>A>	AA	WEST-WARD PHARMS INT	5MG/5ML	A074653	001	Jul 29, 1998	Nov CAHN

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

	AB	AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016	May NEWA
	AB		4MG	A205814	002	May 13, 2016	May NEWA
	AB		8MG	A205814	003	May 13, 2016	May NEWA
	AB	MALLINCKRODT	2MG	A076855	002	Sep 19, 2007	Aug CMS1
	AB		4MG	A076855	003	Sep 19, 2007	Aug CMS1
>D>	AB	ROXANE	4MG	A074597	003	May 29, 2009	Nov CAHN
>D>	AB		8MG	A074597	001	Jul 29, 1998	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	4MG	A074597	003	May 29, 2009	Nov CAHN
>A>	AB		8MG	A074597	001	Jul 29, 1998	Nov CAHN

TABLET, EXTENDED RELEASE; ORAL

EXALGO

AB	+ MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Jun CFTG
AB	ACTAVIS LABS FL INC	32MG	A202144	004	Jun 30, 2016	Jun NEWA
AB	OSMOTICA	8MG	A205629	001	Jul 07, 2016	Jun NEWA

TABLET, EXTENDED RELEASE;ORAL
HYDROMORPHONE HYDROCHLORIDE

AB		12MG	A205629	002	Jul 07, 2016	Jun NEWA
AB		16MG	A205629	003	Jul 07, 2016	Jun NEWA
AB		32MG	A205629	004	Jul 07, 2016	Jun NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION
CYANOKIT

@ SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Jan CAHN
+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Jan CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL
HYDROXYCHLOROQUINE SULFATE

AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb CMFD
----	-------------	-------	---------	-----	--------------	----------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION
HYDROXYPROGESTERONE CAPROATE

@ ALLERGAN SALES LLC	125MG/ML	N017439	001		Jul CAHN	
@	250MG/ML	N017439	002		Jul CAHN	
+	ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015	Jan CAHN
SOLUTION;INTRAMUSCULAR						
MAKENA						
+	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Jun CAHN
MAKENA PRESERVATIVE FREE						
+	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Oct CTNA
+		250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun CAHN
+	LUMARA HEALTH INC	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Feb NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	10MG	A087869	001	Dec 20, 1982	Feb CAHN	
@	25MG	A087870	001	Dec 20, 1982	Feb CAHN	
@	50MG	A087871	001	Dec 20, 1982	Feb CAHN	
AB	ECI PHARMS LLC	10MG	A040804	001	Jun 30, 2008	May CAHN
AB		25MG	A040804	002	Jun 30, 2008	May CAHN
AB		50MG	A040804	003	Jun 30, 2008	May CAHN
AB	ELITE LABS INC	10MG	A040604	002	Dec 28, 2004	Jun NEWA
AB		25MG	A040604	003	Dec 28, 2004	Jun NEWA
@ SUN PHARM INDS	10MG	A089381	001	May 19, 1986	Mar CAHN	
@	25MG	A089382	001	May 19, 1986	Mar CAHN	
@	50MG	A089383	001	May 19, 1986	Mar CAHN	
@	100MG	A087862	001	Apr 18, 1983	Mar CAHN	

HYDROXYZINE PAMOATE

CAPSULE;ORAL
HYDROXYZINE PAMOATE

AB	IMPAX LABS INC	EQ 25MG HCL	A040156	001	Jul 15, 1996	Aug CAHN
AB		EQ 50MG HCL	A040156	002	Jul 15, 1996	Aug CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS
IBANDRONATE SODIUM

AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan NEWA
----	-----------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

IBANDRONATE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb NEWA
AB	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar CAHN

IBUPROFEN

SUSPENSION;ORAL
IBUPROFEN

AB	HI-TECH PHARMACAL	100MG/5ML	A205647	001	Nov 03, 2016	Oct NEWA
----	-------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

>A>	AB	AIPING PHARM INC	400MG	A202413	001	Nov 23, 2016	Nov NEWA
>A>	AB		600MG	A202413	002	Nov 23, 2016	Nov NEWA
>A>	AB		800MG	A202413	003	Nov 23, 2016	Nov NEWA
>A>		@ AUROLIFE PHARMA LLC	300MG	A070736	002	Jun 12, 1986	Nov CMS1

TABLET; ORAL

IBUPROFEN

>A>	@	400MG	A070736	003	Jun 12, 1986	Nov CMS1
	@	600MG	A070736	001	Jun 12, 1986	Feb CAHN
	@	800MG	A071938	001	Jan 14, 1988	Mar CAHN
AB	CONTRACT PHARMACAL	400MG	A071268	002	Oct 15, 1986	Sep CMS1
AB		800MG	A071268	003	Jul 01, 1988	Sep CMS1
	@ J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986	Jul CAHN
AB	STRIDES PHARMA	400MG	A078329	001	Feb 05, 2009	May CAHN
AB		600MG	A078329	002	Feb 05, 2009	May CAHN
AB		800MG	A078329	003	Feb 05, 2009	May CAHN
	@ SUN PHARM INDS	400MG	A070079	001	Jul 24, 1985	Mar CAHN
	@	600MG	A070080	001	Jul 24, 1985	Mar CAHN
	@	800MG	A071448	001	Feb 18, 1987	Mar CAHN

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYSINE

AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar NEWA
AP	+ RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar CFTG

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	1MG/ML	A065275	001	Dec 14, 2006	Sep CAHN
AP		1MG/ML	A065288	001	May 15, 2007	Sep CAHN

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID

+	ALCON	0.1%	N014169	001		Aug CTEC
	HERPLEX					
@	ALLERGAN	0.1%	N013935	002		Aug DISC

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP	WEST-WARD PHARMS INT	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Oct CAHN
AP		3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Oct CAHN

ILOPERIDONE

TABLET; ORAL

FANAPT

>D>	+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Nov CFTG
>A> AB	+		1MG	N022192	001	May 06, 2009	Nov CFTG
>D>			2MG	N022192	002	May 06, 2009	Nov CFTG
>A> AB			2MG	N022192	002	May 06, 2009	Nov CFTG
>D>			4MG	N022192	003	May 06, 2009	Nov CFTG
>A> AB			4MG	N022192	003	May 06, 2009	Nov CFTG
>D>			6MG	N022192	004	May 06, 2009	Nov CFTG
>A> AB			6MG	N022192	004	May 06, 2009	Nov CFTG
>D>			8MG	N022192	005	May 06, 2009	Nov CFTG
>A> AB			8MG	N022192	005	May 06, 2009	Nov CFTG
>D>			10MG	N022192	006	May 06, 2009	Nov CFTG
>A> AB			10MG	N022192	006	May 06, 2009	Nov CFTG
>D>			12MG	N022192	007	May 06, 2009	Nov CFTG
>A> AB			12MG	N022192	007	May 06, 2009	Nov CFTG
>A>		ILOPERIDONE					
>A> AB		INVENTIA HLTHCARE	1MG	A207231	001	Nov 28, 2016	Nov NEWA
>A> AB			2MG	A207231	002	Nov 28, 2016	Nov NEWA
>A> AB			4MG	A207231	003	Nov 28, 2016	Nov NEWA
>A> AB			6MG	A207231	004	Nov 28, 2016	Nov NEWA
>A> AB			8MG	A207231	005	Nov 28, 2016	Nov NEWA
>A> AB			10MG	A207231	006	Nov 28, 2016	Nov NEWA
>A> AB			12MG	A207231	007	Nov 28, 2016	Nov NEWA

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	APOTEX INC	EQ 100MG BASE	A079179	001	Aug 05, 2016	Jul	NEWA
AB		EQ 400MG BASE	A079179	002	Aug 05, 2016	Jul	NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A204285	001	Aug 04, 2016	Jul	NEWA
AB		EQ 400MG BASE	A204285	002	Aug 04, 2016	Jul	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB	LUPIN LTD	10MG	A090441	002	Mar 11, 2010	Oct	CMS1
AB		25MG	A090441	003	Mar 11, 2010	Oct	CMS1
AB	SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar	CAHN
AB		25MG	A081049	001	Jun 05, 1990	Mar	CAHN
AB		50MG	A081050	001	Jun 05, 1990	Mar	CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

>D>	AB	+	ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Nov	CAHN
	AB	+		EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb	CRLD
>D>	AB			EQ 100MG HCL	A091099	002	Apr 16, 2010	Nov	CAHN
>D>	AB			EQ 125MG HCL	A091099	003	Apr 16, 2010	Nov	CAHN
>D>	AB			EQ 150MG HCL	A091099	004	Apr 16, 2010	Nov	CAHN
>A>	AB	+	WEST-WARD PHARMS INT	EQ 75MG HCL	A091099	001	Apr 16, 2010	Nov	CAHN
>A>	AB			EQ 100MG HCL	A091099	002	Apr 16, 2010	Nov	CAHN
>A>	AB			EQ 125MG HCL	A091099	003	Apr 16, 2010	Nov	CAHN
>A>	AB			EQ 150MG HCL	A091099	004	Apr 16, 2010	Nov	CAHN

INAMRINONE LACTATE

INJECTABLE;INJECTION

AMRINONE LACTATE

+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Oct	CAHN
---	----------------------	----------------	---------	-----	--------------	-----	------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB	AMERIGEN PHARMS LTD	1.25MG	A075201	001	Dec 04, 1998	Sep	CMFD
AB		2.5MG	A075201	002	Dec 04, 1998	Sep	CMFD

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan	CAHN
---	---------------------	------------	---------	-----	--------------	-----	------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION

INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar	CMS1
---	---------------	---------	---------	-----	--------------	-----	------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan	CAHN
---	---------------------	---------	---------	-----	--------------	-----	------

INDOCYANINE GREEN

INJECTABLE;INJECTION

INDOCYANINE GREEN

AP	DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan	CAHN
----	------------------	-----------	---------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

@	SUN PHARM INDS	25MG	A070900	002	Feb 09, 1987	Sep	CMS1
@		50MG	A070900	001	Feb 09, 1987	Sep	CAHN

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
INDOMETHACIN SODIUM

AP	HOSPIRA INC	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Apr	NEWA
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Oct	CAHN

>A> INSULIN DEGLUDEC; LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS
XULTOPHY 100/3.6

>A>	+	NOVO NORDISK INC	300 UNITS/3ML; 10.8MG/3ML (100 UNITS/ML; 3.6MG/ML)	N208583	001	Nov 21, 2016	Nov	NEWA
-----	---	------------------	--	---------	-----	--------------	-----	------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS
LEVEMIR FLEXPEN

@	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb	DISC
---	------------------	------------------------------	---------	-----	--------------	-----	------

>A> INSULIN GLARGINE; LIXISENATIDE

SOLUTION; SUBCUTANEOUS
SOLIQUA 100/33

>A>	+	SANOFI-AVENTIS US	300 UNITS/3ML; 99MCG/3ML (100 UNITS/ML; 33MCG/ML)	N208673	001	Nov 21, 2016	Nov	NEWA
-----	---	-------------------	---	---------	-----	--------------	-----	------

INSULIN HUMAN

SOLUTION; SUBCUTANEOUS
HUMULIN R

+	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan	CAIN
---	-------	---------------------------------	---------	-----	--------------	-----	------

HUMULIN R KWIKPEN

+	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan	NEWA
---	-------	-------------------------------	---------	-----	--------------	-----	------

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION
AFREZZA

+	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar	CAHN
		8 UNITS/INH	N022472	002	Jun 27, 2014	Mar	CAHN
		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar	CAHN

IOXILAN

INJECTABLE; INJECTION
OXILAN-300

@	GUERBET	62%	N020316	001	Dec 21, 1995	Jun	DISC
---	---------	-----	---------	-----	--------------	-----	------

OXILAN-350

@	GUERBET	73%	N020316	002	Dec 21, 1995	Jun	DISC
---	---------	-----	---------	-----	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN	AUROBINDO PHARMA LTD	0.02%	A206543	001	Oct 27, 2016	Oct	NEWA	
	@ MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Jul	DISC	
AN	+	RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul	CRLD

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

>D>	AB	ROXANE	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Nov	CAHN
>D>	AB		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Nov	CAHN
>A>	AB		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Nov	CAHN

IRBESARTAN

TABLET; ORAL
IRBESARTAN

AB	HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May	NEWA	
AB		150MG	A206194	002	Jun 14, 2016	May	NEWA	
AB		300MG	A206194	003	Jun 14, 2016	May	NEWA	
>D>	AB	ROXANE	75MG	A090201	001	Oct 15, 2012	Nov	CAHN
>D>	AB		150MG	A090201	002	Oct 15, 2012	Nov	CAHN
>D>	AB		300MG	A090201	003	Oct 15, 2012	Nov	CAHN
>D>	AB	WATSON LABS INC	75MG	A090720	001	Oct 12, 2012	Nov	DISC
>A>	@	75MG	A090720	001	Oct 12, 2012	Nov	DISC	
>D>	AB		150MG	A090720	002	Oct 12, 2012	Nov	DISC
>A>	@	150MG	A090720	002	Oct 12, 2012	Nov	DISC	
>D>	AB		300MG	A090720	003	Oct 12, 2012	Nov	DISC

TABLET;ORAL
IRBESARTAN

>A>	@	300MG	A090720	003	Oct 12, 2012	Nov DISC
>A>	AB	WEST-WARD PHARMS INT 75MG	A090201	001	Oct 15, 2012	Nov CAHN
>A>	AB	150MG	A090201	002	Oct 15, 2012	Nov CAHN
>A>	AB	300MG	A090201	003	Oct 15, 2012	Nov CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION
CAMPTOSAR

AP	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr CTEC
IRINOTECAN HYDROCHLORIDE							
AP		QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr NEWA
AP			100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr NEWA
AP			300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr NEWA
AP		SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan CAHN
AP			100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan CAHN

IRON DEXTRAN

INJECTABLE;INJECTION
INFED

BP	+	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr CAHN
----	---	--------------------	-----------------	---------	-----	--	----------

ISONIAZID

TABLET;ORAL
ISONIAZID

AA		MIKART	100MG	A040090	001	Jun 26, 1997	Jun CMFD
AA			300MG	A040090	002	Jun 26, 1997	Jun CMFD
	@	SUN PHARM INDS	100MG	A080136	001		Mar CAHN
	@		300MG	A083633	001		Mar CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE;ORAL
DILATRATE-SR

+	AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Mar CAHN
+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Jul CAHN

TABLET;ORAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar CAHN
@		10MG	A086169	001	Sep 19, 1986	Jun CAHN
@		20MG	A086167	001	Sep 19, 1986	Jun CAHN
@		30MG	A087564	001	Sep 18, 1986	Jun CAHN

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun CAHN
@		5MG	A086168	001	Sep 18, 1986	Jun CAHN
@		10MG	A087545	001	Sep 18, 1986	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

@	COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar DISC
+	SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar CTEC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE MONONITRATE

AB		DEXCEL LTD	30MG	A075522	002	Sep 20, 2016	Sep NEWA
----	--	------------	------	---------	-----	--------------	----------

ISOSULFAN BLUE

INJECTABLE;INJECTION
ISOSULFAN BLUE

AP		AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan NEWA
AP	+	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan CTEC

ISOTRETINOIN

CAPSULE;ORAL
ABSORICA

BX		RANBAXY	10MG	N021951	001	May 25, 2012	Aug CAHN
BX			20MG	N021951	002	May 25, 2012	Aug CAHN
			25MG	N021951	005	Aug 15, 2014	Aug CAHN
BX			30MG	N021951	003	May 25, 2012	Aug CAHN
			35MG	N021951	006	Aug 15, 2014	Aug CAHN
BX	+		40MG	N021951	004	May 25, 2012	Aug CAHN

CAPSULE;ORAL
ABSORICA

BX	RANBAXY LABS LTD	10MG	N021951	001	May 25, 2012	Jul CAHN
BX		20MG	N021951	002	May 25, 2012	Jul CAHN
		25MG	N021951	005	Aug 15, 2014	Aug CAHN
		25MG	N021951	005	Aug 15, 2014	Jul CAHN
BX		30MG	N021951	003	May 25, 2012	Jul CAHN
		35MG	N021951	006	Aug 15, 2014	Aug CAHN
		35MG	N021951	006	Aug 15, 2014	Jul CAHN
BX	+	40MG	N021951	004	May 25, 2012	Jul CAHN
	SOTRET					
	@ SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Sep DISC
	@	20MG	A076041	002	Dec 24, 2002	Sep DISC
	@	30MG	A076503	001	Jun 20, 2003	Sep DISC
	@	40MG	A076041	003	Dec 24, 2002	Sep DISC

ITRACONAZOLECAPSULE;ORAL
ITRACONAZOLE

AB	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May NEWA
>A>	AB ALEMBIC PHARMS LTD	100MG	A206741	001	Dec 13, 2016	Nov NEWA
AB	AMNEAL PHARMS	100MG	A205080	001	Sep 26, 2016	Sep NEWA
>A>	AB PAR PHARM INC	100MG	A205724	001	Dec 13, 2016	Nov NEWA

SOLUTION;ORAL

ITRACONAZOLE

@ AMNEAL PHARMS 10MG/ML
SPORANOX

A205573 001 Oct 30, 2015 Apr DISC

+ JANSSEN PHARMS 10MG/ML

N020657 001 Feb 21, 1997 Apr CTEC

IVACAFTOR; LUMACAFTOR

TABLET;ORAL

ORKAMBI

VERTEX PHARMS INC 125MG;100MG

N206038 002 Sep 28, 2016 Sep NEWA

IVERMECTIN

LOTION;TOPICAL

SKLICE

+ ARBOR PHARMS LLC 0.5%

N202736 001 Feb 07, 2012 May CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT EQ 50MG BASE/ML
AP EQ 100MG BASE/ML

A074524 001 Mar 22, 1996 Sep CAHN

A074524 002 Mar 22, 1996 Sep CAHN

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE

@ SUN PHARM INDS 200MG

A075314 001 Jun 15, 1999 Jan CAHN

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

@ AUROLIFE PHARMA LLC 50MG
@ 75MG

A074024 001 Dec 29, 1995 Feb CAHN

A074024 002 Dec 29, 1995 Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP GLAND PHARMA LTD 15MG/ML
AP 30MG/ML

A204216 001 Nov 01, 2016 Oct NEWA

A204216 002 Nov 01, 2016 Oct NEWA

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

+ OMEROS EQ 0.3% BASE;EQ 1% BASE

N205388 001 May 30, 2014 Aug CPOT

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP	SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan CTNA
AP	WEST-WARD PHARMS INT	5MG/ML	A075303	001	May 28, 1999	Oct CAHN
	TRANDATE					
	@ SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan CAHN

LACOSAMIDE

SOLUTION;ORAL

LACOSAMIDE

AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016	Apr NEWA
AA	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Apr CFTG

TABLET;ORAL

LACOSAMIDE

AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204855	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204855	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204855	004	Apr 28, 2016	Apr NEWA
AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204974	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204974	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204974	004	Apr 28, 2016	Apr NEWA
AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	Aug NEWA
AB		100MG	A204857	002	Sep 09, 2016	Aug NEWA
AB		150MG	A204857	003	Sep 09, 2016	Aug NEWA
AB		200MG	A204857	004	Sep 09, 2016	Aug NEWA
AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204994	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204994	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204994	004	Apr 28, 2016	Apr NEWA
AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204921	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204921	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204921	004	Apr 28, 2016	Apr NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205026	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205026	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205026	004	Apr 28, 2016	Apr NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr NEWA
	VIMPAT					
AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr CFTG

LACTULOSE

SOLUTION;ORAL

CONSTULOSE

@ ACTAVIS MID ATLANTIC 10GM/15ML

LACTULOSE

AA	+	HI TECH PHARMA	10GM/15ML	A074076	001	Jul 03, 1995	Aug CRLD
>D> AA		ROXANE	10GM/15ML	A073591	001	May 29, 1992	Nov CAHN
>A> AA		WEST-WARD PHARMS INT	10GM/15ML	A073591	001	May 29, 1992	Nov CAHN

LAMIVUDINE

SOLUTION;ORAL

LAMIVUDINE

>A> AA	AUROBINDO PHARMA LTD	10MG/ML	A077695	001	Nov 21, 2016	Nov NEWA
--------	----------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

LAMIVUDINE

>A> AB	APPCO PHARMA LLC	150MG	A206974	001	Nov 21, 2016	Nov NEWA
>A> AB		300MG	A206974	002	Nov 21, 2016	Nov NEWA
>A> AB	AUROBINDO PHARMA LTD	150MG	A077464	001	Nov 21, 2016	Nov NEWA
>A> AB		300MG	A077464	002	Nov 21, 2016	Nov NEWA
>A> AB	CENTAUR PHARMS PVT	150MG	A203586	001	Nov 21, 2016	Nov NEWA
AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb NEWA

TABLET;ORAL							
LAMIVUDINE							
AB		300MG		A204528	002	Mar 04, 2016	Feb NEWA
<u>LAMOTRIGINE</u>							
TABLET;ORAL							
LAMOTRIGINE							
AB	JUBILANT CADISTA	25MG		A079132	001	Jan 27, 2009	Jun CAHN
AB		100MG		A079132	002	Jan 27, 2009	Jun CAHN
AB		150MG		A079132	003	Jan 27, 2009	Jun CAHN
AB		200MG		A079132	004	Jan 27, 2009	Jun CAHN
TABLET, EXTENDED RELEASE;ORAL							
LAMICTAL XR							
AB	+ GLAXOSMITHKLINE LLC	200MG		N022115	004	May 29, 2009	Jan CRLD
TABLET, ORALLY DISINTEGRATING;ORAL							
LAMOTRIGINE							
AB	SCIEGEN PHARMS INC	25MG		A206382	001	Jun 17, 2016	Jun NEWA
AB		50MG		A206382	002	Jun 17, 2016	Jun NEWA
AB		100MG		A206382	003	Jun 17, 2016	Jun NEWA
AB		200MG		A206382	004	Jun 17, 2016	Jun NEWA
<u>LANSOPRAZOLE</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
LANSOPRAZOLE							
AB	AJANTA PHARMA LTD	15MG		A203957	001	Oct 14, 2016	Oct NEWA
AB		30MG		A203957	002	Oct 14, 2016	Oct NEWA
AB	ANCHEN PHARMS	15MG		A203203	001	Jul 25, 2016	Jul NEWA
AB		30MG		A203203	002	Jul 25, 2016	Jul NEWA
>A> AB	SUN PHARM INDS LTD	15MG		A202637	001	Sep 13, 2013	Nov CAHN
>A> AB		30MG		A091509	001	Sep 13, 2013	Nov CAHN
>D> AB	SUN PHARMA GLOBAL	15MG		A202637	001	Sep 13, 2013	Nov CAHN
>D> AB		30MG		A091509	001	Sep 13, 2013	Nov CAHN
<u>LATANOPROST</u>							
SOLUTION/DROPS;OPHTHALMIC							
LATANOPROST							
AT	FDC LTD	0.005%		A202442	001	Apr 22, 2016	Apr NEWA
<u>LESINURAD</u>							
TABLET;ORAL							
ZURAMPIC							
	+ IRONWOOD PHARMS INC	200MG		N207988	001	Dec 22, 2015	Aug CAHN
<u>LETROZOLE</u>							
TABLET;ORAL							
LETROZOLE							
AB	HIKMA PHARMS	2.5MG		A203796	001	Jun 03, 2016	May NEWA
AB	KREMERS URBAN PHARMS	2.5MG		A091098	001	Jun 03, 2011	Jan CAHN
>D> AB	ROXANE	2.5MG		A090838	001	Jun 03, 2011	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	2.5MG		A090838	001	Jun 03, 2011	Nov CAHN
<u>LEUCOVORIN CALCIUM</u>							
INJECTABLE;INJECTION							
LEUCOVORIN CALCIUM							
AP	+ WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL		A089384	001	Sep 14, 1987	Oct CAHN
AP		EQ 100MG BASE/VIAL		A089717	001	Mar 28, 1988	Oct CAHN
LEUCOVORIN CALCIUM PRESERVATIVE FREE							
	+ WEST-WARD PHARMS INT	EQ 10MG BASE/ML		A040347	001	Apr 25, 2000	Sep CAHN
AP		EQ 200MG BASE/VIAL		A040056	001	May 23, 1995	Sep CAHN
AP		EQ 350MG BASE/VIAL		A040335	001	Apr 20, 2000	Sep CAHN
TABLET;ORAL							
LEUCOVORIN CALCIUM							
	@ IDT AUSTRALIA LTD	EQ 15MG BASE		A075327	001	Mar 24, 1999	May CAHN
>D> AB	ROXANE	EQ 5MG BASE		A072733	001	Feb 22, 1993	Nov CAHN
>D>		EQ 10MG BASE		A072734	001	Feb 22, 1993	Nov CAHN
>D>		EQ 15MG BASE		A072735	001	Feb 22, 1993	Nov CAHN
>D>		EQ 15MG BASE		A072735	001	Feb 22, 1993	Jun CTEC
>D> AB		EQ 25MG BASE		A072736	001	Feb 22, 1993	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	EQ 5MG BASE		A072733	001	Feb 22, 1993	Nov CAHN
>A>		EQ 10MG BASE		A072734	001	Feb 22, 1993	Nov CAHN
>A>		EQ 15MG BASE		A072735	001	Feb 22, 1993	Nov CAHN
>A> AB		EQ 25MG BASE		A072736	001	Feb 22, 1993	Nov CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	IMPAX LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug CAHN
AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug CAHN
AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug CAHN
AN	RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar NEWA
AN		EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar NEWA
AN		EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan NEWA
AP	JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May NEWA
AP	MYLAN LABS LTD	500MG/5ML (100MG/ML)	A203308	001	Sep 16, 2016	Sep NEWA

TABLET; ORAL

LEVETIRACETAM

AB	SECAN PHARMS	500MG	A205102	004	Dec 16, 2015	Oct NEWA
----	--------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb NEWA
AB		750MG	A204511	002	Feb 23, 2016	Feb NEWA
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May NEWA
AB		750MG	A202095	001	Jun 06, 2016	May NEWA
AB	NOSTRUM LABS INC	500MG	A204754	001	Aug 26, 2016	Aug NEWA
AB		750MG	A204754	002	Aug 26, 2016	Aug NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar CAHN
AB		750MG	A091285	002	Sep 12, 2011	Mar CAHN

TABLET, FOR SUSPENSION; ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb CDFR
		500MG	N207958	002	Jul 31, 2015	Feb CDFR
		750MG	N207958	003	Jul 31, 2015	Feb CDFR
+		1GM	N207958	004	Jul 31, 2015	Mar CRLD
		1GM	N207958	004	Jul 31, 2015	Feb CDFR

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

AT	ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Jul CAHN
----	----------------	-------	---------	-----	--------------	----------

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

AP	WEST-WARD PHARMS INT	200MG/ML	A075567	001	Mar 29, 2001	Oct CAHN
----	----------------------	----------	---------	-----	--------------	----------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

@ HOSPIRA INC EQ 500MG/20ML (EQ 25MG/ML)

A078577 001 Aug 12, 2015 Oct DISC

@ EQ 750MG/30ML (EQ 25MG/ML)

A078577 002 Aug 12, 2015 Oct DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP	ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Nov CRLD
>A> AP	+	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Nov CRLD
>D> AP		EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Nov CRLD
>A> AP	+	EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Nov CRLD
>D> AP		EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Nov CRLD
>A> AP	+	EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Nov CRLD
AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT	+	RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan CAHN
----	---	-------------------	------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUMPOWDER; IV (INFUSION)
FUSILEV

AP	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun CFTG
		LEVOLEUCOVORIN CALCIUM					
		ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	Sep NEWA
AP		EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jun NEWA
AP		WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Oct CAHN

LEVONORGESTRELINTRAUTERINE DEVICE; INTRAUTERINE
KYLEENA

	+	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016	Sep NEWA
		TABLET; ORAL					
		LEVONORGESTREL					
AB		JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016	Aug NEWA
AB		LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Aug NEWA
AB	+	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Aug CTEC
	+		0.75MG	A090740	001	Dec 30, 2010	Apr CRLD

LEVOTHYROXINE SODIUMPOWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

AP		FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun NEWA
AP			500MCG/VIAL	A206163	002	Jun 29, 2016	Jun NEWA
AP	+	FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun CFTG
AP	+		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun CFTG

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOLET

@	LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Jul CAHN
@		0.05MG	N021137	002	Jun 06, 2003	Jul CAHN
@		0.075MG	N021137	003	Jun 06, 2003	Jul CAHN
@		0.088MG	N021137	004	Jun 06, 2003	Jul CAHN
@		0.1MG	N021137	005	Jun 06, 2003	Jul CAHN
@		0.112MG	N021137	006	Jun 06, 2003	Jul CAHN
@		0.125MG	N021137	007	Jun 06, 2003	Jul CAHN
@		0.137MG	N021137	008	Jun 06, 2003	Jul CAHN
@		0.15MG	N021137	009	Jun 06, 2003	Jul CAHN
@		0.175MG	N021137	010	Jun 06, 2003	Jul CAHN
@		0.2MG	N021137	011	Jun 06, 2003	Jul CAHN
@		0.3MG	N021137	012	Jun 06, 2003	Jul CAHN

LEVOTHROID

@	LLOYD	0.025MG	N021116	001	Oct 24, 2002	May DISC
@		0.05MG	N021116	002	Oct 24, 2002	May DISC
@		0.075MG	N021116	003	Oct 24, 2002	May DISC
@		0.088MG	N021116	010	Oct 24, 2002	May DISC
@		0.1MG	N021116	004	Oct 24, 2002	May DISC
@		0.112MG	N021116	011	Oct 24, 2002	May DISC
@		0.125MG	N021116	005	Oct 24, 2002	May DISC
@		0.137MG	N021116	012	Dec 07, 2004	May DISC
@		0.15MG	N021116	006	Oct 24, 2002	May DISC
@		0.175MG	N021116	007	Oct 24, 2002	May DISC
@		0.2MG	N021116	008	Oct 24, 2002	May DISC
@		0.3MG	N021116	009	Oct 24, 2002	May DISC

LEVOTHYROXINE SODIUM

AB1,		MYLAN	0.3MG	A076187	011	Jun 05, 2002	May CRLD
AB2,							
AB3,							
AB4,	+						

LIDOCAINEOINTMENT; TOPICAL
LIDOCAINE

AT		GLENMARK PHARMS LTD	5%	A206498	001	Sep 09, 2016	Aug NEWA
AT		SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun CAHN
AT		TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 400MG/100ML N018388 002 Feb DISC

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 800MG/100ML N018388 003 Nov 05, 1982 Feb DISC

JELLY;TOPICAL

ANESTACON

@ BIONPHARMA INC 2% A080429 001 Jan CAHN

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT + VINTAGE 2% A040708 001 Feb 27, 2007 Aug CRLD

LIDOCAINE VISCOUS

>D> AT ROXANE 2% A088802 001 Apr 26, 1985 Nov CAHN

>A> AT WEST-WARD PHARMS INT 2% A088802 001 Apr 26, 1985 Nov CAHN

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

>D> AT ROXANE 4% A088803 001 Apr 03, 1985 Nov CAHN

AT TELIGENT PHARMA INC 4% A204494 001 Mar 12, 2014 May CAHN

>A> AT WEST-WARD PHARMS INT 4% A088803 001 Apr 03, 1985 Nov CAHN

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

XIIDRA

+ SHIRE DEV LLC 5% N208073 001 Jul 11, 2016 Jul NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

JENTADUETO XR

BOEHRINGER INGELHEIM 2.5MG;1GM N208026 001 May 27, 2016 May NEWA

+ 5MG;1GM N208026 002 May 27, 2016 May NEWA

LINEZOLID

FOR SUSPENSION;ORAL

LINEZOLID

>D> AB ROXANE 100MG/5ML A200068 001 Jun 03, 2015 Nov CAHN

>A> AB WEST-WARD PHARMS INT 100MG/5ML A200068 001 Jun 03, 2015 Nov CAHN

SOLUTION;IV (INFUSION)

LINEZOLID

AP AUROBINDO PHARMA LTD 600MG/300ML (2MG/ML) A206917 001 Aug 04, 2016 Jul NEWA

AP FRESENIUS KABI USA 600MG/300ML (2MG/ML) A204764 001 Mar 15, 2016 Feb NEWA

TABLET;ORAL

LINEZOLID

AB GATE PHARMS 600MG A091210 001 Feb 05, 2016 Jan NEWA

AB GLENMARK PHARMS 600MG A078987 001 Dec 21, 2015 Mar CAHN

AB NOVEL LABS INC 600MG A207526 001 Aug 22, 2016 Aug NEWA

LIOETHYRONINE SODIUM

TABLET;ORAL

LIOETHYRONINE SODIUM

AB MAYNE PHARMA INC EQ 0.005MG BASE A090097 001 Mar 20, 2009 Mar CAHN

AB EQ 0.025MG BASE A090097 002 Mar 20, 2009 Mar CAHN

AB EQ 0.05MG BASE A090097 003 Mar 20, 2009 Mar CAHN

AB SUN PHARM INDS LTD EQ 0.005MG BASE A091382 001 Apr 20, 2016 Apr NEWA

AB EQ 0.025MG BASE A091382 002 Apr 20, 2016 Apr NEWA

AB EQ 0.05MG BASE A091382 003 Apr 20, 2016 Apr NEWA

LISINOPRIL

SOLUTION;ORAL

QBRELIS

+ SILVERGATE PHARMS 1MG/ML N208401 001 Jul 29, 2016 Jul NEWA

TABLET;ORAL

ZESTRIL

AB ALVOGEN MALTA 2.5MG N019777 005 Apr 29, 1993 Jan CAHN

AB 5MG N019777 001 May 19, 1988 Jan CAHN

AB 10MG N019777 002 May 19, 1988 Jan CAHN

AB 20MG N019777 003 May 19, 1988 Jan CAHN

AB 30MG N019777 006 Jan 20, 1999 Jan CAHN

AB + 40MG N019777 004 May 19, 1988 Jan CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Feb CAHN
AB			300MG	A076243	001	Jun 27, 2002	Feb CAHN
AB			600MG	A078763	001	Apr 15, 2008	Feb CAHN
AB		HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan CMFD

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		HERITAGE PHARMA	300MG	A205532	001	Sep 29, 2016	Sep NEWA
>D> AB		ROXANE	300MG	A076832	001	Oct 28, 2004	Nov CAHN
>D> AB	+		450MG	A076691	001	Jan 05, 2004	Nov CAHN
>A> AB		WEST-WARD PHARMS INT	300MG	A076832	001	Oct 28, 2004	Nov CAHN
>A> AB	+		450MG	A076691	001	Jan 05, 2004	Nov CAHN

LIXISENATIDE

SOLUTION;SUBCUTANEOUS

ADLYXIN

+		SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016	Aug CPOT
+			0.05MG/ML	N208471	001	Jul 27, 2016	Jul NEWA
+			0.1MG/ML	N208471	002	Jul 27, 2016	Jul NEWA
+			0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016	Aug CPOT

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

>D>	+	ALCON	EQ 0.1% BASE	N020191	001	Sep 23, 1993	Nov CAHN
>A>	+	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020191	001	Sep 23, 1993	Nov CAHN

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

		AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CRLD
	+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CRLD

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

@ J AND J CONSUMER INC 2MG

N017694 001 Feb DISC

LOPERAMIDE HYDROCHLORIDE

AB	+	MYLAN	2MG	A072741	001	Sep 18, 1991	Feb CRLD
----	---	-------	-----	---------	-----	--------------	----------

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM INTENSOL

>D> AA	+	ROXANE	2MG/ML	A072755	001	Jun 28, 1991	Nov CAHN
>A> AA	+	WEST-WARD PHARMS INT	2MG/ML	A072755	001	Jun 28, 1991	Nov CAHN

INJECTABLE;INJECTION

ATIVAN

AP	+	WEST-WARD PHARMS INT	2MG/ML	N018140	001		Oct CAHN
AP	+		4MG/ML	N018140	002		Oct CAHN

TABLET;ORAL

LORAZEPAM

@ FRONTIDA BIOPHARM 0.5MG

A072553 001 Mar 29, 1991 Sep CAHN

@ 1MG

A072554 001 Mar 29, 1991 Sep CAHN

@ 2MG

A072555 001 Mar 29, 1991 Jul CAHN

LORCASERIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BELVIQ XR

+		EISAI INC	20MG	N208524	001	Jul 15, 2016	Jul NEWA
---	--	-----------	------	---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

BX		HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr CTEC
BX			50MG	A203835	002	Aug 12, 2015	Apr CTEC
BX			100MG	A203835	003	Aug 12, 2015	Apr CTEC
AB		LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Oct CTEC
BX			25MG	A078232	001	Oct 06, 2010	Apr CTEC
AB			50MG	A078232	002	Oct 06, 2010	Oct CTEC

TABLET; ORAL

LOSARTAN POTASSIUM

BX		50MG	A078232	002	Oct 06, 2010	Apr CTEC
AB		100MG	A078232	003	Oct 06, 2010	Oct CTEC
BX		100MG	A078232	003	Oct 06, 2010	Apr CTEC
>D>	AB	ROXANE 25MG	A077459	001	Oct 06, 2010	Nov CAHN
>D>	AB	50MG	A077459	002	Oct 06, 2010	Nov CAHN
>D>	AB	100MG	A077459	003	Oct 06, 2010	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT 25MG	A077459	001	Oct 06, 2010	Nov CAHN
>A>	AB	50MG	A077459	002	Oct 06, 2010	Nov CAHN
>A>	AB	100MG	A077459	003	Oct 06, 2010	Nov CAHN

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar CAHN
AB		20MG	A077520	002	Apr 14, 2006	Mar CAHN
AB		40MG	A077520	003	Apr 14, 2006	Mar CAHN

LOXAPINE

POWDER; INHALATION

ADASUVE

+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb CAHN
---	---------------	------	---------	-----	--------------	----------

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

@	WINDTREE THERAP	8.5ML	N021746	001	Mar 06, 2012	Aug CAHN
---	-----------------	-------	---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb NEWA
AP	+ HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
AP	HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb NEWA

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb NEWA
AP		4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb NEWA
AP		2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar NEWA
AP		20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar NEWA
AP		40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar NEWA
AP	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar CFTG
AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar CFTG

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MARAVIROC

>A>	SOLUTION; ORAL					
>A>	SELZENTRY					
>A>	+	VIIV HLTHCARE 20MG/ML	N208984	001	Nov 04, 2016	Nov NEWA
	TABLET; ORAL					
	SELZENTRY					
>A>	VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Nov NEWA
>A>		75MG	N022128	004	Nov 04, 2016	Nov NEWA

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

EMVERM

+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Aug CTNA
	VERMOX					
+	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Oct NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@ RISING PHARMS INC 12.5MG
@ 25MGA040179 001 Jan 30, 1997 Jan CAHN
A040179 002 Jan 30, 1997 Jan CAHN

TABLET, CHEWABLE; ORAL

ANTIVERT

@ CASPER PHARMA LLC 25MG

N010721 005 Jun DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

@ HIKMA INTL PHARMS 250MG

A077699 001 Apr 21, 2010 May CAHN

>D> AB ROXANE 250MG

A076523 001 Oct 01, 2004 Nov CAHN

>A> AB WEST-WARD PHARMS INT 250MG

A076523 001 Oct 01, 2004 Nov CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB + ENDO PHARMS INC 125MG/ML

N021778 001 Jul 05, 2005 Feb CAHN

MEGESTROL ACETATE

>D> AB ROXANE 40MG/ML

A075997 001 Feb 15, 2002 Nov CAHN

>A> AB WEST-WARD PHARMS INT 40MG/ML

A075997 001 Feb 15, 2002 Nov CAHN

TABLET; ORAL

MEGESTROL ACETATE

>D> AB ROXANE 20MG

A074458 001 Sep 29, 1995 Nov CAHN

>D> AB 40MG

A074458 002 Sep 29, 1995 Nov CAHN

>A> AB WEST-WARD PHARMS INT 20MG

A074458 001 Sep 29, 1995 Nov CAHN

>A> AB 40MG

A074458 002 Sep 29, 1995 Nov CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

@ FRONTIDA BIOPHARM 7.5MG

A077935 001 Jul 19, 2006 Jul CAHN

@ 15MG

A077935 002 Jul 19, 2006 Jul CAHN

@ SUN PHARM INDS 7.5MG

A077935 001 Jul 19, 2006 Jan CAHN

@ 15MG

A077935 002 Jul 19, 2006 Jan CAHN

MELPHALAN

TABLET; ORAL

ALKERAN

+ APOTEX INC 2MG

N014691 002 Jan CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP + APOTEX INC EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 Jan CAHN

MELPHALAN HYDROCHLORIDE

AP PAR STERILE PRODUCTS EQ 50MG BASE/VIAL

A204773 001 Aug 22, 2016 Aug NEWA

AP WEST-WARD PHARMS INT EQ 50MG BASE/VIAL

A090303 001 Oct 28, 2010 Oct CAHN

POWDER; IV (INFUSION)

EVOMELA

SPECTRUM PHARMS EQ 50MG BASE/VIAL

N207155 001 Mar 10, 2016 Mar NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

AB AMNEAL PHARMS 7MG

A205825 001 Oct 12, 2016 Oct NEWA

AB 14MG

A205825 002 Oct 12, 2016 Oct NEWA

AB 21MG

A205825 003 Oct 12, 2016 Oct NEWA

AB 28MG

A205825 004 Oct 12, 2016 Oct NEWA

>A> AB APOTEX INC 7MG

A206135 001 Nov 22, 2016 Nov NEWA

>A> AB 14MG

A206135 002 Nov 22, 2016 Nov NEWA

>A> AB 21MG

A206135 003 Nov 22, 2016 Nov NEWA

>A> AB 28MG

A206135 004 Nov 22, 2016 Nov NEWA

AB LUPIN LTD 7MG

A206028 001 Sep 28, 2016 Sep NEWA

AB 14MG

A206028 002 Sep 28, 2016 Sep NEWA

AB 21MG

A206028 003 Sep 28, 2016 Sep NEWA

AB 28MG

A206028 004 Sep 28, 2016 Sep NEWA

AB MYLAN PHARMS INC 7MG

A206032 001 Sep 28, 2016 Sep NEWA

AB 14MG

A206032 002 Sep 28, 2016 Sep NEWA

CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

AB		21MG	A206032	003	Sep 28, 2016	Sep NEWA
AB		28MG	A206032	004	Sep 28, 2016	Sep NEWA
AB	SUN PHARMA GLOBAL	7MG	A205905	001	Sep 28, 2016	Sep NEWA
AB		14MG	A205905	002	Sep 28, 2016	Sep NEWA
AB		21MG	A205905	003	Sep 28, 2016	Sep NEWA
AB		28MG	A205905	004	Sep 28, 2016	Sep NEWA
	NAMENDA XR					
AB	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Sep CFTG
AB		14MG	N022525	002	Jun 21, 2010	Sep CFTG
AB		21MG	N022525	003	Jun 21, 2010	Sep CFTG
AB	+	28MG	N022525	004	Jun 21, 2010	Sep CFTG
	TABLET;ORAL					
	MEMANTINE HYDROCHLORIDE					
AB	SILARX PHARMS INC	5MG	A207236	001	Nov 10, 2016	Oct NEWA
AB		10MG	A207236	002	Nov 10, 2016	Oct NEWA

MEPERIDINE HYDROCHLORIDEINJECTABLE;INJECTION
DEMEROL

@	US PHARM HOLDINGS	25MG/ML	N005010	007		Jan CAHN
@		50MG/ML	N005010	002		Jan CAHN
@		75MG/ML	N005010	009		Jan CAHN
@		100MG/ML	N005010	003		Jan CAHN

SYRUP;ORAL

DEMEROL

@	US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan CAHN
---	-------------------	----------	---------	-----	--	----------

MEPERIDINE HYDROCHLORIDE

>D>	+	ROXANE	50MG/5ML	A088744	001	Jan 30, 1985	Nov CAHN
>A>	+	WEST-WARD PHARMS INT	50MG/5ML	A088744	001	Jan 30, 1985	Nov CAHN

TABLET;ORAL

DEMEROL

AA	+	US PHARM HOLDINGS	50MG	N005010	001		Jan CAHN
AA	+		100MG	N005010	004		Jan CAHN

MEPERIDINE HYDROCHLORIDE

>D>	AA	ROXANE	50MG	A040110	001	Mar 12, 1997	Nov CAHN
>D>	AA		100MG	A040110	002	Mar 12, 1997	Nov CAHN
		@ SUN PHARM INDS	50MG	A080448	001		Mar CAHN
		@	100MG	A080448	002		Mar CAHN
>A>	AA	WEST-WARD PHARMS INT	50MG	A040110	001	Mar 12, 1997	Nov CAHN
>A>	AA		100MG	A040110	002	Mar 12, 1997	Nov CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

@	WEST-WARD PHARMS INT	25MG/ML;25MG/ML	N011730	001		Oct CAHN
---	----------------------	-----------------	---------	-----	--	----------

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

@	AUROLIFE PHARMA LLC	400MG	A080655	001		Feb CAHN
@	SUN PHARM INDS	200MG	A080699	001		Mar CAHN
@		400MG	A080699	002		Mar CAHN

MERCAPTOPURINE

TABLET;ORAL

MERCAPTOPURINE

AB		DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Apr CAHN	
>D>	AB	+	ROXANE	50MG	A040528	001	Feb 13, 2004	Nov CAHN
>A>	AB	+	WEST-WARD PHARMS INT	50MG	A040528	001	Feb 13, 2004	Nov CAHN

PURINETHOL

AB		STASON PHARMS	50MG	N009053	002		Aug CMFD
	@		50MG	N009053	002		Jan CAHN

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP		AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar NEWA
AP			1GM/VIAL	A205883	002	Apr 12, 2016	Mar NEWA
AP		GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016	May NEWA
AP			1GM/VIAL	A206141	002	Jun 08, 2016	May NEWA

INJECTABLE; INJECTION

MEROPENEM

AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	May NEWA
AP		1GM/VIAL	A204139	002	Jun 09, 2016	May NEWA
AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+	APIL	400MG	N204412	001	Feb 01, 2013	Jan CAHN
TABLET, DELAYED RELEASE; ORAL						
ASACOL						
@	APIL	400MG	N019651	001	Jan 31, 1992	Jan CAHN
ASACOL HD						
+	APIL	800MG	N021830	001	May 29, 2008	Jan CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	WEST-WARD PHARMS INT	100MG/ML	A075739	001	Jan 09, 2004	Oct CAHN
----	----------------------	----------	---------	-----	--------------	----------

METAXALONE

TABLET; ORAL

METAXALONE

>A>	AB	LANNETT HOLDINGS INC	800MG	A204770	001	Nov 22, 2016	Nov NEWA
-----	----	----------------------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	CSPC OUYI PHARM CO	500MG	A205096	001	Jul 11, 2016	Jun NEWA
AB		850MG	A205096	002	Jul 11, 2016	Jun NEWA
AB		1GM	A205096	003	Jul 11, 2016	Jun NEWA
AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar CAHN
AB		850MG	A076038	002	Feb 21, 2002	Mar CAHN
AB		1GM	A076038	003	Feb 21, 2002	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

AB3	SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan CTEC	
AB3	+	1GM	N021748	002	Jun 03, 2005	Jan CTEC	
METFORMIN HYDROCHLORIDE							
AB3	ACTAVIS LABS FL INC	500MG	A203755	001	Aug 01, 2016	Jul NEWA	
AB3		1GM	A203755	002	Aug 01, 2016	Jul NEWA	
>A>	AB1	BEXIMCO PHARMS USA	500MG	A207427	001	Dec 13, 2016	Nov NEWA
>A>	AB		750MG	A207427	002	Dec 13, 2016	Nov NEWA
	@	IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar DISC
	@		750MG	A076985	001	Sep 13, 2005	Mar DISC
>A>	AB1	MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016	Nov NEWA
>A>	AB		750MG	A206955	002	Dec 07, 2016	Nov NEWA
AB1	MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr NEWA	
AB		750MG	A090295	002	Apr 29, 2016	Apr NEWA	
	@	SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar CAHN
AB3	SUN PHARMA GLOBAL	500MG	A202917	001	Aug 01, 2016	Jul NEWA	
AB3		1GM	A202917	002	Aug 01, 2016	Jul NEWA	

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016	Oct NEWA
------------	-------------	---------	-----	--------------	----------

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

>D>	AA	ROXANE	10MG/ML	A040180	001	Apr 30, 1998	Nov CAHN
>A>	AA	WEST-WARD PHARMS INT	10MG/ML	A040180	001	Apr 30, 1998	Nov CAHN
METHADONE HYDROCHLORIDE INTENSOL							
>D>	AA	ROXANE	10MG/ML	A089897	001	Sep 06, 1988	Nov CAHN
>A>	AA	WEST-WARD PHARMS INT	10MG/ML	A089897	001	Sep 06, 1988	Nov CAHN
INJECTABLE; INJECTION							
>D>		DOLOPHINE HYDROCHLORIDE					
>D>	+	MYLAN INSTITUTIONAL	10MG/ML	N021624	001		Nov CTNA

		INJECTABLE; INJECTION					
>A>		METHADONE HYDROCHLORIDE					
>A>	+	MYLAN INSTITUTIONAL	10MG/ML	N021624	001		Nov CTNA
		SOLUTION; ORAL					
		METHADONE HYDROCHLORIDE					
>D>	AA	+	ROXANE	5MG/5ML	A087393	001	Nov CAHN
>D>	AA	+		10MG/5ML	A087997	001	Aug 30, 1982 Nov CAHN
>A>	AA	+	WEST-WARD PHARMS INT	5MG/5ML	A087393	001	Nov CAHN
>A>	AA	+		10MG/5ML	A087997	001	Aug 30, 1982 Nov CAHN
		TABLET, FOR SUSPENSION; ORAL					
		METHADOSE					
	AA		MALLINCKRODT INC	40MG	A074184	001	Apr 29, 1993 Aug CAHN
<u>METHAMPHETAMINE HYDROCHLORIDE</u>							
		TABLET; ORAL					
		METHAMPHETAMINE HYDROCHLORIDE					
	AA		MAYNE PHARMA INC	5MG	A091189	001	Apr 21, 2010 Aug CAHN
>D>	AA		ROXANE	5MG	A203846	001	Nov 17, 2015 Nov CAHN
>A>	AA		WEST-WARD PHARMS INT	5MG	A203846	001	Nov 17, 2015 Nov CAHN
<u>METHENAMINE HIPPURATE</u>							
		TABLET; ORAL					
		HIPREX					
AB	+	US PHARM HOLDINGS	1GM	N017681	001		Jan CAHN
		METHENAMINE HIPPURATE					
AB		AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun NEWA
<u>METHIMAZOLE</u>							
		TABLET; ORAL					
		METHIMAZOLE					
AB		ECI PHARMS LLC	5MG	A040547	001	Feb 18, 2005	Jul CAHN
AB			10MG	A040547	002	Feb 18, 2005	Jul CAHN
		@	20MG	A040547	004	Feb 18, 2005	Jul CAHN
AB		RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan CAHN
AB			10MG	A202068	002	Mar 07, 2012	Jan CAHN
<u>METHOCARBAMOL</u>							
		SOLUTION; IM-IV					
		METHOCARBAMOL					
AP		AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May NEWA
AP		MONTEREY PHARMS LLC	1GM/10ML (100MG/ML)	A205354	001	Oct 27, 2016	Oct NEWA
		ROBAXIN					
AP	+	WEST-WARD PHARMS INT	1GM/10ML (100MG/ML)	N011790	001		Oct CAHN
		TABLET; ORAL					
		METHOCARBAMOL					
		@ LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Aug DISC
		@	750MG	A084756	001		Aug DISC
		@ SANDOZ	500MG	A084616	001		Feb DISC
		@	750MG	A084615	001		Feb DISC
		@ SUN PHARM INDS	500MG	A084488	001		Mar CAHN
		@	750MG	A084486	001		Mar CAHN
		ROBAXIN					
AA	+	AUXILIUM PHARMS INC	500MG	N011011	004		Mar CAHN
AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004		Jul CAHN
		ROBAXIN-750					
AA	+	AUXILIUM PHARMS INC	750MG	N011011	006		Mar CAHN
AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Jul CAHN
<u>METHOHEXITAL SODIUM</u>							
		INJECTABLE; INJECTION					
		BREVITAL SODIUM					
		@ PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC
<u>METHOTREXATE</u>							
		SOLUTION; SUBCUTANEOUS					
		OTREXUP					
		@ ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Sep DISC
			12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May NEWA
			17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May NEWA
			22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May NEWA

METHOTREXATE SODIUMINJECTABLE; INJECTION
METHOTREXATE SODIUM

AP	+	WEST-WARD PHARMS INT	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Oct CAHN
	+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Oct CAHN
		METHOTREXATE SODIUM PRESERVATIVE FREE					
AP		SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan CAHN
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan CAHN
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan CAHN
AP	+	WEST-WARD PHARMS INT	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Oct CAHN
AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Oct CAHN
	+		EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Sep CAHN

TABLET; ORAL

METHOTREXATE SODIUM

>D>	AB	ROXANE	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Nov CAHN

METHOXSALLENCAPSULE; ORAL
METHOXSALLEN

	@	IDT AUSTRALIA LTD	10MG	A087781	001	Jun 08, 1982	Aug CAHN
		INJECTABLE; INJECTION					
		UVADEX					
	+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	@	SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986	Mar CAHN
	@		250MG	A070060	001	Oct 09, 1986	Mar CAHN
	@		500MG	A070074	001	Oct 09, 1986	Mar CAHN

METHYLENE BLUESOLUTION; INTRAVENOUS
PROVAYBLUE

	+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr NEWA
--	---	----------------	--------------------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

	@	EDISON THERAPS LLC	0.2MG	N006035	003		Jan DISC
		METHYLERGONOVINE MALEATE					
	+	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan CRLD

METHYLNALTREXONE BROMIDESOLUTION; SUBCUTANEOUS
RELISTOR

	+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Jul CRLD
--	---	--------------	-----------------------	---------	-----	--------------	----------

TABLET; ORAL

RELISTOR

	+	SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016	Jul NEWA
--	---	------------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB2		COREPHARMA	10MG	A205105	001	Jul 28, 2016	Jul NEWA
AB2			20MG	A205105	002	Jul 28, 2016	Jul NEWA
AB2			30MG	A205105	003	Jul 28, 2016	Jul NEWA
AB2			40MG	A205105	004	Jul 28, 2016	Jul NEWA
AB2			50MG	A205105	005	Jul 28, 2016	Jul NEWA
AB2			60MG	A205105	006	Jul 28, 2016	Jul NEWA
AB1		MAYNE PHARMA	20MG	A078458	001	Dec 01, 2011	Aug CAHN
AB1			30MG	A078458	002	Dec 01, 2011	Aug CAHN
AB1			40MG	A078458	003	Dec 01, 2011	Aug CAHN
AB1			60MG	A078458	004	Jun 23, 2016	Aug CAHN
AB1		WATSON LABS INC	60MG	A078458	004	Jun 23, 2016	Jun NEWA

CAPSULE, EXTENDED RELEASE;ORAL									
RITALIN LA									
AB1	+	NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun	CFTG	
SOLUTION;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
>A>	AA	ABHAI	5MG/5ML	A207485	001	Nov 18, 2016	Nov	NEWA	
>A>	AA		10MG/5ML	A207485	002	Nov 18, 2016	Nov	NEWA	
	AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb	CAHN	
	AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb	CAHN	
TABLET;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
AB		CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016	Sep	NEWA	
AB			10MG	A206840	002	Sep 15, 2016	Sep	NEWA	
AB			20MG	A206840	003	Sep 15, 2016	Sep	NEWA	
TABLET, CHEWABLE;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
AB		NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Oct	CTEC	
AB			5MG	A204115	002	Feb 25, 2015	Oct	CTEC	
AB	+		10MG	A204115	003	Feb 25, 2015	Oct	CTEC	
AB		TEDOR PHARMA INC	2.5MG	A205756	001	Nov 07, 2016	Oct	NEWA	
AB			5MG	A205756	002	Nov 07, 2016	Oct	NEWA	
AB			10MG	A205756	003	Nov 07, 2016	Oct	NEWA	
TABLET, EXTENDED RELEASE;ORAL									
CONCERTA									
AB		JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Oct	CTEC	
AB			27MG	N021121	004	Apr 01, 2002	Oct	CTEC	
AB			36MG	N021121	002	Aug 01, 2000	Oct	CTEC	
AB	+		54MG	N021121	003	Dec 08, 2000	Oct	CTEC	
METHYLPHENIDATE HYDROCHLORIDE									
AB		CNTY LINE PHARMS	10MG	A204772	001	Feb 29, 2016	Aug	CAHN	
AB			20MG	A204772	002	Feb 29, 2016	Aug	CAHN	
AB		MYLAN PHARMS INC	18MG	A206726	001	Oct 21, 2016	Oct	NEWA	
AB			27MG	A206726	002	Oct 21, 2016	Oct	NEWA	
AB			36MG	A206726	003	Oct 21, 2016	Oct	NEWA	
AB			54MG	A206726	004	Oct 21, 2016	Oct	NEWA	
AB		TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb	NEWA	
AB			20MG	A204772	002	Feb 29, 2016	Feb	NEWA	
<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>									
INJECTABLE;INJECTION									
METHYLPREDNISOLONE SODIUM SUCCINATE									
AP		AMNEAL PHARMS CO	EQ 40MG BASE/VIAL	A207549	001	Nov 09, 2016	Oct	NEWA	
AP			EQ 125MG BASE/VIAL	A207549	002	Nov 09, 2016	Oct	NEWA	
AP		HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb	NEWA	
AP			EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb	NEWA	
AP		SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan	CAHN	
AP			EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan	CAHN	
AP			EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan	CAHN	
AP			EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan	CAHN	
AP			EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan	CAHN	
<u>METHYLTESTOSTERONE</u>									
TABLET;ORAL									
ANDROID 10									
	@	VALEANT PHARM INTL	10MG	A086450	001		Apr	DISC	
METHYLTESTOSTERONE									
	@	IMPAX LABS	25MG	A084310	001		Mar	DISC	
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
REGLAN									
	@	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862	001		Oct	CAHN	
	@		EQ 10MG BASE/ML	N017862	004	May 28, 1987	Oct	CAHN	
SOLUTION;ORAL									
METOCLOPRAMIDE HYDROCHLORIDE									
	@	SILARX	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992	Aug	DISC	
TABLET;ORAL									
METOCLOPRAMIDE HYDROCHLORIDE									
AB		IMPAX LABS INC	EQ 5MG BASE	A072750	001	Dec 28, 1995	Aug	CAHN	
AB			EQ 10MG BASE	A071250	001	Feb 03, 1988	Aug	CAHN	
AB		SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar	CAHN	
	@		EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar	CAHN	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

>A>	AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Nov	NEWA
>A>	AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Nov	NEWA
>A>	AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Nov	NEWA
>A>	AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Nov	NEWA

METOPROLOL TARTRATE

TABLET;ORAL
METOPROLOL TARTRATE

		@ SANDOZ	50MG	A073288	001	Mar 25, 1994	May	DISC
		@	100MG	A073289	001	Mar 25, 1994	May	DISC
AB		SUN PHARM INDS	25MG	A073654	002	Jul 15, 2009	Mar	CAHN
AB			100MG	A073654	001	Dec 21, 1993	Mar	CAHN

METRONIDAZOLE

GEL;VAGINAL
NUVESSA

+	ALLERGAN SALES LLC	1.3%	N205223	001	Mar 24, 2014	Apr	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

TABLET;ORAL
METRONIDAZOLE

AB		FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	May	NEWA
AB			500MG	A207309	002	May 16, 2016	May	NEWA
AB		STRIDES PHARMA	250MG	A208162	001	May 25, 2016	May	NEWA
AB			500MG	A208162	002	May 25, 2016	May	NEWA
AB		VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	May	CMFD
AB			500MG	A070039	001	Jan 29, 1985	May	CMFD
AB		ZYDUS PHARMS USA INC	250MG	A206560	001	Nov 16, 2016	Oct	NEWA
AB			500MG	A206560	002	Nov 16, 2016	Oct	NEWA

MICAFUNGIN SODIUM

INJECTABLE;IV (INFUSION)
MYCAMINE

+	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	Sep	CPOT
+		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	Sep	CPOT

MICONAZOLE

TABLET;BUCCAL
ORAVIG

+	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

SYRUP;ORAL
MIDAZOLAM HYDROCHLORIDE

>D>	AA	+	ROXANE	EQ 2MG BASE/ML	A075873	001	Apr 30, 2002	Nov	CAHN
>A>	AA	+	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A075873	001	Apr 30, 2002	Nov	CAHN

MIGLITOL

TABLET;ORAL
GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb	CRLD
AB			100MG	N020682	003	Dec 18, 1996	Feb	CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Apr	NEWA
AB			25MG	A205081	002	Apr 22, 2016	Apr	NEWA
AB			50MG	A205081	003	Apr 22, 2016	Apr	NEWA
AB			100MG	A205081	004	Apr 22, 2016	Apr	NEWA
		@ LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan	DISC
			12.5MG	A205071	001	Jan 27, 2016	Jan	NEWA
		@	25MG	A205071	002	Jan 27, 2016	Jan	DISC
			25MG	A205071	002	Jan 27, 2016	Jan	NEWA
		@	50MG	A205071	003	Jan 27, 2016	Jan	DISC
			50MG	A205071	003	Jan 27, 2016	Jan	NEWA
		@	100MG	A205071	004	Jan 27, 2016	Jan	DISC
			100MG	A205071	004	Jan 27, 2016	Jan	NEWA
		SAVELLA						
AB		CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr	CFTG

TABLET;ORAL							
SAVELLA							
AB		25MG	N022256	002	Jan 14, 2009	Apr	CFTG
AB	+	50MG	N022256	003	Jan 14, 2009	Apr	CFTG
AB		100MG	N022256	004	Jan 14, 2009	Apr	CFTG
<u>MILRINONE LACTATE</u>							
INJECTABLE;INJECTION							
MILRINONE LACTATE IN DEXTROSE 5%							
AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar	CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@ B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004	Sep	DISC
	@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar	CAHN
<u>MINOCYCLINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
DYNACIN							
	@ CNTY LINE PHARMS	EQ 50MG BASE	A063067	003	Aug 14, 1990	Oct	CMS1
MINOCYCLINE HYDROCHLORIDE							
AB	ZYDUS WORLDWIDE	EQ 50MG BASE	A063011	001	Mar 02, 1992	Aug	CAHN
AB		EQ 75MG BASE	A063009	002	Aug 12, 2003	Aug	CAHN
AB	+	EQ 100MG BASE	A063009	001	Mar 02, 1992	Aug	CAHN
TABLET;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan	NEWA
AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan	NEWA
AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan	NEWA
TABLET, EXTENDED RELEASE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	ALKEM LABS LTD	EQ 45MG BASE	A204453	001	Sep 28, 2016	Sep	NEWA
AB		EQ 80MG BASE	A204453	002	Sep 28, 2016	Sep	NEWA
AB		EQ 90MG BASE	A204453	003	Sep 28, 2016	Sep	NEWA
AB		EQ 105MG BASE	A204453	004	Sep 28, 2016	Sep	NEWA
AB		EQ 135MG BASE	A204453	005	Sep 28, 2016	Sep	NEWA
AB	AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May	NEWA
AB		EQ 105MG BASE	A202261	007	Jun 13, 2016	May	NEWA
	@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar	DISC
	@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar	DISC
	@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar	DISC
<u>MINOXIDIL</u>							
TABLET;ORAL							
MINOXIDIL							
AB	SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar	CAHN
<u>MIPOMERSEN SODIUM</u>							
SOLUTION;SUBCUTANEOUS							
KYNAMRO							
	+ KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun	CAHN
<u>MIRTAZAPINE</u>							
TABLET;ORAL							
MIRTAZAPINE							
	@ ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan	DISC
	@	30MG	A076336	002	Jun 20, 2003	Jan	DISC
	@	45MG	A076336	003	Jun 20, 2003	Jan	DISC
	@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Oct	CAHN
AB		15MG	A076219	001	Jun 19, 2003	Oct	CAHN
	@	30MG	A076189	002	Jun 19, 2003	Oct	CAHN
AB		30MG	A076219	002	Jun 19, 2003	Oct	CAHN
	@	45MG	A076189	003	Jun 19, 2003	Oct	CAHN
AB		45MG	A076219	003	Jun 19, 2003	Oct	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
MIRTAZAPINE							
AB	IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005	Aug	CAHN
AB		30MG	A076901	002	Jun 28, 2005	Aug	CAHN
AB		45MG	A076901	003	Jun 28, 2005	Aug	CAHN

MITOMYCININJECTABLE;INJECTION
MITOMYCIN

AP	EUROHLTH INTL SARL	5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MITOXANTRONE HYDROCHLORIDEINJECTABLE;INJECTION
MITOXANTRONE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Oct CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Oct CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Oct CAHN

MODAFINILTABLET;ORAL
MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOEXIPRIL HYDROCHLORIDETABLET;ORAL
MOEXIPRIL HYDROCHLORIDE

AB	+ TEVA	15MG	A076204	002	May 08, 2003	Aug CRLD
----	--------	------	---------	-----	--------------	----------

MOMETASONE FUROATECREAM;TOPICAL
ELOCON

AB	@ MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987	Aug DISC
AB	+	0.1%	N019625	002	Apr 19, 2013	Aug CRLD

SPRAY, METERED;NASAL
MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA
AB	NASONEX					
AB	+ MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MONTELUKAST SODIUMTABLET;ORAL
MONTELUKAST SODIUM

AB	CIPLA LTD	EQ 10MG BASE	A207463	001	Oct 28, 2016	Oct NEWA
>D> AB	ROXANE	EQ 10MG BASE	A090655	001	Aug 03, 2012	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	EQ 10MG BASE	A090655	001	Aug 03, 2012	Nov CAHN

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM

>D> AB	ROXANE	EQ 4MG BASE	A091128	001	Aug 03, 2012	Nov CAHN
>D> AB		EQ 5MG BASE	A091128	002	Aug 03, 2012	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	EQ 4MG BASE	A091128	001	Aug 03, 2012	Nov CAHN
>A> AB		EQ 5MG BASE	A091128	002	Aug 03, 2012	Nov CAHN

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB		20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB		30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB		40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB		50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB		60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB		70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB		80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+	100MG	N020616	003	Jul 03, 1996	Feb CTEC
AB	+	200MG	N020616	007	Feb 27, 2007	Feb CTEC
AB	+ ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB		20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB		30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB		40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB		50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB		60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB		70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB		80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+	100MG	N020616	003	Jul 03, 1996	Apr CAHN

CAPSULE, EXTENDED RELEASE;ORAL
KADIAN

		130MG	N020616	011	Jul 09, 2012	Apr CAHN
		150MG	N020616	012	Jul 09, 2012	Apr CAHN
+		200MG	N020616	007	Feb 27, 2007	Apr CAHN
	MORPHINE SULFATE					
AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB		30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB		50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB		60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB		80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
AB		30MG	A200812	002	Nov 10, 2011	Feb CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC
AB		30MG	A202718	002	Dec 29, 2014	Feb CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb CTEC

INJECTABLE;INJECTION
DURAMORPH PF

AP	+	WEST-WARD PHARMS INT	0.5MG/ML	N018565	001	Sep 18, 1984	Oct CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Oct CAHN
	INFUMORPH						
	+	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991	Oct CAHN
	+		25MG/ML	N018565	004	Jul 19, 1991	Oct CAHN

SOLUTION;ORAL

	MORPHINE SULFATE					
AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar CAHN
AA		100MG/5ML	A204053	001	Oct 06, 2016	Sep NEWA
AA	PHARM ASSOC	100MG/5ML	A206573	001	Nov 14, 2016	Oct NEWA
AA	RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun NEWA
AA	TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL

	MORPHINE SULFATE					
AB	COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun NEWA
AB		30MG	A091357	002	Jun 23, 2016	Jun NEWA
AB		60MG	A091357	003	Jun 23, 2016	Jun NEWA
AB		100MG	A091357	004	Jun 23, 2016	Jun NEWA
AB		200MG	A091357	005	Jun 23, 2016	Jun NEWA
AB	MAYNE PHARMA INC	15MG	A205386	001	Oct 28, 2016	Oct NEWA
AB		30MG	A205386	002	Oct 28, 2016	Oct NEWA
AB		60MG	A205386	003	Oct 28, 2016	Oct NEWA
AB		100MG	A205386	004	Oct 28, 2016	Oct NEWA
AB	SUN PHARM INDS LTD	15MG	A205634	001	Aug 25, 2016	Aug NEWA
AB		30MG	A205634	002	Aug 25, 2016	Aug NEWA
AB		60MG	A205634	003	Aug 25, 2016	Aug NEWA
AB		100MG	A205634	004	Aug 25, 2016	Aug NEWA
AB		200MG	A205634	005	Aug 25, 2016	Aug NEWA

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXEZA

>D>	AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Nov CAHN
>A>	AT2	+	NOVARTIS PHARMS CORP	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Nov CAHN

TABLET;ORAL					
MOXIFLOXACIN HYDROCHLORIDE					
AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016 Jan NEWA
<u>MYCOPHENOLATE MOFETIL</u>					
CAPSULE;ORAL					
MYCOPHENOLATE MOFETIL					
AB	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014 Jun CAHN
>D> AB	ROXANE	250MG	A065410	001	Jul 29, 2008 Nov CAHN
>A> AB	WEST-WARD PHARMS INT	250MG	A065410	001	Jul 29, 2008 Nov CAHN
TABLET;ORAL					
MYCOPHENOLATE MOFETIL					
AB	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014 Jun CAHN
>D> AB	ROXANE	500MG	A065413	001	Jul 29, 2008 Nov CAHN
>A> AB	WEST-WARD PHARMS INT	500MG	A065413	001	Jul 29, 2008 Nov CAHN
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE</u>					
INJECTABLE;INJECTION					
CELLCEPT					
AP	+ ROCHE PALO	500MG/VIAL	N050758	001	Aug 12, 1998 Oct CFTG
MYCOPHENOLATE MOFETIL HYDROCHLORIDE					
AP	PAR STERILE PRODUCTS	500MG/VIAL	A203575	001	Oct 28, 2016 Oct NEWA
<u>NABUMETONE</u>					
TABLET;ORAL					
NABUMETONE					
AB	IMPAX LABS INC	500MG	A075189	001	May 26, 2000 Aug CAHN
AB	+	750MG	A075189	002	Sep 24, 2001 Aug CAHN
<u>NAFTIFINE HYDROCHLORIDE</u>					
CREAM;TOPICAL					
NAFTIFINE HYDROCHLORIDE					
AB	TARO	1%	A205975	001	Sep 08, 2016 Aug NEWA
<u>NALBUPHINE HYDROCHLORIDE</u>					
INJECTABLE;INJECTION					
NUBAIN					
	@ PAR PHARM INC	10MG/ML	N018024	001	Aug CAHN
	@	20MG/ML	N018024	002	May 27, 1982 Aug CAHN
<u>NALIDIXIC ACID</u>					
TABLET;ORAL					
NALIDIXIC ACID					
	@ SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988 Mar CAHN
	@	500MG	A070271	001	Jun 29, 1988 Jun CAHN
	@	1GM	A070272	001	Jun 29, 1988 Mar CAHN
<u>NALOXONE HYDROCHLORIDE</u>					
INJECTABLE;INJECTION					
NALOXONE					
AP	WEST-WARD PHARMS INT	0.4MG/ML	A070299	001	Sep 24, 1986 Oct CAHN
NALOXONE HYDROCHLORIDE					
AP	MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016 Jun NEWA
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
EVZIO					
+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014 Oct CPOT
+		2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016 Oct NEWA
<u>NALTREXONE HYDROCHLORIDE</u>					
TABLET;ORAL					
NALTREXONE HYDROCHLORIDE					
AB	+ MALLINCKRODT	50MG	A076264	002	Mar 22, 2002 Oct CRLD
REVIA					
	@ TEVA WOMENS	50MG	N018932	001	Nov 20, 1984 Oct DISC
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE</u>					
CAPSULE, EXTENDED RELEASE;ORAL					
TROXYCA ER					
	PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016 Aug NEWA
		2.4MG;20MG	N207621	002	Aug 19, 2016 Aug NEWA
		3.6MG;30MG	N207621	003	Aug 19, 2016 Aug NEWA

CAPSULE, EXTENDED RELEASE;ORAL
TROXYCA ER4.8MG;40MG
7.2MG;60MG
9.6MG;80MGN207621 004 Aug 19, 2016 Aug NEWA
N207621 005 Aug 19, 2016 Aug NEWA
N207621 006 Aug 19, 2016 Aug NEWANAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB + ATNAHS PHARMA US 25MG/ML
NAPROXEN

N018965 001 Mar 23, 1987 Jun CAHN

>D> AB ROXANE 25MG/ML

A074190 001 Mar 30, 1994 Nov CAHN

>A> AB WEST-WARD PHARMS INT 25MG/ML

A074190 001 Mar 30, 1994 Nov CAHN

TABLET;ORAL

NAPROSYN

AB ATNAHS PHARMA US 250MG

N017581 002 Feb CAHN

AB 375MG

N017581 003 Feb CAHN

AB + 500MG

N017581 004 Apr 15, 1982 Feb CAHN

NAPROXEN

@ SANDOZ 250MG

A074140 001 Dec 21, 1993 Feb DISC

@ 375MG

A074140 002 Dec 21, 1993 Feb DISC

@ 500MG

A074140 003 Dec 21, 1993 Feb DISC

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

AB + ATNAHS PHARMA US 375MG

N020067 002 Oct 14, 1994 Feb CAHN

AB + 500MG

N020067 003 Oct 14, 1994 Feb CAHN

NAPROXEN

@ SANDOZ 375MG

A075061 001 Feb 18, 1998 Feb DISC

@ 500MG

A075061 002 Feb 18, 1998 Feb DISC

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

AB ATNAHS PHARMA US EQ 250MG BASE

N018164 001 Feb CAHN

ANAPROX DS

AB + ATNAHS PHARMA US EQ 500MG BASE

N018164 003 Sep 30, 1987 Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

AB + ALVOGEN MALTA EQ 750MG BASE

N020353 003 Jan 05, 1996 Aug CFTG

NAPROXEN SODIUM

AB ACTAVIS LABS FL INC EQ 750MG BASE

A075416 003 Aug 11, 2016 Aug NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

>D> AB ROXANE EQ 1MG BASE

A090381 001 Jul 07, 2010 Nov CAHN

>D> AB EQ 2.5MG BASE

A090381 002 Jul 07, 2010 Nov CAHN

>A> AB WEST-WARD PHARMS INT EQ 1MG BASE

A090381 001 Jul 07, 2010 Nov CAHN

>A> AB EQ 2.5MG BASE

A090381 002 Jul 07, 2010 Nov CAHN

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

AB ZYDUS PHARMS USA INC 60MG

A205248 001 Jul 06, 2016 Jun NEWA

AB 120MG

A205248 002 Jul 06, 2016 Jun NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

FOREST LABS LLC EQ 5MG BASE;80MG

N206302 001 Jun 03, 2016 Jun NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

@ SUN PHARM INDS LTD 50MG

A076409 001 Sep 16, 2003 Feb DISC

@ 100MG

A076409 002 Sep 16, 2003 Feb DISC

@ 150MG

A076409 003 Sep 16, 2003 Feb DISC

@ 200MG

A076409 004 Sep 16, 2003 Feb DISC

@ 250MG

A076409 005 Sep 16, 2003 Feb DISC

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA LANNETT HOLDINGS INC 500MG

A204435 001 Jun 10, 2016 May NEWA

NEPAFENAC

SUSPENSION/DROPS;OPHTHALMIC

ILEVRO

>D> + ALCON RES LTD 0.3%

N203491 001 Oct 16, 2012 Nov CAHN

>A> + NOVARTIS PHARMS CORP 0.3%

N203491 001 Oct 16, 2012 Nov CAHN

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

>A> AB AUROBINDO PHARMA LTD 100MG

A208616 001 Nov 23, 2016 Nov NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

CARDENE

@ CHIESI USA INC 20MG

N019488 001 Dec 21, 1988 May DISC

@ 30MG

N019488 002 Dec 21, 1988 May DISC

NICARDIPINE HYDROCHLORIDE

AB + MYLAN 30MG

A074642 002 Jul 18, 1996 May CRLD

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB VALIDUS PHARMS 10MG

A073250 001 Oct 08, 1991 Jul CMFD

@ 10MG

A073250 001 Oct 08, 1991 Mar CAHN

AB 20MG

A074045 001 Apr 30, 1992 Jul CMFD

@ 20MG

A074045 001 Apr 30, 1992 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

AB1 ALVOGEN 30MG

N020198 001 Apr 21, 1993 Feb CAHN

AB1 + 60MG

N020198 002 Apr 21, 1993 Feb CAHN

AB1 + 90MG

N020198 003 Apr 21, 1993 Feb CAHN

NIFEDIPINE

AB1 NOVAST LABS LTD 30MG

A202987 001 Aug 25, 2016 Aug NEWA

AB1 60MG

A202987 002 Aug 25, 2016 Aug NEWA

AB1 90MG

A202987 003 Aug 25, 2016 Aug NEWA

AB2 OSMOTICA PHARM US 30MG

A077127 001 Nov 21, 2005 Jun CAHN

AB2 60MG

A077127 002 Nov 21, 2005 Jun CAHN

AB1 VALEANT PHARMS NORTH 30MG

A075269 001 Dec 04, 2000 Jan CAHN

AB1 60MG

A075269 002 Dec 04, 2000 Jan CAHN

AB1 90MG

A076070 001 Aug 16, 2002 Jan CAHN

NILUTAMIDE

TABLET;ORAL

NILANDRON

AB + CONCORDIA PHARMS INC 150MG

N020169 002 Apr 30, 1999 Jul CFTG

NILUTAMIDE

AB ANI PHARMS INC 150MG

A207631 001 Jul 15, 2016 Jul NEWA

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB + BIONPHARMA INC 30MG

A076740 001 Jan 17, 2008 Jan CAHN

AB HERITAGE PHARMS INC 30MG

A077811 001 May 02, 2007 Aug CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

SULAR

>A> AB + COVIS PHARMA SARL 8.5MG

N020356 008 Jan 02, 2008 Nov CAHN

>A> @ 10MG

N020356 001 Feb 02, 1995 Nov CAHN

>A> AB + 17MG

N020356 007 Jan 02, 2008 Nov CAHN

>A> @ 20MG

N020356 002 Feb 02, 1995 Nov CAHN

>A> @ 25.5MG

N020356 006 Jan 02, 2008 Nov CAHN

>A> @ 30MG

N020356 003 Feb 02, 1995 Nov CAHN

>A> AB + 34MG

N020356 005 Jan 02, 2008 Nov CAHN

>A> @ 40MG

N020356 004 Feb 02, 1995 Nov CAHN

>D> AB + SHIONOGI INC 8.5MG

N020356 008 Jan 02, 2008 Nov CAHN

TABLET, EXTENDED RELEASE;ORAL
SULAR

>D>	@	10MG	N020356	001	Feb 02, 1995	Nov CAHN
>D> AB	+	17MG	N020356	007	Jan 02, 2008	Nov CAHN
>D>	@	20MG	N020356	002	Feb 02, 1995	Nov CAHN
>D>	@	25.5MG	N020356	006	Jan 02, 2008	Nov CAHN
>D>	@	30MG	N020356	003	Feb 02, 1995	Nov CAHN
>D> AB	+	34MG	N020356	005	Jan 02, 2008	Nov CAHN
>D>	@	40MG	N020356	004	Feb 02, 1995	Nov CAHN

NITISINONE

CAPSULE;ORAL
ORFADIN

+	SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Jun NEWA
---	----------------	------	---------	-----	--------------	----------

SUSPENSION;ORAL
ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016	Apr NEWA
---	----------------	--------	---------	-----	--------------	----------

NITRIC OXIDE

GAS; INHALATION
INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan CAHN
---	-------------------	--------	---------	-----	--------------	----------

NITROFURANTOIN

SUSPENSION;ORAL
FURADANTIN

AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001	Jun CAHN
----	---	-------------------	----------	---------	-----	----------

AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr NEWA
----	--	----------------------	----------	---------	-----	--------------	----------

AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb CAHN
----	--	------------------	----------	---------	-----	--------------	----------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

AB		IMPAX LABS INC	50MG	A073671	001	Jan 28, 1993	Aug CAHN
AB			100MG	A073652	001	Jan 28, 1993	Aug CAHN
AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb NEWA
AB			50MG	A201722	002	Feb 16, 2016	Feb NEWA
AB			100MG	A201722	003	Feb 16, 2016	Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
MACROBID

AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan CAHN
----	---	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May CAHN
-----	--	----------------------	----------	---------	-----	--------------	----------

POWDER;SUBLINGUAL
GONITRO

+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun NEWA
---	--------------	--------------	---------	-----	--------------	----------

TABLET;SUBLINGUAL
NITROGLYCERIN

AB		DR REDDYS LABS INC	0.3MG	A208191	001	Aug 26, 2016	Aug NEWA
AB			0.4MG	A208191	002	Aug 26, 2016	Aug NEWA
AB			0.6MG	A208191	003	Aug 26, 2016	Aug NEWA

NITROSTAT

AB		PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000	Aug CFTG
AB			0.4MG	N021134	002	May 01, 2000	Aug CFTG
AB	+		0.6MG	N021134	003	May 01, 2000	Aug CFTG

NIZATIDINE

SOLUTION;ORAL
NIZATIDINE

+	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Feb CRLD
---	---------------	---------	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

AP	CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan CAHN
----	--------	----------------	---------	-----	--------------	----------

NORETHINDRONE

TABLET; ORAL-28
CAMILA

AB1	MAYNE PHARMA	0.35MG	A076177	001	Oct 21, 2002	Aug CAHN
-----	--------------	--------	---------	-----	--------------	----------

AB2	MAYNE PHARMA	0.35MG	A076225	001	Oct 21, 2002	Aug CAHN
-----	--------------	--------	---------	-----	--------------	----------

AB1	AUROBINDO PHARMA LTD	0.35MG	A207304	001	Sep 23, 2016	Sep NEWA
-----	----------------------	--------	---------	-----	--------------	----------

AB1	NOR-QD					
-----	--------	--	--	--	--	--

AB1	+ APIL	0.35MG	N017060	001		Jan CAHN
-----	--------	--------	---------	-----	--	----------

NORETHINDRONE

>A>	AB1	ACCORD HLTHCARE	0.35MG	A206807	001	Dec 13, 2016	Nov NEWA
-----	-----	-----------------	--------	---------	-----	--------------	----------

AB1	AMNEAL PHARMS	0.35MG	A202260	001	Aug 01, 2013	Aug CAHN
-----	---------------	--------	---------	-----	--------------	----------

AB2	GLENMARK GENERICS	0.35MG	A091209	001	Jul 22, 2010	Oct CMS1
-----	-------------------	--------	---------	-----	--------------	----------

NORETHINDRONE ACETATE

TABLET; ORAL
NORETHINDRONE ACETATE

AB	JAI PHARMA LTD	5MG	A205278	001	Nov 10, 2016	Oct NEWA
----	----------------	-----	---------	-----	--------------	----------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
--	-----------------------	--------------	---------	-----	--------------	----------

	@	EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
--	---	--------------	---------	-----	--------------	----------

	@	EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
--	---	--------------	---------	-----	--------------	----------

	@	EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN
--	---	--------------	---------	-----	--------------	----------

	@ IDT AUSTRALIA LTD	EQ 10MG BASE	A074054	001	Dec 31, 1992	May CAHN
--	---------------------	--------------	---------	-----	--------------	----------

	@	EQ 25MG BASE	A074054	002	Dec 31, 1992	May CAHN
--	---	--------------	---------	-----	--------------	----------

	@	EQ 50MG BASE	A074054	003	Dec 31, 1992	May CAHN
--	---	--------------	---------	-----	--------------	----------

	@	EQ 75MG BASE	A074054	004	Dec 31, 1992	May CAHN
--	---	--------------	---------	-----	--------------	----------

AB	MAYNE PHARMA	EQ 10MG BASE	A073553	001	Mar 30, 1992	Aug CAHN
----	--------------	--------------	---------	-----	--------------	----------

AB		EQ 25MG BASE	A073554	001	Mar 30, 1992	Aug CAHN
----	--	--------------	---------	-----	--------------	----------

AB		EQ 50MG BASE	A073555	001	Mar 30, 1992	Aug CAHN
----	--	--------------	---------	-----	--------------	----------

AB		EQ 75MG BASE	A073556	001	Mar 30, 1992	Aug CAHN
----	--	--------------	---------	-----	--------------	----------

NYSTATIN

POWDER; TOPICAL
NYSTATIN

AT	+ MAYNE PHARMA INC	100,000 UNITS/GM	A065203	001	Jul 15, 2004	Aug CAHN
----	--------------------	------------------	---------	-----	--------------	----------

TABLET; ORAL
NYSTATIN

AA	SUN PHARM INDS	500,000 UNITS	A062838	001	Dec 22, 1988	Mar CAHN
----	----------------	---------------	---------	-----	--------------	----------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	DR REDDYS LABS LTD	100,000 UNITS/GM; 0.1%	A208326	001	Oct 26, 2016	Oct NEWA
----	--------------------	------------------------	---------	-----	--------------	----------

AT	GLENMARK PHARMS LTD	100,000 UNITS/GM; 0.1%	A208136	001	Oct 24, 2016	Oct NEWA
----	---------------------	------------------------	---------	-----	--------------	----------

NYSTATIN TRIAMCINOLONE ACETONIDE

	@ PHARMADERM	100,000 UNITS/GM; 0.1%	A062596	001	Oct 08, 1985	Mar CMS1
--	--------------	------------------------	---------	-----	--------------	----------

OINTMENT; TOPICAL
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM; 0.1%	A062733	001	Mar 06, 1987	May CMS1
----	------------------	------------------------	---------	-----	--------------	----------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	GLENMARK PHARMS LTD	100,000 UNITS/GM; 0.1%	A208300	001	Jun 23, 2016	Jun NEWA
----	---------------------	------------------------	---------	-----	--------------	----------

OBETICHOLIC ACID

TABLET; ORAL
OCALIVA

	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May NEWA
--	----------------------	-----	---------	-----	--------------	----------

	+	10MG	N207999	002	May 27, 2016	May NEWA
--	---	------	---------	-----	--------------	----------

OCTREOTIDE ACETATEINJECTABLE; INJECTION
OCTREOTIDE ACETATE

AP	+	WEST-WARD PHARMS INT	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005	Oct CAHN
AP	+		EQ 1MG BASE/ML	A076330	002	Apr 08, 2005	Oct CAHN
	@	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan DISC
	@		EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan DISC
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
AP	+	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005	Oct CAHN
AP	+		EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005	Oct CAHN
AP	+		EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005	Oct CAHN
	@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan DISC
	@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan DISC
	@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan DISC
		OCTREOTIDE ACETATE PRESERVATIVE FREE					
	@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb CMS1
	@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb CMS1
	@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb CMS1

OFLOXACINSOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

AT		ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Mar CAHN
		SOLUTION/DROPS; OTIC					
		OFLOXACIN					
AT		ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Mar CAHN
AT	+	BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb CRLD

OLANZAPINETABLET; ORAL
OLANZAPINE

AB		AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016	Aug NEWA
AB			5MG	A206711	002	Aug 30, 2016	Aug NEWA
AB			7.5MG	A206711	003	Aug 30, 2016	Aug NEWA
AB			10MG	A206711	004	Aug 30, 2016	Aug NEWA
AB			15MG	A206711	005	Aug 30, 2016	Aug NEWA
AB			20MG	A206711	006	Aug 30, 2016	Aug NEWA
AB		INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb NEWA
AB			5MG	A203333	002	Mar 15, 2016	Feb NEWA
AB			7.5MG	A203333	003	Mar 15, 2016	Feb NEWA
AB			10MG	A203333	004	Mar 15, 2016	Feb NEWA
AB			15MG	A203333	005	Mar 15, 2016	Feb NEWA
AB			20MG	A203333	006	Mar 15, 2016	Feb NEWA
AB		QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan NEWA
AB			5MG	A204319	002	Jan 27, 2016	Jan NEWA
AB			7.5MG	A204319	003	Jan 27, 2016	Jan NEWA
AB			10MG	A204319	004	Jan 27, 2016	Jan NEWA
AB			15MG	A204319	005	Jan 27, 2016	Jan NEWA
AB			20MG	A204319	006	Jan 27, 2016	Jan NEWA
		TABLET, ORALLY DISINTEGRATING; ORAL					
		OLANZAPINE					
AB		INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb NEWA
AB			10MG	A203456	002	Mar 16, 2016	Feb NEWA
AB			15MG	A203456	003	Mar 16, 2016	Feb NEWA
AB			20MG	A203456	004	Mar 16, 2016	Feb NEWA

OLMESARTAN MEDOXOMILTABLET; ORAL
BENICAR

AB		DAIICHI SANKYO	5MG	N021286	001	Apr 25, 2002	Oct CFTG
AB			20MG	N021286	003	Apr 25, 2002	Oct CFTG
AB	+		40MG	N021286	004	Apr 25, 2002	Oct CFTG
		OLMESARTAN MEDOXOMIL					
AB		MYLAN PHARMS INC	5MG	A078276	001	Oct 26, 2016	Oct NEWA
AB			20MG	A078276	002	Oct 26, 2016	Oct NEWA
AB			40MG	A078276	003	Oct 26, 2016	Oct NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT		SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar CAHN	
		SPRAY, METERED;NASAL						
		PATANASE						
>D>	AB	+	ALCON PHARMS LTD	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Nov CAHN
>A>	AB	+	NOVARTIS PHARMS CORP	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Nov CAHN

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1
----	--	---------------	--	---------	-----	--------------	----------

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD

OMEPRAZOLE; SODIUM BICARBONATECAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	20MG;1.1GM	A204228	001	Jul 15, 2016	Jul NEWA
AB			40MG;1.1GM	A204228	002	Jul 15, 2016	Jul NEWA
AB		AUROLIFE PHARMA LLC	20MG;1.1GM	A204922	001	Aug 19, 2016	Aug NEWA
AB			40MG;1.1GM	A204922	002	Aug 19, 2016	Aug NEWA
AB		DR REDDYS LABS LTD	20MG;1.1GM	A204068	001	Jul 15, 2016	Jul NEWA
AB			40MG;1.1GM	A204068	002	Jul 15, 2016	Jul NEWA
>A>	AB	SCIEGEN PHARMS INC	20MG;1.1GM	A207476	001	Dec 06, 2016	Nov NEWA
>A>	AB		40MG;1.1GM	A207476	002	Dec 06, 2016	Nov NEWA
		FOR SUSPENSION;ORAL					
		OMEPRAZOLE AND SODIUM BICARBONATE					
AA		AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jul NEWA
AA			40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jul NEWA
		ZEGERID					
AA		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul CTEC
AA	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul CTEC

ONDANSETRONFILM;ORAL
ZUPLENZ

MIDATECH PHARMA US

		4MG	N022524	001	Jul 02, 2010	Jun CAHN
--	--	-----	---------	-----	--------------	----------

+		8MG	N022524	002	Jul 02, 2010	Jun CAHN
---	--	-----	---------	-----	--------------	----------

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP	+	CLARIS	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CRLD
	@	LANNETT	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010	Aug DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA
AP	+	CLARIS	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CRLD
		ZOFRAN					
	@	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC
		ZOFRAN PRESERVATIVE FREE					
	@	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Aug DISC
		SOLUTION;ORAL					
		ONDANSETRON HYDROCHLORIDE					
>D>	AA	ROXANE	EQ 4MG BASE/5ML	A076960	001	Dec 26, 2006	Nov CAHN
>A>	AA	WEST-WARD PHARMS INT	EQ 4MG BASE/5ML	A076960	001	Dec 26, 2006	Nov CAHN
		TABLET;ORAL					
		ONDANSETRON HYDROCHLORIDE					
	@	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
	@		EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
	@		EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN

ORPHENADRINE CITRATEINJECTABLE;INJECTION
ORPHENADRINE CITRATE

AP	WEST-WARD PHARMS INT	30MG/ML	A040463	001	Mar 04, 2003	Sep CAHN
----	----------------------	---------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATECAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB	NATCO PHARMA LTD	EQ 30MG BASE	A202595	001	Aug 03, 2016	Jul NEWA
AB		EQ 45MG BASE	A202595	002	Aug 03, 2016	Jul NEWA
AB		EQ 75MG BASE	A202595	003	Aug 03, 2016	Jul NEWA
TAMIFLU						
AB	ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul CFTG
AB		EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul CFTG
AB	+	EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul CFTG

OXALIPLATININJECTABLE;IV (INFUSION)
OXALIPLATIN

AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May NEWA
AP		50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May NEWA
AP		100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
	+	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun CRLD
AP		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May NEWA
	@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Aug DISC
	@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Aug DISC

OXAZEPAMCAPSULE;ORAL
OXAZEPAM

@	FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987	Oct CAHN
@		15MG	A071026	003	Aug 10, 1987	Oct CAHN
@		30MG	A071026	001	Aug 10, 1987	Oct CAHN
@	SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Mar CAHN
@		15MG	A071026	003	Aug 10, 1987	Mar CAHN
@		30MG	A071026	001	Aug 10, 1987	Mar CAHN

TABLET;ORAL

OXAZEPAM						
@	FRONTIDA BIOPHARM	15MG	A070683	001	Jan 16, 1987	Jul CAHN
@	SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jun CAHN

OXCARBAZEPINESUSPENSION;ORAL
OXCARBAZEPINE

>D>	AB	ROXANE	300MG/5ML	A201193	001	Oct 03, 2012	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	300MG/5ML	A201193	001	Oct 03, 2012	Nov CAHN

TABLET;ORAL

OXCARBAZEPINE							
AB	ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jun CMFD	
AB		300MG	A078005	002	Dec 11, 2007	Jun CMFD	
AB		600MG	A078005	003	Dec 11, 2007	Jun CMFD	
>D>	AB	ROXANE	150MG	A077795	001	Oct 09, 2007	Nov CAHN
>D>	AB		300MG	A077795	002	Oct 09, 2007	Nov CAHN
>D>	AB		600MG	A077795	003	Oct 09, 2007	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	150MG	A077795	001	Oct 09, 2007	Nov CAHN
>A>	AB		300MG	A077795	002	Oct 09, 2007	Nov CAHN
>A>	AB		600MG	A077795	003	Oct 09, 2007	Nov CAHN

OXICONAZOLE NITRATECREAM;TOPICAL
OXICONAZOLE NITRATE

AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb NEWA	
OXISTAT							
AB	+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

AB	+	ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr CAHN
		GEL, METERED;TRANSDERMAL					
		GELNIQUE 3%					
	+	ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Apr CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL
GELNIQUE

	+	ALLERGAN SALES LLC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Apr CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		OXYBUTYNIN CHLORIDE					
AB		ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb NEWA
AB			10MG	A207138	002	Feb 29, 2016	Feb NEWA
AB			15MG	A207138	003	Feb 29, 2016	Feb NEWA
AB		OSMOTICA PHARM US	5MG	A078503	001	Feb 04, 2009	Jun CAHN
AB			10MG	A078503	002	Feb 04, 2009	Jun CAHN
AB			15MG	A078503	003	Feb 04, 2009	Jun CAHN
AB		UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	May NEWA
AB			10MG	A206121	002	May 27, 2016	May NEWA
AB			15MG	A206121	003	May 27, 2016	May NEWA

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL
XTAMPZA ER

		COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016	May CAIN
			13.5MG	N208090	002	Apr 26, 2016	May CAIN
			18MG	N208090	003	Apr 26, 2016	May CAIN
			27MG	N208090	004	Apr 26, 2016	May CAIN
	+		36MG	N208090	005	Apr 26, 2016	May CAIN

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL
OXYCODONE HYDROCHLORIDE

AB		ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar NEWA
AB		MAYNE PHARMA INC	5MG	A203107	001	Jul 26, 2012	Aug CAHN

CAPSULE, EXTENDED RELEASE;ORAL
XTAMPZA ER

		COLLEGIUM PHARM INC	EQ 9MG BASE	N208090	001	Apr 26, 2016	Apr NEWA
			EQ 13.5MG BASE	N208090	002	Apr 26, 2016	Apr NEWA
			EQ 18MG BASE	N208090	003	Apr 26, 2016	Apr NEWA
			EQ 27MG BASE	N208090	004	Apr 26, 2016	Apr NEWA
	+		EQ 36MG BASE	N208090	005	Apr 26, 2016	May CRLD
			EQ 36MG BASE	N208090	005	Apr 26, 2016	Apr NEWA

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA		MAYNE PHARMA INC	100MG/5ML	A204092	001	Jun 05, 2014	Aug CAHN
>D>	AA	ROXANE	5MG/5ML	A204037	001	Jul 15, 2013	Nov CAHN
>D>	AA		100MG/5ML	A203208	001	Jul 12, 2013	Nov CAHN
>A>	AA	WES PHARMA INC	5MG/5ML	A207511	001	Nov 23, 2016	Nov NEWA
>A>	AA	WEST-WARD PHARMS INT	5MG/5ML	A204037	001	Jul 15, 2013	Nov CAHN
>A>	AA		100MG/5ML	A203208	001	Jul 12, 2013	Nov CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB		ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan CAHN
AB			15MG	A202116	002	Dec 30, 2011	Jan CAHN
AB			30MG	A202116	003	Dec 30, 2011	Jan CAHN
AB		COASTAL PHARMS	10MG	A091313	004	Apr 29, 2016	Apr NEWA
AB			20MG	A091313	005	Apr 29, 2016	Apr NEWA
AB		KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar NEWA
AB			10MG	A207119	002	Apr 12, 2016	Mar NEWA
AB			15MG	A207119	003	Apr 12, 2016	Mar NEWA
AB			20MG	A207119	004	Apr 12, 2016	Mar NEWA
AB			30MG	A207119	005	Apr 12, 2016	Mar NEWA
AB		MAYNE PHARMA INC	5MG	A091313	001	Feb 18, 2011	Aug CAHN
AB			10MG	A091313	004	Apr 29, 2016	Aug CAHN
AB			15MG	A091313	002	Feb 18, 2011	Aug CAHN
AB			20MG	A091313	005	Apr 29, 2016	Aug CAHN
AB			30MG	A091313	003	Feb 18, 2011	Aug CAHN

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL
KOVANAZE

+ ST RENATUS 0.1MG/SPRAY;6MG/SPRAY N208032 001 Jun 29, 2016 Jun NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr NEWA
AB		10MG	A204459	002	Apr 26, 2016	Apr NEWA
>D> AB	ROXANE	5MG	A090964	001	Sep 27, 2010	Nov CAHN
>D> AB		10MG	A090964	002	Sep 27, 2010	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	5MG	A090964	001	Sep 27, 2010	Nov CAHN
>A> AB		10MG	A090964	002	Sep 27, 2010	Nov CAHN

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

>D> AB	ROXANE	5MG	A200822	002	Jul 15, 2013	Nov CAHN
>D> AB		7.5MG	A200822	003	Jul 15, 2013	Nov CAHN
>D> AB		10MG	A200822	004	Jul 15, 2013	Nov CAHN
>D> AB		15MG	A200822	005	Jul 15, 2013	Nov CAHN
>D> AB		20MG	A200822	006	Jul 15, 2013	Nov CAHN
>D> AB		30MG	A200822	007	Jul 15, 2013	Nov CAHN
>D> AB		40MG	A200822	001	Jul 15, 2013	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	5MG	A200822	002	Jul 15, 2013	Nov CAHN
>A> AB		7.5MG	A200822	003	Jul 15, 2013	Nov CAHN
>A> AB		10MG	A200822	004	Jul 15, 2013	Nov CAHN
>A> AB		15MG	A200822	005	Jul 15, 2013	Nov CAHN
>A> AB		20MG	A200822	006	Jul 15, 2013	Nov CAHN
>A> AB		30MG	A200822	007	Jul 15, 2013	Nov CAHN
>A> AB		40MG	A200822	001	Jul 15, 2013	Nov CAHN

OXYTOCIN

INJECTABLE;INJECTION
OXYTOCIN

AP	+	WEST-WARD PHARMS INT	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Oct CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Oct CAHN

PACLITAXEL

INJECTABLE;INJECTION
PACLITAXEL

AP		GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Aug NEWA
AP		SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan CAHN
AP		WEST-WARD PHARMS INT	6MG/ML	A075190	001	Jan 28, 2002	Oct CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA SUSTENNA

		JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar CRLD
	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr NEWA
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr NEWA

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

		DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar NEWA
			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar NEWA
		EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016	Aug NEWA

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan CAHN
AP	WEST-WARD PHARMS INT	30MG/VIAL	A075290	001	Apr 30, 2001	Oct CAHN
AP	+	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Sep CAHN
AP		90MG/VIAL	A075290	003	Apr 30, 2001	Oct CAHN
AP	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Sep CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL
PERTZYE

	DIGESTIVE CARE INC	15,125USP UNITS;4,000USP UNITS;14,375USP UNITS	N022175	003	Oct 06, 2016	Oct NEWA
--	--------------------	--	---------	-----	--------------	----------

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar NEWA
		TABLET, DELAYED RELEASE;ORAL				
		PANTOPRAZOLE SODIUM				
AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan NEWA
AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan NEWA

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN
AB	ECI PHARMS LLC	1MCG	A206710	001	Feb 24, 2016	Oct CAHN
AB		2MCG	A206710	002	Feb 24, 2016	Oct CAHN
AB		4MCG	A206710	003	Feb 24, 2016	Oct CAHN
AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb NEWA
AB		2MCG	A206710	002	Feb 24, 2016	Feb NEWA
AB		4MCG	A206710	003	Feb 24, 2016	Feb NEWA
AB	MARKSANS PHARMA	1MCG	A204948	001	Oct 07, 2016	Sep NEWA
AB		2MCG	A204948	002	Oct 07, 2016	Sep NEWA
AB		4MCG	A204948	003	Oct 07, 2016	Sep NEWA
AB	+	TEVA PHARMS USA	A090829	003	Sep 27, 2013	Aug CRLD
		ZEMPLAR				
		@ ABBVIE	N021606	003	May 26, 2005	Aug DISC
		SOLUTION;INTRAVENOUS				
		PARICALCITOL				
AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb NEWA
AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb NEWA
AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb NEWA
AP	DR REDDYS LABS LTD	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Aug NEWA
AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Aug NEWA
AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Aug NEWA

PAROXETINE HYDROCHLORIDE

TABLET;ORAL
PAROXETINE HYDROCHLORIDE

	@ UPSHER-SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004	Oct CAHN
	@	EQ 20MG BASE	A075566	002	Mar 08, 2004	Oct CAHN
	@	EQ 30MG BASE	A075566	003	Mar 08, 2004	Oct CAHN
	@	EQ 40MG BASE	A075566	004	Mar 08, 2004	Oct CAHN

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

AB	KREMERS URBAN PHARMS	EQ 12.5MG BASE	A204744	001	Jun 10, 2016	May NEWA
AB		EQ 25MG BASE	A204744	002	Jun 10, 2016	May NEWA
AB		EQ 37.5MG BASE	A204744	003	Jun 10, 2016	May NEWA

PAROXETINE MESYLATE

CAPSULE;ORAL
BRISDELLE

+	SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Aug CAHN
---	--------------------	---------------	---------	-----	--------------	----------

TABLET;ORAL

PEXEVA

SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	Aug CAHN
	EQ 20MG BASE	N021299	002	Jul 03, 2003	Aug CAHN
	EQ 30MG BASE	N021299	003	Jul 03, 2003	Aug CAHN
+	EQ 40MG BASE	N021299	004	Jul 03, 2003	Aug CAHN

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

@ AUXILIUM PHARMS INC	10MG	N018976	001	Dec 30, 1987	Mar CAHN
@	20MG	N018976	004	Jan 05, 1989	Mar CAHN
@ AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Aug CAHN
@	20MG	N018976	004	Jan 05, 1989	Aug CAHN

PENCICLOVIR

CREAM;TOPICAL

DENA VIR

+	DENCO ASSET	1%	N020629	001	Sep 24, 1996	Apr CAIN
---	-------------	----	---------	-----	--------------	----------

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Apr CMFD
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb CAHN

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Apr CMFD
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb CAHN

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

NEMBUTAL SODIUM

AP	+	OAK PHARMS	50MG/ML	A083246	001		May CTEC
AP		PENTOBARBITAL SODIUM					
AP		MYLAN INSTITUTIONAL	50MG/ML	A206404	001	May 23, 2016	May NEWA

PENTOSTATIN

INJECTABLE;INJECTION

PENTOSTATIN

AP		WEST-WARD PHARMS INT	10MG/VIAL	A077841	001	Aug 07, 2007	Oct CAHN
----	--	----------------------	-----------	---------	-----	--------------	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar CRLD
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar DISC
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar DISC

PERAMPANEL

SUSPENSION;ORAL

FYCOMPA

+	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016	Apr NEWA
---	-----------	----------	---------	-----	--------------	----------

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

>D>	AB	ROXANE	2MG	A090072	001	Nov 10, 2009	Nov CAHN
>D>	AB		4MG	A090072	002	Nov 10, 2009	Nov CAHN
>D>	AB		8MG	A090072	003	Nov 10, 2009	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	2MG	A090072	001	Nov 10, 2009	Nov CAHN
>A>	AB		4MG	A090072	002	Nov 10, 2009	Nov CAHN
>A>	AB		8MG	A090072	003	Nov 10, 2009	Nov CAHN

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	SANDOZ	2MG	A089685	002	Dec 08, 1988	Sep CMS1
AB		4MG	A089685	003	Dec 08, 1988	Sep CMS1
AB	+	16MG	A089685	004	Dec 08, 1988	Sep CMS1
AB	WATSON LABS INC	2MG	A207582	001	Oct 17, 2016	Oct NEWA
AB		4MG	A207582	002	Oct 17, 2016	Oct NEWA
AB		8MG	A207582	003	Oct 17, 2016	Oct NEWA
AB		16MG	A207582	004	Oct 17, 2016	Oct NEWA
AB	WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan CAHN
AB		4MG	A205973	002	Dec 17, 2015	Jan CAHN
AB		8MG	A205973	003	Dec 17, 2015	Jan CAHN
AB		16MG	A205973	004	Dec 17, 2015	Jan CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@ ABLE	200MG, N/A, N/A; N/A, 800MG, 160MG	N021105	001	Jun 26, 2001	Jan CMS1
--------	------------------------------------	---------	-----	--------------	----------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

>D> AB	ROXANE	10MG	A201050	001	Jul 16, 2012	Nov CAHN
>A> AB	WEST-WARD PHARMS INT	10MG	A201050	001	Jul 16, 2012	Nov CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	15MG	A204318	001	Nov 09, 2016	Oct NEWA
AA		30MG	A204318	002	Nov 09, 2016	Oct NEWA
AA	SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar CAHN
@		37.5MG	A040527	001	Oct 23, 2003	Mar CAHN

TABLET; ORAL

LOMAIRA

+ AVANTHI INC 8MG

A203495 001 Sep 12, 2016 Aug NEWA

PHENTERMINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan CAHN
>A> AA	POLYGEN PHARMS	37.5MG	A206342	001	Nov 18, 2016	Nov NEWA
AA	SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

@ CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun DISC
@	30MG	N202088	002	Jun 13, 2011	Jun DISC
@	37.5MG	N202088	003	Mar 27, 2012	Jun DISC

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

@ LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Aug DISC
@	EQ 30MG BASE	A040872	002	Jul 28, 2011	Aug DISC

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

AP	WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	Sep CAHN
----	----------------------	----------	---------	-----	--------------	----------

PHENYL BUTAZONE

CAPSULE; ORAL

PHENYL BUTAZONE

@ SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985	Mar CAHN
------------------	-------	---------	-----	--------------	----------

TABLET; ORAL

PHENYL BUTAZONE

@ SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985	Mar CAHN
------------------	-------	---------	-----	--------------	----------

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Apr	NEWA
---	-------------------	--------------	---------	-----	--------------	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

	@ IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May	CAHN
	@	10MG	A073609	001	Mar 29, 1993	May	CAHN
AB	SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	Mar	CAHN
AB		10MG	A074063	002	Jan 27, 1994	Mar	CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Aug	NEWA
AB		20MG	A207938	002	Sep 09, 2016	Aug	NEWA
AB	MYLAN IRELAND LTD	10MG	A074116	001	Jun 15, 1993	Aug	CAHN
AB		20MG	A074118	001	Jun 15, 1993	Aug	CAHN
AB	MYLAN PHARMS INC	20MG	A074118	001	Jun 15, 1993	Jan	CAHN
	@ SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993	Mar	CAHN

PODOFILOX

GEL; TOPICAL

CONDYLOX

+	ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997	Mar	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CONDYLOX

AT	+	ALLERGAN SALES LLC	0.5%	N019795	001	Dec 13, 1990	Mar	CAHN
----	---	--------------------	------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

	@ MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	May	DISC
--	---------------	---	---------	-----	--------------	-----	------

COLYTE WITH FLAVOR PACKS

AA	MEDA PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CTEC
----	-------------	--	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE

AP	AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr	NEWA
AP	+	WEST-WARD PHARMS INT	EQ 500,000 UNITS BASE/VIAL	A060716	001		Sep CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan	NEWA
AB	KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar	NEWA
AB		10MEQ	A204210	002	Mar 28, 2016	Mar	NEWA
AB	NOVEL LABS INC	8MEQ	A204828	001	Aug 16, 2016	Aug	NEWA
AB		10MEQ	A204828	002	Aug 16, 2016	Aug	NEWA
AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb	NEWA
AB		10MEQ	A201944	002	Mar 04, 2016	Feb	NEWA

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

+	PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Jul	CRLD
---	---------------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1	GLENMARK PHARMS LTD	10MEQ	A203562	001	Jul 26, 2016	Jul	NEWA
AB1		20MEQ	A203562	002	Jul 26, 2016	Jul	NEWA
AB2	NOVEL LABS INC	8MEQ	A206759	001	Aug 09, 2016	Jul	NEWA
AB1		10MEQ	A206347	001	Jan 21, 2016	Jan	NEWA
AB2		10MEQ	A206759	002	Aug 09, 2016	Jul	NEWA
AB1		20MEQ	A206347	002	Jan 21, 2016	Jan	NEWA
AB2	SIGMAPHARM LABS LLC	8MEQ	A207528	001	Aug 19, 2016	Aug	NEWA
AB2		10MEQ	A207528	002	Aug 19, 2016	Aug	NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr	NEWA
AB		0.75MG	A201963	002	Apr 21, 2016	Apr	NEWA
AB		1.5MG	A201963	003	Apr 21, 2016	Apr	NEWA
AB		2.25MG	A203615	001	Oct 14, 2016	Oct	NEWA
AB		3MG	A201963	004	Apr 21, 2016	Apr	NEWA
AB		4.5MG	A201963	005	Apr 21, 2016	Apr	NEWA
AB	MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun	NEWA
AB		0.75MG	A206156	002	Jun 24, 2016	Jun	NEWA
AB		1.5MG	A206156	003	Jun 24, 2016	Jun	NEWA
AB		2.25MG	A206156	004	Jun 24, 2016	Jun	NEWA
AB		3MG	A206156	005	Jun 24, 2016	Jun	NEWA
AB		4.5MG	A206156	007	Jun 24, 2016	Jun	NEWA
AB	SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul	CDFR
AB		0.75MG	A202353	002	Dec 04, 2014	Jul	CDFR
AB		1.5MG	A202353	003	Dec 04, 2014	Jul	CDFR
AB		3MG	A202353	004	Dec 04, 2014	Jul	CDFR
AB		4.5MG	A202353	005	Dec 04, 2014	Jul	CDFR

>A> PRASTERONE

>A> INSERT;VAGINAL

>A> INTRAROSA

>A>	+	ENDOCEUTICS INC	6.5MG	N208470	001	Nov 16, 2016	Nov	NEWA
-----	---	-----------------	-------	---------	-----	--------------	-----	------

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>A>	AB	ACCORD HLTHCARE	10MG	A207068	001	Nov 17, 2016	Nov	NEWA
>A>	AB		20MG	A207068	002	Nov 17, 2016	Nov	NEWA
>A>	AB		40MG	A207068	003	Nov 17, 2016	Nov	NEWA
>A>	AB		80MG	A207068	004	Nov 17, 2016	Nov	NEWA
>D>	AB	APOTEX	10MG	A076341	001	Oct 23, 2006	Nov	CAHN
>D>	AB		20MG	A076341	002	Oct 23, 2006	Nov	CAHN
>D>	AB		40MG	A076341	003	Oct 23, 2006	Nov	CAHN
>D>	AB		80MG	A076341	004	Dec 28, 2007	Nov	CAHN
>A>	AB	APOTEX INC	10MG	A076341	001	Oct 23, 2006	Nov	CAHN
>A>	AB		20MG	A076341	002	Oct 23, 2006	Nov	CAHN
>A>	AB		40MG	A076341	003	Oct 23, 2006	Nov	CAHN
>A>	AB		80MG	A076341	004	Dec 28, 2007	Nov	CAHN
	AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar	NEWA
		@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar	DISC
		@	20MG	A077013	002	Oct 23, 2006	Mar	DISC
		@	40MG	A077013	003	Oct 23, 2006	Mar	DISC
		@	80MG	A077013	004	Dec 28, 2007	Mar	DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May	CAHN
	@		EQ 2MG BASE	A072577	001	May 16, 1989	May	CAHN
	@		EQ 5MG BASE	A072578	001	May 16, 1989	May	CAHN
AB		TEVA PHARMS	EQ 1MG BASE	A071745	002	Sep 12, 1988	Sep	CMS1
AB			EQ 2MG BASE	A071745	003	Sep 12, 1988	Sep	CMS1

PREDNISOLONE

TABLET;ORAL

PREDNISOLONE

	@	AUROLIFE PHARMA LLC	5MG	A084773	001		Feb	CAHN
--	---	---------------------	-----	---------	-----	--	-----	------

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

>D>	AB	ALCON	1%	N017469	001		Nov	CAHN
>A>	AB	NOVARTIS PHARMS CORP	1%	N017469	001		Nov	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	+	WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD
----	---	-----------	------------------	---------	-----	--------------	----------

PREDNISONE

SOLUTION;ORAL

PREDNISONE

>D>	+	ROXANE	5MG/5ML	A088703	001	Nov 08, 1984	Nov CAHN
>A>	+	WEST-WARD PHARMS INT	5MG/5ML	A088703	001	Nov 08, 1984	Nov CAHN

PREDNISONE INTENSOL

>D>	+	ROXANE	5MG/ML	A088810	001	Feb 20, 1985	Nov CAHN
>A>	+	WEST-WARD PHARMS INT	5MG/ML	A088810	001	Feb 20, 1985	Nov CAHN

TABLET;ORAL

PREDNISONE

	@	AUROLIFE PHARMA LLC	5MG	A084774	001		Mar CAHN
	@		10MG	A089983	001	Jan 12, 1989	Mar CAHN
	@		20MG	A085813	001		Mar CAHN
	@		50MG	A089984	001	Jan 12, 1989	Mar CAHN
AB		DELCOR ASSET CORP	5MG	A080292	001		Mar CAHN
AB			10MG	A088832	001	Dec 04, 1985	Mar CAHN
AB			20MG	A083677	001		Mar CAHN
>D> AB	+	ROXANE	1MG	A087800	001	Apr 22, 1982	Nov CAHN
>D> AB	+		2.5MG	A087801	001	Apr 22, 1982	Nov CAHN
>D> AB	+		5MG	A080352	001		Nov CAHN
>D> AB	+		10MG	A084122	001		Nov CAHN
>D> AB	+		20MG	A087342	001		Nov CAHN
>D> AB	+		50MG	A084283	001		Nov CAHN
AB		SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar CAHN
	@		50MG	A086596	001		Jun CAHN
>A> AB	+	WEST-WARD PHARMS INT	1MG	A087800	001	Apr 22, 1982	Nov CAHN
>A> AB	+		2.5MG	A087801	001	Apr 22, 1982	Nov CAHN
>A> AB	+		5MG	A080352	001		Nov CAHN
>A> AB	+		10MG	A084122	001		Nov CAHN
>A> AB	+		20MG	A087342	001		Nov CAHN
>A> AB	+		50MG	A084283	001		Nov CAHN

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE PHOSPHATE

AB		INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016	Jun NEWA
----	--	-------------------	--------------	---------	-----	--------------	----------

PRIMIDONE

TABLET;ORAL

PRIMIDONE

AB		FRONTIDA BIOPHARM	50MG	A040626	001	Sep 29, 2005	Jul CAHN
AB			250MG	A040626	002	Sep 29, 2005	Jul CAHN
	@	HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006	Jul CAHN
AB			250MG	A040667	002	Jul 27, 2006	Jul CAHN
	@	IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar DISC
	@		250MG	A040717	002	Feb 12, 2008	Mar DISC
AB		SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Mar CAHN
AB			250MG	A040626	002	Sep 29, 2005	Mar CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL

PROCAINAMIDE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	375MG	A089220	001	Jul 01, 1986	May CAHN
--	---	-------------------	-------	---------	-----	--------------	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

	@	AMPHASTAR PHARMS INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Aug DISC
AP			EQ 5MG BASE/ML	A040540	001	May 28, 2004	Jun CAHN
AP	+	EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Oct CTEC
	+		EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Sep CTEC
AP	+		EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Aug CRLD
AP		EUROHLTH INTL SARL	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Apr CAHN
AP			EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Oct CMFD
	@		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Aug DISC

PROGESTERONE

CAPSULE;ORAL					
PROGESTERONE					
AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013 Jan CAHN
AB		200MG	A200900	002	Aug 16, 2013 Jan CAHN
PROMETRIUM					
AB	VIRTUS PHARMS	100MG	N019781	001	May 14, 1998 Jun CAHN
AB	+	200MG	N019781	002	Oct 15, 1999 Jun CAHN
	@	300MG	N019781	003	Oct 15, 1999 Jun CAHN
GEL;VAGINAL					
CRINONE					
+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997 Apr CAHN
+		8%	N020701	002	Jul 31, 1997 Apr CAHN
INJECTABLE;INJECTION					
PROGESTERONE					
AO	+	ALLERGAN SALES LLC 50MG/ML	N017362	002	Apr CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL					
PROMETHAZINE HYDROCHLORIDE					
AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009 Feb CAHN
TABLET;ORAL					
PROMETHAZINE HYDROCHLORIDE					
	@ IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008 Mar DISC
	@	25MG	A040724	002	Feb 12, 2008 Mar DISC
	@	50MG	A040791	001	May 20, 2008 Mar DISC
>A> AB	KVK TECH	50MG	A040712	003	Jul 31, 2006 Nov CMS1
	@ SUN PHARM INDS	12.5MG	A084555	001	Mar CAHN
	@	25MG	A084554	001	Mar CAHN
	@	50MG	A084557	001	Jan CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
PROPAFENONE HYDROCHLORIDE					
AB	MYLAN PHARMS INC	225MG	A203803	001	Apr 29, 2016 Apr NEWA
AB		325MG	A203803	002	Apr 29, 2016 Apr NEWA
AB		425MG	A203803	003	Apr 29, 2016 Apr NEWA
TABLET;ORAL					
PROPAFENONE HYDROCHLORIDE					
AB	ORION CORP ORION	150MG	A202445	001	May 11, 2016 Apr NEWA
AB		225MG	A202445	002	May 11, 2016 Apr NEWA
AB		300MG	A202445	003	May 11, 2016 Apr NEWA
AB	SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001 Mar CAHN
AB		225MG	A075998	002	Nov 29, 2001 Mar CAHN
AB		300MG	A075998	003	Nov 29, 2001 Mar CAHN

PROPANTHELINE BROMIDE

TABLET;ORAL					
PROPANTHELINE BROMIDE					
>D>	@ ROXANE	7.5MG	A080927	001	Nov CAHN
>D>	+	15MG	A080927	002	Nov CAHN
>A>	@ WEST-WARD PHARMS INT	7.5MG	A080927	001	Nov CAHN
>A>	+	15MG	A080927	002	Nov CAHN

PROPOFOL

INJECTABLE;INJECTION					
PROPOFOL					
AB	SAGENT PHARMS	10MG/ML	A075102	001	Jan 04, 1999 Aug CAHN
	@ WEST-WARD PHARMS INT	10MG/ML	A074848	001	Apr 19, 2005 Sep CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
INDERAL LA					
AB	ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987 Apr CAHN
AB		80MG	N018553	002	Apr 19, 1983 Apr CAHN
AB		120MG	N018553	003	Apr 19, 1983 Apr CAHN
AB	+	160MG	N018553	001	Apr 19, 1983 Apr CAHN
PROPRANOLOL HYDROCHLORIDE					
BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009 Jun CMFD
	@	60MG	A078311	001	Mar 06, 2009 May DISC
BX		60MG	A078311	001	Mar 06, 2009 Mar CTEC

CAPSULE, EXTENDED RELEASE;ORAL
PROPRANOLOL HYDROCHLORIDE

BX		80MG	A078311	002	Mar 06, 2009	Jun CMFD
	@	80MG	A078311	002	Mar 06, 2009	May DISC
BX		80MG	A078311	002	Mar 06, 2009	Mar CTEC
BX		120MG	A078311	003	Mar 06, 2009	Jun CMFD
	@	120MG	A078311	003	Mar 06, 2009	May DISC
BX		120MG	A078311	003	Mar 06, 2009	Mar CTEC
BX		160MG	A078311	004	Mar 06, 2009	Jun CMFD
	@	160MG	A078311	004	Mar 06, 2009	May DISC
BX		160MG	A078311	004	Mar 06, 2009	Mar CTEC

INJECTABLE;INJECTION
PROPRANOLOL HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000	Jun CAHN
AP	EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Apr CAHN
	@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar DISC

SOLUTION;ORAL
PROPRANOLOL HYDROCHLORIDE

>D>	+	ROXANE	20MG/5ML	A070979	001	May 15, 1987	Nov CAHN
>D>	+		40MG/5ML	A070690	001	May 15, 1987	Nov CAHN
>A>	+	WEST-WARD PHARMS INT	20MG/5ML	A070979	001	May 15, 1987	Nov CAHN
>A>	+		40MG/5ML	A070690	001	May 15, 1987	Nov CAHN

TABLET;ORAL
PROPRANOLOL HYDROCHLORIDE

	@	FRONTIDA BIOPHARM	10MG	A070319	001	Oct 22, 1985	Jul CAHN
	@		20MG	A070320	001	Oct 22, 1985	Jul CAHN
	@		40MG	A070103	001	Oct 22, 1985	Jul CAHN
	@		60MG	A070321	001	Sep 24, 1986	Jul CAHN
	@		80MG	A070322	001	Aug 04, 1986	Jul CAHN
AB		IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988	Aug CAHN
AB			20MG	A071973	001	Apr 06, 1988	Aug CAHN
AB			40MG	A071974	001	Apr 06, 1988	Aug CAHN
AB			60MG	A071975	001	Apr 06, 1988	Aug CAHN
AB	+		80MG	A071976	001	Apr 06, 1988	Aug CAHN
	@	SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar CAHN
	@		20MG	A070320	001	Oct 22, 1985	Mar CAHN
	@		40MG	A070103	001	Oct 22, 1985	Mar CAHN
	@		60MG	A070321	001	Sep 24, 1986	Jun CAHN
	@		80MG	A070322	001	Aug 04, 1986	Mar CAHN

PROPYLTHIOURACILTABLET;ORAL
PROPYLTHIOURACIL

	@	HIKMA INTL PHARMS	50MG	A080154	001		Jul CAHN
	@	SUN PHARM INDS	50MG	A083982	001		Mar CAHN

PROTRIPTYLINE HYDROCHLORIDETABLET;ORAL
PROTRIPTYLINE HYDROCHLORIDE

>D>	AB	ROXANE	5MG	A078913	001	Sep 16, 2008	Nov CAHN
>D>	AB		10MG	A078913	002	Sep 16, 2008	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	5MG	A078913	001	Sep 16, 2008	Nov CAHN
>A>	AB		10MG	A078913	002	Sep 16, 2008	Nov CAHN

PYRIDOSTIGMINE BROMIDETABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan CAHN
----	---------------	-------	---------	-----	--------------	----------

PYRIDOXINE HYDROCHLORIDEINJECTABLE;INJECTION
PYRIDOXINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	100MG/ML	A080618	001		Jul CTEC
AP		MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016	Jul NEWA

QUAZEPAMTABLET;ORAL
DORAL

	@	CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar CAHN
	+		15MG	N018708	001	Dec 27, 1985	Apr CMFD
	@		15MG	N018708	001	Dec 27, 1985	Mar CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

	@	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr	DISC
	@		EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr	DISC
	@		EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr	DISC
	@		EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr	DISC
	@		EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr	DISC
	@		EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr	DISC
	@		EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr	DISC
AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May	NEWA
AB			EQ 50MG BASE	A203359	002	May 17, 2016	May	NEWA
AB			EQ 100MG BASE	A203359	003	May 17, 2016	May	NEWA
AB			EQ 200MG BASE	A203359	004	May 17, 2016	May	NEWA
AB			EQ 300MG BASE	A203359	005	May 17, 2016	May	NEWA
AB			EQ 400MG BASE	A203359	006	May 17, 2016	May	NEWA
>D> AB		ROXANE	EQ 25MG BASE	A090120	001	Mar 27, 2012	Nov	CAHN
>D> AB			EQ 50MG BASE	A090749	001	Mar 27, 2012	Nov	CAHN
>D> AB			EQ 100MG BASE	A090749	002	Mar 27, 2012	Nov	CAHN
>D> AB			EQ 200MG BASE	A090749	003	Mar 27, 2012	Nov	CAHN
>D> AB			EQ 300MG BASE	A090749	004	Mar 27, 2012	Nov	CAHN
>D> AB			EQ 400MG BASE	A090749	005	Mar 27, 2012	Nov	CAHN
AB		UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb	NEWA
AB			EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb	NEWA
AB			EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb	NEWA
AB			EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb	NEWA
AB			EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb	NEWA
AB			EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb	NEWA
>A> AB		WEST-WARD PHARMS INT	EQ 25MG BASE	A090120	001	Mar 27, 2012	Nov	CAHN
>A> AB			EQ 50MG BASE	A090749	001	Mar 27, 2012	Nov	CAHN
>A> AB			EQ 100MG BASE	A090749	002	Mar 27, 2012	Nov	CAHN
>A> AB			EQ 200MG BASE	A090749	003	Mar 27, 2012	Nov	CAHN
>A> AB			EQ 300MG BASE	A090749	004	Mar 27, 2012	Nov	CAHN
>A> AB			EQ 400MG BASE	A090749	005	Mar 27, 2012	Nov	CAHN

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE INC	EQ 400MG BASE	A090681	004	Nov 01, 2016	Oct	NEWA
		SEROQUEL XR						
AB		ASTRAZENECA	EQ 400MG BASE	N022047	004	May 17, 2007	Oct	CFTG

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan	DISC
	@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan	DISC
	@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan	DISC
	@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan	DISC
AB		PRINSTON INC	EQ 5MG BASE	A205823	001	Sep 15, 2016	Sep	NEWA
AB			EQ 10MG BASE	A205823	002	Sep 15, 2016	Sep	NEWA
AB			EQ 20MG BASE	A205823	003	Sep 15, 2016	Sep	NEWA
AB			EQ 40MG BASE	A205823	004	Sep 15, 2016	Sep	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

	@	AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar	CAHN
BX	+	SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar	CAHN

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

	@	SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun	CAHN
AB			200MG	A081030	001	Apr 14, 1989	Mar	CAHN
AB			300MG	A081031	001	Apr 14, 1989	Mar	CAHN

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

AB	+	SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun	CAHN
----	---	----------------	-------	---------	-----	--------------	-----	------

RABEPRAZOLE SODIUMCAPSULE, DELAYED RELEASE;ORAL
ACIPHEX SPRINKLEFSC THERAP 5MG
+ 10MGN204736 001 Mar 26, 2013 Jun CAHN
N204736 002 Mar 26, 2013 Jun CAHNRALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB AMNEAL PHARMS 60MG
AB GLENMARK PHARMS LTD 60MG
AB SCIEGEN PHARMS INC 60MGA208206 001 Apr 08, 2016 Mar NEWA
A204491 001 Mar 22, 2016 Mar NEWA
A206384 001 Oct 12, 2016 Oct NEWARAMELTEON

TABLET;ORAL

RAMELTEON

AB DR REDDYS LABS INTL 8MG

A091693 001 Jul 26, 2013 Aug CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

>D> AB ROXANE 1.25MG
>D> AB 2.5MG
>D> AB 5MG
>D> AB 10MG
@ SANDOZ 1.25MG
@ 2.5MG
@ 5MG
@ 10MG
>A> AB WEST-WARD PHARMS INT 1.25MG
>A> AB 2.5MG
>A> AB 5MG
>A> AB 10MGA077900 001 Jun 18, 2008 Nov CAHN
A077900 002 Jun 18, 2008 Nov CAHN
A077900 003 Jun 18, 2008 Nov CAHN
A077900 004 Jun 18, 2008 Nov CAHN
A077514 001 Jun 18, 2008 Aug DISC
A077514 002 Jun 18, 2008 Aug DISC
A077514 003 Jun 18, 2008 Aug DISC
A077514 004 Jun 18, 2008 Aug DISC
A077900 001 Jun 18, 2008 Nov CAHN
A077900 002 Jun 18, 2008 Nov CAHN
A077900 003 Jun 18, 2008 Nov CAHN
A077900 004 Jun 18, 2008 Nov CAHNRANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP MYLAN LABS LTD EQ 25MG BASE/ML
AP WEST-WARD PHARMS INT EQ 25MG BASE/ML
AP EQ 25MG BASE/ML
AP ZYDUS PHARMS USA INC EQ 25MG BASE/MLA079076 001 Jun 09, 2016 May NEWA
A074777 001 Mar 02, 2005 Sep CAHN
A077458 001 Feb 16, 2006 Oct CAHN
A091534 001 Feb 22, 2013 May CPOT

ZANTAC

AP + IGI LABS INC EQ 25MG BASE/ML
ZANTAC IN PLASTIC CONTAINER
@ IGI LABS INC EQ 1MG BASE/ML
@ EQ 50MG BASE/100MLN019090 001 Oct 19, 1984 Jan CAHN
N019593 002 Sep 27, 1991 Jan CAHN
N019593 001 Dec 17, 1986 Jan CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA NOSTRUM LABS INC EQ 15MG BASE/ML
@ WOCKHARDT EQ 15MG BASE/ML
@ EQ 15MG BASE/MLA091091 001 Sep 20, 2011 Mar CAHN
A079211 001 May 26, 2009 Apr DISC
A079212 001 Feb 23, 2009 Apr DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB STRIDES PHARMA EQ 150MG BASE
AB EQ 300MG BASEA205512 001 Aug 22, 2016 Aug NEWA
A205512 002 Aug 22, 2016 Aug NEWARASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB ORCHID HLTHCARE EQ 0.5MG BASE
AB EQ 1MG BASE
>D> @ WATSON LABS INC EQ 0.5MG BASE
>A> AB EQ 0.5MG BASE
>D> @ EQ 1MG BASE
>A> AB EQ 1MG BASEA201970 001 Mar 15, 2016 Feb NEWA
A201970 002 Mar 15, 2016 Feb NEWA
A201823 001 Jul 01, 2013 Nov CMFD
A201823 001 Jul 01, 2013 Nov CMFD
A201823 002 Jul 01, 2013 Nov CMFD
A201823 002 Jul 01, 2013 Nov CMFD

RESERPINETABLET; ORAL
RESERPINE

@	HIKMA INTL PHARMS	0.1MG	A080975	001		Feb	CAHN
@		0.25MG	A080975	002		Feb	CAHN
@		1MG	A080975	003		Feb	CAHN

RETAPAMULINOINTMENT; TOPICAL
ALTABAX

+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan	CAHN
---	-----------------	----	---------	-----	--------------	-----	------

RIBAVIRINFOR SOLUTION; INHALATION
RIBAVIRIN

AN		NAVINTA LLC	6GM/VIAL	A207366	001	Oct 06, 2016	Sep	NEWA
		VIRAZOLE						
AN	+	VALEANT PHARM INTL	6GM/VIAL	N018859	001	Dec 31, 1985	Sep	CFTG

RIBOFLAVIN 5'-PHOSPHATE SODIUMSOLUTION/DROPS; OPHTHALMIC
PHOTREXA

+	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr	NEWA
	PHOTREXA VISCOUS IN DEXTRAN 20%						
+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun	CMS1
	PHOTREXA VISCOUS IN DEXTROSE 20%						
+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Apr	NEWA

RIFAMPININJECTABLE; INJECTION
RIFAMPIN

AP		HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb	NEWA
AP		WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan	NEWA

RILUZOLETABLET; ORAL
RILUZOLE

AB		ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar	NEWA
----	--	----------------	------	---------	-----	--------------	-----	------

RIMEXOLONESUSPENSION/DROPS; OPHTHALMIC
VEXOL

@	ALCON	1%	N020474	001	Dec 30, 1994	Jun	DISC
---	-------	----	---------	-----	--------------	-----	------

RISEDRONATE SODIUMTABLET; ORAL
ACTONEL

AB		APIL	5MG	N020835	002	Apr 14, 2000	Jan	CAHN
AB			30MG	N020835	001	Mar 27, 1998	Jan	CAHN
AB	+		35MG	N020835	003	May 25, 2002	Jan	CAHN
	@		75MG	N020835	004	Apr 16, 2007	Jan	CAHN
AB	+		150MG	N020835	005	Apr 22, 2008	Jan	CAHN
		RISEDRONATE SODIUM						
AB		AUROBINDO PHARMA LTD	150MG	A206768	001	Oct 21, 2016	Oct	NEWA
>A>	AB	MACLEODS PHARMS LTD	35MG	A203533	003	Nov 29, 2016	Nov	NEWA
		TABLET, DELAYED RELEASE; ORAL						
		ATELVIA						
AB	+	APIL	35MG	N022560	001	Oct 08, 2010	Jan	CAHN

RISPERIDONESOLUTION; ORAL
RISPERIDONE

>D>	AA	AUROBINDO PHARMA	1MG/ML	A078452	001	Sep 04, 2009	Nov	CAHN
>A>	AA	LIFESTAR PHARMA	1MG/ML	A078452	001	Sep 04, 2009	Nov	CAHN
>D>	AA	ROXANE	1MG/ML	A076904	001	Jul 29, 2009	Nov	CAHN
	@	SILARX PHARMS INC	1MG/ML	A202386	001	Jan 12, 2015	Aug	DISC
>A>	AA	WEST-WARD PHARMS INT	1MG/ML	A076904	001	Jul 29, 2009	Nov	CAHN
	@	WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009	Apr	DISC

RITONAVIR

TABLET;ORAL

RITONAVIR

>D>	AB	ROXANE	100MG	A202573	001	Jan 15, 2015	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	100MG	A202573	001	Jan 15, 2015	Nov CAHN

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELON

AB	+ NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
	RIVASTIGMINE TARTRATE					
AB	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB		EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB		EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB		EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

>D>	AB	ROXANE	EQ 0.25MG BASE	A077852	001	May 05, 2008	Nov CAHN
>D>	AB		EQ 0.5MG BASE	A077852	002	May 05, 2008	Nov CAHN
>D>	AB		EQ 1MG BASE	A077852	003	May 05, 2008	Nov CAHN
>D>	AB		EQ 2MG BASE	A077852	004	May 05, 2008	Nov CAHN
>D>	AB		EQ 3MG BASE	A077852	005	May 05, 2008	Nov CAHN
>D>	AB		EQ 4MG BASE	A077852	006	May 05, 2008	Nov CAHN
>D>	AB		EQ 5MG BASE	A077852	007	May 19, 2008	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 0.25MG BASE	A077852	001	May 05, 2008	Nov CAHN
>A>	AB		EQ 0.5MG BASE	A077852	002	May 05, 2008	Nov CAHN
>A>	AB		EQ 1MG BASE	A077852	003	May 05, 2008	Nov CAHN
>A>	AB		EQ 2MG BASE	A077852	004	May 05, 2008	Nov CAHN
>A>	AB		EQ 3MG BASE	A077852	005	May 05, 2008	Nov CAHN
>A>	AB		EQ 4MG BASE	A077852	006	May 05, 2008	Nov CAHN
>A>	AB		EQ 5MG BASE	A077852	007	May 19, 2008	Nov CAHN

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar NEWA
	SOLUTION;INJECTION					
	NAROPIN					
	@ FRESSENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May DISC
		50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May NEWA
AP		20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May CMS1
AP		20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar CDFR
AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar NEWA
	@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr DISC
		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr NEWA
AP		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun CFTG
		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May CMS1
		100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar CDFR
AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar NEWA
AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar CDFR
AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar NEWA
AP		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun CFTG
		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar NEWA
AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar NEWA
		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar NEWA

SOLUTION; INJECTION
NAROPIN

500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr CMS1
500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar NEWA
1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr CMS1
1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar NEWA

ROPIVACAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun NEWA
AP		100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun NEWA
AP		100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun NEWA
AP		150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun NEWA
AP		150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun NEWA
AP		200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun NEWA
AP		200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun NEWA
AP	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar CDFR
AP		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar NEWA
AP		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar CDFR
AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar CDFR

ROSUVASTATIN CALCIUM

TABLET; ORAL
CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr CFTG
	ROSUVASTATIN CALCIUM					
AB	ACCORD HLTHCARE INC	5MG	A206434	001	Oct 31, 2016	Oct NEWA
AB		10MG	A206434	002	Oct 31, 2016	Oct NEWA
AB		20MG	A206434	003	Oct 31, 2016	Oct NEWA
AB		40MG	A206434	004	Oct 31, 2016	Oct NEWA
AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079145	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079145	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079145	004	Jul 19, 2016	Jul NEWA
AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079170	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079170	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079170	004	Jul 19, 2016	Jul NEWA
AB	BIOCON LTD	5MG	A207752	001	Oct 31, 2016	Oct NEWA
AB		10MG	A207752	002	Oct 31, 2016	Oct NEWA
AB		20MG	A207752	003	Oct 31, 2016	Oct NEWA
AB		40MG	A207752	004	Oct 31, 2016	Oct NEWA
>A>	AB	CADILA PHARMS LTD	A207453	001	Nov 23, 2016	Nov NEWA
>A>	AB		A207453	002	Nov 23, 2016	Nov NEWA
>A>	AB		A207453	003	Nov 23, 2016	Nov NEWA
>A>	AB		A207453	004	Nov 23, 2016	Nov NEWA
AB	CHANGZHOU PHARM	5MG	A207408	001	Oct 31, 2016	Oct NEWA
AB		10MG	A207408	002	Oct 31, 2016	Oct NEWA
AB		20MG	A207408	003	Oct 31, 2016	Oct NEWA
AB		40MG	A207408	004	Oct 31, 2016	Oct NEWA
AB	GLENMARK PHARMS	5MG	A079172	001	Jul 19, 2016	Sep CAHN
AB		10MG	A079172	002	Jul 19, 2016	Sep CAHN
AB		20MG	A079172	003	Jul 19, 2016	Sep CAHN
AB		40MG	A079172	004	Jul 19, 2016	Sep CAHN
AB	GLENMARK PHARMS LTD	5MG	A079172	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079172	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079172	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079172	004	Jul 19, 2016	Jul NEWA
AB	HETERO LABS LTD V	5MG	A207616	001	Oct 31, 2016	Oct NEWA
AB		10MG	A207616	002	Oct 31, 2016	Oct NEWA
AB		20MG	A207616	003	Oct 31, 2016	Oct NEWA
AB		40MG	A207616	004	Oct 31, 2016	Oct NEWA
AB	JUBILANT GENERICS	5MG	A207062	001	Oct 31, 2016	Oct NEWA
AB		10MG	A207062	002	Oct 31, 2016	Oct NEWA

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB		20MG	A207062	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207062	004	Oct 31, 2016	Oct	NEWA
AB	MYLAN PHARMS INC	5MG	A079161	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079161	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079161	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079161	004	Jul 19, 2016	Jul	NEWA
AB	PAR PHARM INC	5MG	A079168	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079168	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079168	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079168	004	Jul 19, 2016	Jul	NEWA
AB	SANDOZ INC	5MG	A079171	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079171	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079171	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079171	004	Jul 19, 2016	Jul	NEWA
AB	SUN PHARMA GLOBAL	5MG	A079169	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079169	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079169	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079169	004	Jul 19, 2016	Jul	NEWA
AB	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079166	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079166	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079166	004	Jul 19, 2016	Jul	NEWA
AB	TORRENT PHARMS LLC	5MG	A201619	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A201619	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A201619	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A201619	004	Oct 31, 2016	Oct	NEWA
AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	NEWA
AB		10MG	A079167	002	Apr 29, 2016	Apr	NEWA
AB		20MG	A079167	003	Apr 29, 2016	Apr	NEWA
AB		40MG	A079167	004	Apr 29, 2016	Apr	NEWA

RUBIDIUM CHLORIDE RB-82

SOLUTION;INTRAVENOUS

RUBY-FILL

JUBILANT DRAXIMAGE

N/A

N202153 001 Sep 30, 2016 Sep NEWA

RUFINAMIDE

TABLET;ORAL

BANZEL

AB	EISAI INC	200MG	N021911	002	Nov 14, 2008	May	CFTG
AB	+	400MG	N021911	003	Nov 14, 2008	May	CFTG

RUFINAMIDE

AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May	NEWA
AB		400MG	A205075	002	May 16, 2016	May	NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May	NEWA
AB		400MG	A205095	002	May 16, 2016	May	NEWA
>D> AB	ROXANE	200MG	A204988	001	May 16, 2016	Nov	CAHN
AB		200MG	A204988	001	May 16, 2016	May	NEWA
>D> AB		400MG	A204988	002	May 16, 2016	Nov	CAHN
AB		400MG	A204988	002	May 16, 2016	May	NEWA
>A> AB	WEST-WARD PHARMS INT	200MG	A204988	001	May 16, 2016	Nov	CAHN
>A> AB		400MG	A204988	002	May 16, 2016	Nov	CAHN

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

TRANSDERM SCOP

AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001		May	CAHN
----	---	---------------------	----------	---------	-----	--	-----	------

SECOBARBITAL SODIUM

CAPSULE;ORAL

SECONAL SODIUM

+	VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983	Aug	CAHN
+		100MG	A086101	002	Oct 03, 1983	Aug	CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ FRONTIDA BIOPHARM EQ 25MG BASE
 @ EQ 50MG BASE
 @ EQ 100MG BASE
 @ SUN PHARM INDS EQ 25MG BASE

A077818 001 Feb 06, 2007 Jul CAHN
 A077818 002 Feb 06, 2007 Jul CAHN
 A077818 003 Feb 06, 2007 Jul CAHN
 A077818 001 Feb 06, 2007 Mar CAHN

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	EQ 50MG BASE	A077818	002	Feb 06, 2007	Mar CAHN
@	EQ 100MG BASE	A077818	003	Feb 06, 2007	Mar CAHN

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	@ ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr DISC
	RUBICON RES PVT LTD	EQ 20MG BASE	A204883	001	Jun 20, 2016	Jun NEWA
	@ TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb DISC
		EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb NEWA
	@	EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb DISC
		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb NEWA
	@	EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb DISC
		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr CAHN
		8MG	N022206	002	Oct 08, 2008	Apr CAHN

SIMVASTATIN

SUSPENSION;ORAL

SIMVASTATIN

	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr NEWA
+		40MG/5ML	N206679	002	Apr 21, 2016	Apr NEWA

TABLET;ORAL

SIMVASTATIN

	@ SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb DISC
	@	10MG	A076285	002	Dec 20, 2006	Feb DISC
	@	20MG	A076285	003	Dec 20, 2006	Feb DISC
	@	40MG	A076285	004	Dec 20, 2006	Feb DISC
	@	80MG	A076285	005	Jun 23, 2006	Feb DISC

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)

AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG
		SODIUM PHENYLACETATE AND SODIUM BENZOATE					
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb NEWA
AP		NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	Jul NEWA

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

	HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb NEWA
--	-------------	-----------	---------	-----	--------------	----------

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	HOSPIRA	450MG/100ML	N018090	001		Aug CRLD
		SODIUM CHLORIDE 0.9%					
		B BRAUN	900MG/10ML	N019635	005	Aug 11, 2016	Aug NEWA
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May NEWA
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Aug CRLD

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May NEWA
AP		ZEVAOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

JUBILANT DRAXIMAGE

0.009-0.1mCi

N021305 006 May 19, 2005 Mar CMS1

@

2-200mCi

N021305 004 Nov 18, 2004 Mar CMS1

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

NITROPRESS

>D> + HOSPIRA 25MG/ML

A071961 001 Aug 01, 1988 Nov CTEC

>A> AP + 25MG/ML

A071961 001 Aug 01, 1988 Nov CTEC

SODIUM NITROPRUSSIDE

>A> AP NAMIGEN LLC 25MG/ML

A207426 001 Dec 08, 2016 Nov NEWA

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB + HORIZON PHARMA INC 3GM/TEASPOONFUL

N020573 001 Apr 30, 1996 Mar CAHN

SODIUM PHENYLBUTYRATE

AB PAR PHARM 3GM/TEASPOONFUL

A203918 001 Jun 15, 2016 Jun NEWA

TABLET;ORAL

BUPHENYL

AB + HORIZON PHARMA INC 500MG

N020572 001 May 13, 1996 Mar CAHN

SODIUM PHENYLBUTYRATE

>D> AB AMPOLGEN 500MG

A090910 001 Nov 18, 2011 Nov CAHN

>A> AB FERA PHARMS LLC 500MG

A090910 001 Nov 18, 2011 Nov CAHN

AB PAR PHARM 500MG

A204395 001 Apr 15, 2016 Apr NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA BELCHER PHARMS LLC 454GM/BOT

A205727 001 Feb 23, 2016 Feb NEWA

AA INVATECH PHARMA 454GM/BOT

A206815 001 Feb 18, 2016 Feb NEWA

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>D> AA ROXANE 15GM/60ML

A089049 001 Nov 17, 1986 Nov CAHN

>A> AA WEST-WARD PHARMS INT 15GM/60ML

A089049 001 Nov 17, 1986 Nov CAHN

SOFOBUVIR; VELPATASVIR

TABLET;ORAL

EPCLUSA

+ GILEAD SCIENCES INC 400MG;100MG

N208341 001 Jun 28, 2016 Jun NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

AB1 BEXIMCO PHARMS USA 80MG

A207428 001 Oct 21, 2016 Oct NEWA

AB1 120MG

A207428 002 Oct 21, 2016 Oct NEWA

AB1 160MG

A207428 003 Oct 21, 2016 Oct NEWA

@ IMPAX PHARMS 80MG

A075663 001 Nov 07, 2000 Mar DISC

@ 120MG

A075663 002 Nov 07, 2000 Mar DISC

@ 160MG

A075663 003 Nov 07, 2000 Mar DISC

@ 240MG

A075663 004 Nov 07, 2000 Mar DISC

@ SUN PHARM INDS 80MG

A075515 001 Oct 15, 2001 Mar CAHN

@ 80MG

A076576 001 Apr 08, 2004 Mar CAHN

@ 120MG

A075515 004 Oct 15, 2001 Mar CAHN

@ 120MG

A076576 002 Apr 08, 2004 Mar CAHN

@ 160MG

A075515 002 Oct 15, 2001 Mar CAHN

@ 160MG

A076576 003 Apr 08, 2004 Mar CAHN

@ 240MG

A075515 003 Oct 15, 2001 Mar CAHN

AB1 UPSHER-SMITH LABS 80MG

A075366 001 May 01, 2000 Oct CAHN

AB1 120MG

A075366 002 May 01, 2000 Oct CAHN

AB1 160MG

A075366 003 May 01, 2000 Oct CAHN

AB1 240MG

A075366 004 May 01, 2000 Oct CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB ACCORD HLTHCARE INC 25MG

A203512 001 Sep 19, 2016 Sep NEWA

AB 50MG

A203512 002 Sep 19, 2016 Sep NEWA

AB 100MG

A203512 003 Sep 19, 2016 Sep NEWA

TABLET;ORAL							
SPIRONOLACTONE							
AB	SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar	CAHN
AB		50MG	A089424	002	Aug 11, 1999	Mar	CAHN
AB		100MG	A089424	003	Aug 11, 1999	Mar	CAHN
<u>SUCRALFATE</u>							
TABLET;ORAL							
SUCRALFATE							
AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan	CAHN
<u>SUFENTANIL CITRATE</u>							
INJECTABLE;INJECTION							
SUFENTANIL CITRATE							
AP	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Oct	CAHN
<u>SUGAMMADEX SODIUM</u>							
SOLUTION;INTRAVENOUS							
BRIDION							
	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan	CPOT
+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan	CPOT
<u>SULCONAZOLE NITRATE</u>							
SOLUTION;TOPICAL							
EXELDERM							
+	SUN PHARM INDS LTD	1%	N018738	001	Aug 30, 1985	Oct	CAHN
<u>SULFAMETHOXAZOLE</u>							
TABLET;ORAL							
SULFAMETHOXAZOLE							
	@ AUROLIFE PHARMA LLC	500MG	A085844	001		Feb	CAHN
<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>							
INJECTABLE;INJECTION							
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
	@ WEST-WARD PHARMS INT	80MG/ML;16MG/ML	A070627	001	Dec 29, 1987	Oct	CAHN
	@	80MG/ML;16MG/ML	A070628	001	Dec 29, 1987	Oct	CAHN
SUSPENSION;ORAL							
BACTRIM							
	@ SUN PHARM INDS	200MG/5ML;40MG/5ML	N017560	001		Jun	CAHN
BACTRIM PEDIATRIC							
	@ SUN PHARM INDS	200MG/5ML;40MG/5ML	N017560	002		Jun	CAHN
TABLET;ORAL							
BACTRIM							
AB	SUN PHARM INDS	400MG;80MG	N017377	001		Mar	CAHN
BACTRIM DS							
AB	+ SUN PHARM INDS	800MG;160MG	N017377	002		Mar	CAHN
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
AB	SUN PHARM INDS	800MG;160MG	A071017	001	Aug 25, 1986	Mar	CAHN
<u>SULFASALAZINE</u>							
TABLET;ORAL							
SULFASALAZINE							
	@ SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987	Mar	CAHN
<u>SULFISOXAZOLE</u>							
TABLET;ORAL							
SULFISOXAZOLE							
	@ AUROLIFE PHARMA LLC	500MG	A085628	001		Feb	CAHN
<u>SULINDAC</u>							
TABLET;ORAL							
SULINDAC							
AB	SUN PHARM INDS	150MG	A072050	001	Apr 17, 1991	Mar	CAHN
AB		200MG	A072051	001	Apr 17, 1991	Mar	CAHN

SUMATRIPTAN

SPRAY;NASAL							
IMITREX							
AB	+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997	Feb CFTG
AB	+		20MG/SPRAY	N020626	003	Aug 26, 1997	Feb CFTG
SUMATRIPTAN							
AB		LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016	Feb NEWA
AB			20MG/SPRAY	A204841	002	Feb 19, 2016	Feb NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS							
ALSUMA							
	@	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Sep DISC
POWDER;INHALATION							
ONZETRA XSAIL							
+		AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan NEWA
SOLUTION;SUBCUTANEOUS							
ZEMBRACE SYMTOUCH							
	DR	REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan NEWA

TACROLIMUS

OINTMENT;TOPICAL							
PROTOPIC							
AB	+	LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun CAHN
AB	+		0.1%	N050777	002	Dec 08, 2000	Jun CAHN

TAMOXIFEN CITRATE

SOLUTION;ORAL							
SOLTAMOX							
		MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005	Jan CAHN
TABLET;ORAL							
TAMOXIFEN CITRATE							
	@	ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003	Jan DISC
	@		EQ 20MG BASE	A076179	002	Feb 20, 2003	Jan DISC
AB		MAYNE PHARMA	EQ 10MG BASE	A075797	001	Feb 20, 2003	Aug CAHN
AB	+		EQ 20MG BASE	A074858	001	Feb 20, 2003	Aug CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS							
ULTRA-TECHNEKOW FM							
+		MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
	@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE;INJECTION							
MPI DMSA KIDNEY REAGENT							
	@	GE HEALTHCARE	N/A	N017944	001	May 18, 1982	Aug DISC

TEGASEROD MALEATE

TABLET;ORAL							
ZELNORM							
	@	US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jan CAHN
	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Jan CAHN

TELITHROMYCIN

TABLET;ORAL							
KETEK							
	@	SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005	Mar DISC
	@		400MG	N021144	001	Apr 01, 2004	Mar DISC

TELMISARTAN

TABLET;ORAL							
TELMISARTAN							
AB		HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016	Apr NEWA
AB			40MG	A205901	002	Apr 22, 2016	Apr NEWA
AB			80MG	A205901	003	Apr 22, 2016	Apr NEWA
AB		JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Aug NEWA
AB			40MG	A204164	002	Aug 22, 2016	Aug NEWA
AB			80MG	A204164	003	Aug 22, 2016	Aug NEWA

TEMAZEPAMCAPSULE; ORAL
TEMAZEPAM

AB	AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	May	NEWA
AB		15MG	A203482	002	May 23, 2016	May	NEWA
AB		22.5MG	A203482	003	May 23, 2016	May	NEWA
AB		30MG	A203482	004	May 23, 2016	May	NEWA
AB	SUN PHARM INDS	7.5MG	A078581	001	Sep 08, 2009	Mar	CAHN
	@	15MG	A071174	001	Jul 10, 1986	Mar	CAHN
AB		22.5MG	A071175	002	Sep 14, 2009	Mar	CAHN
	@	30MG	A071175	001	Jul 10, 1986	Mar	CAHN

TEMOZOLOMIDECAPSULE; ORAL
TEMOZOLOMIDE

AB	AMERIGEN PHARMS LTD	5MG	A203490	001	Jul 13, 2016	Jul	NEWA
AB		20MG	A203490	002	Jul 13, 2016	Jul	NEWA
AB		100MG	A203490	003	Jul 13, 2016	Jul	NEWA
AB		140MG	A203490	004	Jul 13, 2016	Jul	NEWA
AB		180MG	A203490	005	Jul 13, 2016	Jul	NEWA
AB		250MG	A203490	006	Jul 13, 2016	Jul	NEWA
>A> AB	CHEMI SPA	5MG	A204639	001	Nov 23, 2016	Nov	NEWA
>A> AB		20MG	A204639	002	Nov 23, 2016	Nov	NEWA
>A> AB		100MG	A204639	003	Nov 23, 2016	Nov	NEWA
>A> AB		140MG	A204639	004	Nov 23, 2016	Nov	NEWA
>A> AB		180MG	A204639	005	Nov 23, 2016	Nov	NEWA
>A> AB		250MG	A204639	006	Nov 23, 2016	Nov	NEWA
AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA
AB		20MG	A206413	002	Apr 12, 2016	Mar	NEWA
AB		100MG	A206413	003	Apr 12, 2016	Mar	NEWA
AB		140MG	A206413	004	Apr 12, 2016	Mar	NEWA
AB		180MG	A206413	005	Apr 12, 2016	Mar	NEWA
AB		250MG	A206413	006	Apr 12, 2016	Mar	NEWA
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA
AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA
AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA
AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA
AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA
AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA
AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Jun	NEWA
AB		20MG	A205227	002	Jun 29, 2016	Jun	NEWA
AB		100MG	A205227	003	Jun 29, 2016	Jun	NEWA
AB		140MG	A205227	004	Jun 29, 2016	Jun	NEWA
AB		180MG	A205227	005	Jun 29, 2016	Jun	NEWA
AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA

>A> TENOFOVIR ALAFENAMIDE FUMARATE>A> TABLET; ORAL
>A> VEMPLIDY

>A>	+	GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016	Nov	NEWA
-----	---	---------------------	--------------	---------	-----	--------------	-----	------

TERBUTALINE SULFATEINJECTABLE; INJECTION
BRETHINE@ PHARMACARE 1MG/ML
TERBUTALINE SULFATE

AP	+	AMPHASTAR PHARMS INC	1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
AP	+	EUROHLTH INTL SARL	1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN

TABLET; ORAL
BRETHINE

>D>	@	LEHIGH VALLEY	2.5MG	N017849	001		Nov	CAHN
>D>	@		5MG	N017849	002		Nov	CAHN
>A>	@	PHARMACARE LTD	2.5MG	N017849	001		Nov	CAHN
>A>	@		5MG	N017849	002		Nov	CAHN

TERBUTALINE SULFATE

@ IMPAX LABS 2.5MG
@ 5MG
LANNETT 2.5MG
5MG

A075877	001	Jun 26, 2001	Mar	DISC
A075877	002	Jun 26, 2001	Mar	DISC
A077152	001	Mar 25, 2005	Mar	CTEC
A077152	002	Mar 25, 2005	Mar	CTEC

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL
ANDRODERM

+	ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011	Mar CAHN
@		2.5MG/24HR	N020489	001	Sep 29, 1995	Mar CAHN
+		4MG/24HR	N020489	004	Oct 20, 2011	Mar CAHN
@		5MG/24HR	N020489	002	May 02, 1997	Mar CAHN

GEL, METERED;NASAL
NATESTO

	AYTU BIOSCIENCE INC	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun CAHN
--	---------------------	-------------------------	---------	-----	--------------	----------

PELLET;IMPLANTATION
TESTOPEL

+	AUXILIUM PHARMS INC	75MG	A080911	001		Mar CAHN
---	---------------------	------	---------	-----	--	----------

TABLET, EXTENDED RELEASE;BUCCAL
STRIANT

+	AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	Mar CAHN
---	---------------------	------	---------	-----	--------------	----------

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE

AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL
TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Apr CMFD
AB		500MG	A062752	002	Aug 12, 1988	Apr CMFD
	@ IDT AUSTRALIA LTD	250MG	A061471	001		Aug CAHN
	@ SUN PHARM INDS	250MG	A060736	001		Mar CAHN
	@	500MG	A060736	002		Mar CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL
THEO-24

	AUXILIUM PHARMS INC	200MG	A087943	001	Aug 22, 1983	Mar CAHN
		300MG	A087944	001	Aug 22, 1983	Mar CAHN
+		400MG	A081034	001	Feb 28, 1992	Mar CAHN
	AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	Jul CAHN
		300MG	A087944	001	Aug 22, 1983	Jul CAHN

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

+	NOSTRUM LABS INC	80MG/15ML	A085186	001		Jan CAHN
---	------------------	-----------	---------	-----	--	----------

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jan CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jan CAHN

THEOPHYLLINE

AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	Jan CAHN
AB	RHODES PHARMS	400MG	A087571	001	Sep 01, 1982	Aug CTNA

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar CAHN
	@	15MG	A088461	001	Nov 18, 1983	Mar CAHN
AB		25MG	A089953	003	Aug 01, 1986	Mar CAHN
AB		50MG	A089953	002	Aug 01, 1986	Mar CAHN
AB		100MG	A089953	001	Oct 07, 1988	Mar CAHN
	@	150MG	A088737	001	Sep 26, 1984	Mar CAHN
	@	200MG	A088738	001	Oct 16, 1984	Mar CAHN

THIOTEPA

INJECTABLE;INJECTION
THIOTEPA

+	WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Sep CAHN
---	----------------------	-----------	---------	-----	--------------	----------

THIOTHIXENE

CAPSULE; ORAL

NAVANE

@	PFIZER	1MG	N016584	001		Aug	DISC
@		2MG	N016584	002		Aug	DISC
@		5MG	N016584	003		Aug	DISC
@		10MG	N016584	004		Aug	DISC

THIOTHIXENE

MYLAN

		1MG	A071093	002	Jun 23, 1987	Aug	CTEC
		2MG	A071093	003	Jun 23, 1987	Aug	CTEC
+		5MG	A071093	004	Jun 23, 1987	Aug	CRLD
		10MG	A071093	001	Jun 23, 1987	Aug	CTEC
@	SANDOZ	1MG	A071529	002	Jun 24, 1987	Sep	CMS1
@		2MG	A071529	003	Jun 24, 1987	Sep	CMS1
@		5MG	A071529	001	Jun 24, 1987	Mar	DISC
@		10MG	A071529	004	Jun 24, 1987	Sep	CMS1

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

AT	+	OAK PHARMS INC	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Sep	CFTG
AT	+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Sep	CFTG

TIMOLOL

AT		AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Sep	NEWA
AT			EQ 0.5% BASE	A205309	002	Sep 30, 2016	Sep	NEWA

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

>D>	AB	ROXANE	250MG	A201172	001	Apr 30, 2012	Nov	CAHN
>D>	AB		500MG	A201172	002	Apr 30, 2012	Nov	CAHN
	BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr	CTEC
	BX		500MG	A202489	002	Oct 09, 2013	Apr	CTEC
>A>	AB	WEST-WARD PHARMS INT	250MG	A201172	001	Apr 30, 2012	Nov	CAHN
>A>	AB		500MG	A201172	002	Apr 30, 2012	Nov	CAHN

TIROFIBAN HYDROCHLORIDE

SOLUTION; INJECTION

AGGRASTAT

+	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016	Aug	NEWA
---	----------	---	---------	-----	--------------	-----	------

TOBRAMYCIN

SOLUTION; INHALATION

BETHKIS

+	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Sep	CRLD
---	----------------	-----------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP		CLARIS	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Jun	NEWA
	@	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991	Oct	CAHN
	@		EQ 10MG BASE/ML	A063128	001	Nov 27, 1991	Oct	CAHN
AP			EQ 40MG BASE/ML	A063117	001	Apr 26, 1991	Oct	CAHN
	@		EQ 40MG BASE/ML	A063118	001	Jul 29, 1991	Oct	CAHN
	@		EQ 40MG BASE/ML	A063127	001	Nov 27, 1991	Oct	CAHN

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE; ORAL

XELJANZ XR

+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb	NEWA
---	------------	--------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@	SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar	CAHN
@		250MG	A071358	001	Jul 16, 1987	Mar	CAHN
@		500MG	A071359	001	Jul 16, 1987	Mar	CAHN

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

@ SUN PHARM INDS

EQ 400MG BASE

A073311 001 Nov 27, 1991 Mar CAHN

TABLET;ORAL

TOLMETIN SODIUM

AB SUN PHARM INDS

EQ 200MG BASE

A073310 001 Nov 27, 1991 Mar CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

>A> AB TEVA PHARMS USA

2MG

A079141 001 Nov 22, 2016 Nov NEWA

>A> AB

4MG

A079141 002 Nov 22, 2016 Nov NEWA

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

@ ACTAVIS TOTOWA

25MG

A078637 001 Feb 27, 2013 Apr DISC

AB

25MG

A078637 001 Feb 27, 2013 Jan CAHN

@

50MG

A078637 002 Feb 27, 2013 Apr DISC

AB

50MG

A078637 002 Feb 27, 2013 Jan CAHN

@

100MG

A078637 003 Feb 27, 2013 Apr DISC

AB

100MG

A078637 003 Feb 27, 2013 Jan CAHN

@

200MG

A078637 004 Feb 27, 2013 Apr DISC

AB

200MG

A078637 004 Feb 27, 2013 Jan CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

>A> AP INGENUS PHARMS LLC

EQ 4MG BASE/VIAL

A206962 001 Nov 30, 2016 Nov NEWA

TORSEMIDE

INJECTABLE;INJECTION

TORSEMIDE

@ WEST-WARD PHARMS INT

20MG/2ML (10MG/ML)

A078007 001 Jun 11, 2008 Oct CAHN

@

50MG/5ML (10MG/ML)

A078007 002 Jun 11, 2008 Oct CAHN

TABLET;ORAL

TORSEMIDE

>D> AB ROXANE

5MG

A076943 001 Mar 01, 2005 Nov CAHN

>D> AB

10MG

A076943 002 Mar 01, 2005 Nov CAHN

>D> AB

20MG

A076943 003 Mar 01, 2005 Nov CAHN

>A> AB WEST-WARD PHARMS INT

5MG

A076943 001 Mar 01, 2005 Nov CAHN

>A> AB

10MG

A076943 002 Mar 01, 2005 Nov CAHN

>A> AB

20MG

A076943 003 Mar 01, 2005 Nov CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB ACI HEALTHCARE LTD

50MG

A202075 001 Nov 28, 2011 Mar CAHN

AB SUN PHARM INDS

50MG

A076100 001 Jun 20, 2002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

AB1 + LUPIN LTD

100MG

A200503 001 Aug 29, 2011 Oct CRLD

ULTRAM ER

@ VALEANT PHARMS

100MG

N021692 001 Sep 08, 2005 Oct DISC

AB1 +

100MG

N021692 001 Sep 08, 2005 Mar CAHN

@

200MG

N021692 002 Sep 08, 2005 Oct DISC

AB1

200MG

N021692 002 Sep 08, 2005 Mar CAHN

@

300MG

N021692 003 Sep 08, 2005 Oct DISC

AB1

300MG

N021692 003 Sep 08, 2005 Mar CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP AKORN

100MG/ML

A206634 001 Jun 09, 2016 May NEWA

AP AUROBINDO PHARMA LTD

100MG/ML

A205035 001 Jan 14, 2016 Jan NEWA

AP NORTH CREEK PHARMS

100MG/ML

A202755 001 Feb 25, 2016 Feb NEWA

TABLET;ORAL

TRANEXAMIC ACID

@ AMERIGEN PHARMS LTD

650MG

A203256 001 Jul 25, 2016 Jul DISC

AB

650MG

A203256 001 Jul 25, 2016 Jul NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb CAHN
AB	SUN PHARM INDS	50MG	A073137	002	Mar 24, 1993	Mar CAHN
AB		100MG	A073137	001	Mar 24, 1993	Mar CAHN
AB		150MG	A073137	003	Dec 22, 1995	Mar CAHN

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

	UNITED THERAP	EQ 5MG BASE	N203496	005	Oct 07, 2016	Oct NEWA
--	---------------	-------------	---------	-----	--------------	----------

TRETINOIN

CREAM;TOPICAL

TRETINOIN

	+ ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Jul CAHN
		0.075%	A202209	001	Oct 11, 2012	Jul CAHN
AB	ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Feb CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Feb CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Feb CAHN
AB	PERRIGO PHARMA INTL	0.025%	A075264	001	Dec 24, 1998	Jul CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Jul CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Jul CAHN

GEL;TOPICAL

TRETINOIN

AB	ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Feb CAHN
AB	PERRIGO PHARMA INTL	0.01%	A075589	001	Jun 11, 2002	Jul CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Jul CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

KENALOG

>D>	@ DELCOR ASSET CORP	0.025%	N011601	003		Nov CMFD
>D>	@	0.1%	N011601	006		Nov CMFD

TRIAMCINOLONE ACETONIDE

>A>	AT	DELCOR ASSET CORP	0.025%	N011601	003	Nov CMFD
>A>	AT		0.1%	N011601	006	Nov CMFD
	AT	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016 Jul NEWA

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	TELIGENT PHARMA INC	0.025%	A204608	001	Jul 07, 2016	Jun NEWA
AT		0.1%	A204606	001	Jul 07, 2016	Jun NEWA

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul NEWA
AT	TELIGENT PHARMA INC	0.1%	A205373	001	May 13, 2016	May NEWA

SPRAY;TOPICAL

KENALOG

AT	+ RANBAXY LABS LTD	0.147MG/GM	N012104	001		Jul CAHN
	TRIAMCINOLONE ACETONIDE					
>A>	AT	AKORN	0.147MG/GM	A207094	001	Dec 07, 2016 Nov NEWA
	SPRAY, METERED;NASAL					
	TRIAMCINOLONE ACETONIDE					
	@ TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Oct DISC

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

>D>	AB	ROXANE	0.125MG	A074224	001	Jun 01, 1994 Nov CAHN
>D>	AB		0.25MG	A074224	002	Jun 01, 1994 Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	0.125MG	A074224	001	Jun 01, 1994 Nov CAHN
>A>	AB		0.25MG	A074224	002	Jun 01, 1994 Nov CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar CAHN
----	----------------	-------	---------	-----	--------------	----------

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

AB	+	MAYNE PHARMA	100MG	N018679	001	Jul 30, 1982	Aug CAHN
	@	SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun CAHN
	@		200MG	A070495	001	Sep 24, 1986	Mar CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

+	AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun CAHN
@	AYTU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun CMS2
@		EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jan CAHN
+		EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr NEWA
AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr NEWA
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr NEWA

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

TRELSTAR

+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

AB	+	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Aug CRLD
	@	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr DISC
	@	UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015	Oct CAHN

TABLET;ORAL

TROSPIUM CHLORIDE

AB	+	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Aug CRLD
AB		HERITAGE PHARMS INC	20MG	A204945	001	Aug 30, 2016	Aug NEWA
AB		INVAGEN PHARMS	20MG	A091688	001	Aug 23, 2016	Aug NEWA

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	+	@ ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
	+		300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

>D>	AB	ROXANE	EQ 500MG BASE	A078656	001	May 24, 2010	Nov CAHN
>D>	AB		EQ 1GM BASE	A078656	002	May 24, 2010	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 500MG BASE	A078656	001	May 24, 2010	Nov CAHN
>A>	AB		EQ 1GM BASE	A078656	002	May 24, 2010	Nov CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	Jul CFTG
----	---	-------------------	---------	---------	-----	--------------	----------

VALGANCICLOVIR HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	50MG/ML	A205220	001	Jul 18, 2016	Jul NEWA
----	--	---------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar NEWA
AB		HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar NEWA

VALPROATE SODIUMINJECTABLE; INJECTION
VALPROATE SODIUM

AP	AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun CAHN
AP	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACIDCAPSULE; ORAL
VALPROIC ACID

AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

SYRUP; ORAL
VALPROIC ACID

AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
----	------------------	-----------	---------	-----	--------------	----------

VALSARTANTABLET; ORAL
VALSARTAN

AB	MACLEODS PHARMS LTD	40MG	A202696	001	Sep 16, 2016	Sep NEWA
AB		80MG	A202696	002	Sep 16, 2016	Sep NEWA
AB		160MG	A202696	003	Sep 16, 2016	Sep NEWA
AB		320MG	A202696	004	Sep 16, 2016	Sep NEWA

VANCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION
VANCOLED

@	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Oct CAHN
@		EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Oct CAHN
@		EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Oct CAHN
@		EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Oct CAHN
@		EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Oct CAHN

VANCOMYCIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar NEWA
AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar NEWA
AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar NEWA
AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar NEWA
AP	CFT PHARMS LLC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015	Jul CAHN
AP		EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015	Jul CAHN
AP		EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Jul CAHN
AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Jul CAHN
AP	FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A062663	005	Aug 17, 2016	Aug NEWA
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan NEWA
AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan NEWA
	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988	Oct CAHN
	@	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988	Oct CAHN

VANDETANIBTABLET; ORAL
CAPRELSA

	GENZYME CORP	100MG	N022405	001	Apr 06, 2011	Jun CAHN
+		300MG	N022405	002	Apr 06, 2011	Jun CAHN

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

AP	GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May NEWA
AP		20MG/VIAL	A205390	002	May 26, 2016	May NEWA
AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan CAHN
AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan CAHN

VENETOCLAXTABLET; ORAL
VENCLEXTA

	ABBVIE INC	10MG	N208573	001	Apr 11, 2016	Apr NEWA
		50MG	N208573	002	Apr 11, 2016	Apr NEWA
+		100MG	N208573	003	Apr 11, 2016	Apr NEWA

VERAPAMIL HYDROCHLORIDE

	SOLUTION; INTRAVENOUS									
	VERAPAMIL HYDROCHLORIDE									
AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr	CMFD			
	TABLET; ORAL									
	CALAN									
	@ GD SEARLE LLC	40MG	N018817	003	Feb 23, 1988	Sep	DISC			
	VERAPAMIL HYDROCHLORIDE									
	@ SUN PHARM INDS	80MG	A071489	002	Jan 13, 1988	Jun	CAHN			
	@	120MG	A071489	001	Jan 13, 1988	Jun	CAHN			
	TABLET, EXTENDED RELEASE; ORAL									
	VERAPAMIL HYDROCHLORIDE									
AB	+ GLENMARK GENERICS	180MG	A090700	002	Aug 03, 2011	Aug	CRLD			

VINBLASTINE SULFATE

INJECTABLE; INJECTION		VINBLASTINE SULFATE							
	+ WEST-WARD PHARMS INT	10MG/VIAL	A089395	001	Apr 09, 1987	Oct	CAHN		

VORAPAXAR SULFATE

TABLET; ORAL		ZONTIVITY							
	+ ARALEZ PHARMS	EQ 2.08MG BASE	N204886	001	May 08, 2014	Sep	CAHN		

VORICONAZOLE

FOR SUSPENSION;ORAL									
VORICONAZOLE									
AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar	NEWA		
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May	NEWA		
INJECTABLE;IV (INFUSION)									
VORICONAZOLE									
AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar	NEWA		
TABLET;ORAL									
VORICONAZOLE									
AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May	NEWA		
AB		200MG	A206181	002	May 24, 2016	May	NEWA		
>A>	AB	AKORN	A207049	001	Sep 07, 2016	Nov	CAHN		
>A>	AB	200MG	A207049	002	Sep 07, 2016	Nov	CAHN		
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May	NEWA		
AB		200MG	A206762	002	May 24, 2016	May	NEWA		
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan	NEWA		
AB		200MG	A206837	002	Jan 22, 2016	Jan	NEWA		
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May	NEWA		
AB		200MG	A207371	002	May 24, 2016	May	NEWA		
AB	PRINSTON INC	50MG	A206654	001	Aug 08, 2016	Jul	NEWA		
AB		200MG	A206654	002	Aug 08, 2016	Jul	NEWA		
>D>	AB	VERSAPHARM INC	A207049	001	Sep 07, 2016	Nov	CAHN		
AB		50MG	A207049	001	Sep 07, 2016	Aug	NEWA		
>D>	AB	200MG	A207049	002	Sep 07, 2016	Nov	CAHN		
AB		200MG	A207049	002	Sep 07, 2016	Aug	NEWA		
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May	NEWA		
AB		200MG	A206747	002	May 24, 2016	May	NEWA		

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL		TRINTELLIX							
	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun	CTNA		
		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun	CTNA		
		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun	CTNA		
	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun	CTNA		

XENON XE-133

GAS; INHALATION		XENON XE 133							
	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb	CTEC		
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD		
		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD		

ZALEPLONCAPSULE;ORAL
ZALEPLON

>D>	AB	ROXANE	5MG	A 077237	001	Jun 06, 2008	Nov CAHN
>D>	AB		10MG	A 077237	002	Jun 06, 2008	Nov CAHN
>D>	AB	UPSHER SMITH	5MG	A 078706	001	Jun 06, 2008	Nov DISC
>A>	@		5MG	A 078706	001	Jun 06, 2008	Nov DISC
>D>	AB		10MG	A 078706	002	Jun 06, 2008	Nov DISC
>A>	@		10MG	A 078706	002	Jun 06, 2008	Nov DISC
	@	UPSHER-SMITH LABS	5MG	A 078095	001	Jun 06, 2008	Oct CAHN
	@		10MG	A 078095	002	Jun 06, 2008	Oct CAHN
>A>	AB	WEST-WARD PHARMS INT	5MG	A 077237	001	Jun 06, 2008	Nov CAHN
>A>	AB		10MG	A 077237	002	Jun 06, 2008	Nov CAHN

ZIDOVUDINETABLET;ORAL
ZIDOVUDINE

>D>	AB	ROXANE	300MG	A 076844	001	Sep 19, 2005	Nov CAHN
	@	SUNSHINE LAKE	300MG	A 202058	001	Oct 07, 2011	Aug DISC
>A>	AB	WEST-WARD PHARMS INT	300MG	A 076844	001	Sep 19, 2005	Nov CAHN

ZIPRASIDONE HYDROCHLORIDECAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

>D>	AB	APOTEX CORP	EQ 20MG BASE	A 077561	001	Mar 02, 2012	Nov CAHN
>D>	AB		EQ 40MG BASE	A 077561	002	Mar 02, 2012	Nov CAHN
>D>	AB		EQ 60MG BASE	A 077561	003	Mar 02, 2012	Nov CAHN
>D>	AB		EQ 80MG BASE	A 077561	004	Mar 02, 2012	Nov CAHN
>A>	AB	APOTEX INC	EQ 20MG BASE	A 077561	001	Mar 02, 2012	Nov CAHN
>A>	AB		EQ 40MG BASE	A 077561	002	Mar 02, 2012	Nov CAHN
>A>	AB		EQ 60MG BASE	A 077561	003	Mar 02, 2012	Nov CAHN
>A>	AB		EQ 80MG BASE	A 077561	004	Mar 02, 2012	Nov CAHN

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

>A>	AP	ACCORD HLTHCARE	EQ 4MG BASE/5ML	A 205279	001	Nov 28, 2016	Nov NEWA
	AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A 207751	001	Sep 26, 2016	Sep NEWA
	AP	GLAND PHARMA LTD	EQ 5MG BASE/100ML	A 204217	001	Aug 18, 2016	Aug NEWA

ZOLMITRIPTANTABLET;ORAL
ZOLMITRIPTAN

	AB	AJANTA PHARMA LTD	2.5MG	A 204041	001	May 20, 2016	May NEWA
	AB		5MG	A 204041	002	May 20, 2016	May NEWA
	AB	AUROBINDO PHARMA LTD	2.5MG	A 207021	001	May 11, 2016	Apr NEWA
	AB		5MG	A 207021	002	May 11, 2016	Apr NEWA
		TABLET, ORALLY DISINTEGRATING;ORAL					
		ZOLMITRIPTAN					
>A>	AB	ALEMBIC PHARMS LTD	2.5MG	A 205074	001	Dec 01, 2016	Nov NEWA
>A>	AB		5MG	A 205074	002	Dec 01, 2016	Nov NEWA

ZOLPIDEM TARTRATETABLET;ORAL
ZOLPIDEM TARTRATE

	AB	SANDOZ INC	5MG	A 077322	001	Apr 23, 2007	Aug CAHN
	AB		10MG	A 077322	002	Apr 23, 2007	Aug CAHN
	@	SUN PHARM INDS	5MG	A 077288	001	Apr 23, 2007	Mar CAHN
	@		10MG	A 077288	002	Apr 23, 2007	Mar CAHN
		TABLET;SUBLINGUAL					
		EDLUAR					
	AB	MEDA PHARMS	5MG	N 021997	001	Mar 13, 2009	Jul CFTG
	AB	+	10MG	N 021997	002	Mar 13, 2009	Jul CFTG
		ZOLPIDEM TARTRATE					
>A>	AB	DR REDDYS LABS INC	1.75MG	A 204503	001	Nov 18, 2016	Nov NEWA
>A>	AB		3.5MG	A 204503	002	Nov 18, 2016	Nov NEWA
	AB	MYLAN PHARMS INC	5MG	A 202657	001	Aug 08, 2016	Jul NEWA
	AB		10MG	A 202657	002	Aug 08, 2016	Jul NEWA
	AB	PAR FORM	5MG	A 201509	001	Aug 01, 2016	Jul NEWA
	AB		10MG	A 201509	002	Aug 01, 2016	Jul NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb CAHN
	ZONISAMIDE					
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN
	@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar CAHN
	@	50MG	A077635	002	Dec 22, 2005	Mar CAHN
	@	100MG	A077635	003	Dec 22, 2005	Mar CAHN
	@ UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Oct CAHN
	@	50MG	A077644	002	Dec 22, 2005	Oct CAHN
	@	100MG	A077644	003	Dec 22, 2005	Oct CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

AUROBINDO PHARMA LTD 650MG

A207229 001 Nov 09, 2016 Oct NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG;250MG;65MG

N020802 001 Jan 14, 1998 Feb CAHN

ADAPALENE

GEL;TOPICAL

DIFFERIN

+ GALDERMA LABS LP 0.1%

N020380 002 Jul 08, 2016 Aug NEWA

BUDESONIDE

SPRAY, METERED;NASAL
BUDESONIDE

APOTEX INC 0.032MG/SPRAY

A078949 002 Nov 20, 2015 Apr NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG

A077355 001 Feb 06, 2008 Aug CTNA

800MG;10MG;165MG

A204782 001 Aug 29, 2016 Aug NEWA

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX INC 10MG

A207235 001 Aug 12, 2016 Aug NEWA

BIONPHARMA INC 5MG

N022429 001 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG

N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 002 Jul 23, 2009 Jan CAHN

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ CYPRESS PHARM 5MG/5ML

A090300 001 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML

A091327 001 Oct 17, 2011 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CYPRESS PHARM 5MG/5ML

A090300 002 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML

A091327 002 Oct 17, 2011 Mar CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG

A206793 001 Mar 08, 2016 Feb NEWA

10MG

A206793 002 Mar 08, 2016 Feb NEWA

CHLORHEXIDINE GLUCONATE

SPONGE;TOPICAL

CHLORHEXIDINE GLUCONATE

+ BECTON DICKINSON 4%

A072525 001 Oct 24, 1989 Jun CRLD

PHARMASEAL SCRUB CARE

@ CAREFUSION 4%

N019793 001 Dec 02, 1988 Jun DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+ BECTON DICKINSON CO 2%;70% (3ML)

N020832 001 Jul 14, 2000 May CAHN

+ 2%;70% (10.5ML)

N020832 004 Aug 20, 2003 May CAHN

+ 2%;70% (26ML)

N020832 006 Nov 21, 2006 May CAHN

CHLORAPREP ONE-STEP FREPP

+ BECTON DICKINSON CO 2%;70% (1.5ML)

N020832 003 Apr 26, 2002 May CAHN

CHLORAPREP WITH TINT

+ BECTON DICKINSON CO 2%;70% (26ML)

N020832 002 May 03, 2005 May CAHN

+ 2%;70% (10.5ML)

N020832 005 Apr 03, 2006 May CAHN

+ 2%;70% (3ML)

N020832 007 Oct 10, 2006 May CAHN

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+ BECTON DICKINSON CO 2%;70% (0.67ML)

N021555 001 Oct 07, 2002 May CAHN

SWAB;TOPICAL

CHLORAPREP SINGLE SWABSTICK

+ BECTON DICKINSON CO 2%;70% (1.75ML)	N021555	002	May 10, 2005	May CAHN
---------------------------------------	---------	-----	--------------	----------

CHLORAPREP TRIPLE SWABSTICK

+ BECTON DICKINSON CO 2%;70% (5.25ML)	N021555	003	Jun 10, 2009	May CAHN
---------------------------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 12MG	A070797	001	Aug 12, 1988	Feb CAHN
----------------------------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN
---	---------	-----	--------------	----------

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

AUROBINDO PHARMA LTD 10MG	A206531	001	Apr 26, 2016	Apr NEWA
20MG	A206531	002	Apr 26, 2016	Apr NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

HETERO LABS LTD V 30MG	A204097	001	Aug 19, 2016	Aug NEWA
------------------------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE ALLERGY

HETERO LABS LTD V 60MG	A204097	002	Aug 19, 2016	Aug NEWA
180MG	A204097	003	Aug 19, 2016	Aug NEWA

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+ GLAXOSMITHKLINE 0.0275MG/SPRAY	N022051	002	Aug 02, 2016	Aug NEWA
----------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

APOTEX INC 0.05MG/SPRAY	A208150	001	Feb 29, 2016	Jul CAHN
-------------------------	---------	-----	--------------	----------

APOTEX TECHNOLOGIES 0.05MG/SPRAY	A208150	001	Feb 29, 2016	Feb NEWA
----------------------------------	---------	-----	--------------	----------

>D> ROXANE 0.05MG/SPRAY	A207957	001	May 26, 2016	Nov CAHN
-------------------------	---------	-----	--------------	----------

0.05MG/SPRAY	A207957	001	May 26, 2016	May NEWA
--------------	---------	-----	--------------	----------

>A> WEST-WARD PHARMS INT 0.05MG/SPRAY	A207957	001	May 26, 2016	Nov CAHN
---------------------------------------	---------	-----	--------------	----------

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
--	---------	-----	--------------	----------

HUMANWELL PURACAP EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016	Sep CAHN
---	---------	-----	--------------	----------

PURACAP PHARM LLC EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016	Jun NEWA
---	---------	-----	--------------	----------

SOFGEN PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016	Aug NEWA
---	---------	-----	--------------	----------

MIDOL LIQUID GELS

+ BIONPHARMA INC 200MG	N021472	001	Oct 18, 2002	Jan CAHN
------------------------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

GRANULES INDIA LTD 200MG	A202312	001	Oct 07, 2016	Sep NEWA
--------------------------	---------	-----	--------------	----------

STRIDES PHARMA 200MG	A079129	001	Mar 28, 2011	May CAHN
----------------------	---------	-----	--------------	----------

200MG	A091355	001	Apr 04, 2011	May CAHN
-------	---------	-----	--------------	----------

@ SUN PHARM INDS 200MG	A070493	001	Dec 24, 1985	Mar CAHN
------------------------	---------	-----	--------------	----------

@ 200MG	A070908	001	Sep 26, 1986	Mar CAHN
---------	---------	-----	--------------	----------

@ 200MG	A071462	001	Oct 02, 1986	Mar CAHN
---------	---------	-----	--------------	----------

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
KETOTIFEN FUMARATE

+	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Aug CRLD
	ZADITOR					
@	ALCON PHARMA	EQ 0.025% BASE	N021066	002	Oct 19, 2006	Aug DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

	MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016	May NEWA
	PREVACID 24 HR					
+	GLAXOSMITHKLINE CONS	15MG	N022327	001	May 18, 2009	Aug CAHN
	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL					
	LANSOPRAZOLE					
	DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016	Jun NEWA

LEVONORGESTREL

TABLET;ORAL
HER STYLE

	NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016	Feb NEWA
	LEVONORGESTREL					
	GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016	Mar NEWA
	JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016	Aug NEWA
	LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Aug NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

	BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005	Jan CAHN
+		2MG	N021855	002	Aug 04, 2005	Jan CAHN

LORATADINE

CAPSULE;ORAL
LORATADINE

	MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016	Sep NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL					
	LORATADINE					
	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003	Oct CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
LORATADINE AND PSEUDOEPHEDRINE SULFATE

	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003	Oct CAHN
		10MG;240MG	A075989	001	Mar 04, 2004	Oct CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
MONISTAT 3 COMBINATION PACK

+	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996	Mar CMS1
---	------------------	----------	---------	-----	--------------	----------

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM

+	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar CAHN
	TABLET;ORAL					
	NAPROXEN SODIUM					
	AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016	Mar NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
HABITROL

	DR REDDYS LABS INC	7MG/24HR	N020076	004	Nov 12, 1999	Aug CRLD
		14MG/24HR	N020076	005	Nov 12, 1999	Aug CRLD
	NICODERM CQ					
	SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996	Aug CRLD
		14MG/24HR	N020165	005	Aug 02, 1996	Aug CRLD

NICOTINE POLACRILEXGUM, CHEWING;BUCCAL
NICOTINE POLACRILEXACTAVIS LABS NY INC EQ 2MG BASE
EQ 4MG BASEA204794 001 May 10, 2016 Apr NEWA
A204833 001 Feb 26, 2016 Feb NEWAOMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

ACTAVIS ELIZABETH 20MG;1.1GM
AUROLIFE PHARMA LLC 20MG;1.1GM
PAR PHARM 20MG;1.1GM
PERRIGO R AND D 20MG;1.1GMA204137 001 Jul 15, 2016 Jul NEWA
A204923 001 Nov 07, 2016 Oct NEWA
A201946 001 Jul 15, 2016 Jul NEWA
A201361 001 Jul 15, 2016 Jul NEWAOXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

NUVO PHARM INC 17GM/SCOOPFUL
STRIDES PHARMA 17GM/SCOOPFUL
17GM/PACKETA206105 001 Oct 28, 2016 Oct NEWA
A203928 001 Aug 24, 2016 Aug NEWA
A203928 002 Aug 24, 2016 Aug NEWAPOTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>A> APOTEX INC EQ 75MG BASE
STRIDES PHARMA EQ 75MG BASE
>D> TORPHARM EQ 75MG BASEA075167 001 May 04, 2000 Nov CAHN
A201745 001 Feb 29, 2012 May CAHN
A075167 001 May 04, 2000 Nov CAHNTRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

TEVA PHARMS 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Oct NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2016

NO NOVEMBER 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ABACAVIR SULFATE; LAMIVUDINE - ABACAVIR SULFATE AND LAMIVUDINE</u>						
A 079246 001					PC	Mar 28, 2017
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP			
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	9399012	Sep 11, 2031	U-1882			
	9399012*PED	Mar 11, 2032				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001 >A>	9468636	May 16, 2032	U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jul 24, 2018	DP U-1006			
	6514980	Jul 24, 2018	DP U-1484			
	7223387	Nov 13, 2022	DP U-1006			
	7223387	Nov 13, 2022	DP U-1484			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 002					RTO	Jul 08, 2019
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	9463289	May 18, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
	9440922	Jun 09, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					M-177	Apr 05, 2019
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	>A> 9474752	Dec 11, 2027	U-1754			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	>A> 9474752	Dec 11, 2027	U-1754			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	6559183	Nov 12, 2019	DP U-804		NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>APREPITANT - EMEND</u>						
N 207865 001	>A> 6096742	Jul 01, 2018	DS DP U-1916			
	>A> 8258132	Sep 26, 2027	DP U-1916			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9452131	Mar 19, 2035	U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9452131	Mar 19, 2035	U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9452131	Mar 19, 2035	U-543			
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156 004					PC	Nov 28, 2016
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP		U-1893	
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP		U-1893	
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032			U-1731	
	9226892	Sep 29, 2032			U-1732	
	9226892	Sep 29, 2032			U-1733	
	9351984	Dec 19, 2021	DP			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	6926907	Feb 28, 2023	DP		U-1902	
	8206741	Feb 28, 2023	DP		U-1902	
					NC	Sep 14, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9364439	May 31, 2022	DP U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP PED	Feb 20, 2018 Aug 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
	8163723*PED	Feb 29, 2024				
	9259428	Jun 13, 2023	U-644			
	9259428*PED	Dec 13, 2023				
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	9463289	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	9463289	May 18, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	>A> 9504704	Jun 03, 2029	DP U-124			
	>A> 9504704	Jun 03, 2029	DP U-134			
	>A> 9504704	Jun 03, 2029	DP U-818			
	>A> 9504704	Jun 03, 2029	DP U-916			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
	9433630	Aug 31, 2030	DP U-1858			
	9439911	Aug 31, 2030	DP U-1858			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006					M-186	Sep 23, 2019
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9421265	Jun 17, 2030	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9474751	Apr 19, 2022	DP U-1524			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					I-735	May 20, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001	6723340	Oct 25, 2021	DP	I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493	NC	Aug 08, 2017
		7943788	Jul 14, 2027	DS DP	NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	002	7943582	Feb 26, 2029	DS DP U-493	I-735	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NC	Aug 08, 2017
		8222219	Jul 30, 2024	U-493	NCE	Mar 29, 2018
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	003	6723340	Oct 25, 2021	DP	I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493	NC	Aug 08, 2017
		7943788	Jul 14, 2027	DS DP	NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	004	7943582	Feb 26, 2029	DS DP U-493	I-735	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NC	Aug 08, 2017
		8222219	Jul 30, 2024	U-493	NCE	Mar 29, 2018
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	9295687	Jul 10, 2035	DP		
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	7635773	Mar 13, 2029	DP	>A> ODE	Oct 07, 2023
		8410077	Mar 13, 2029	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	9463246	Dec 26, 2028	DP U-219		
<u>CAREFILZOMIB - KYPROLIS</u>						
N 202714	001	7417042	Jul 20, 2026	DS DP	I-722	Jan 21, 2019
		8129346	Apr 14, 2025	U-1260	I-723	Jan 21, 2019
<u>CAREFILZOMIB - KYPROLIS</u>						
N 202714	002	7232818	Apr 14, 2025	DS DP	I-712	Jul 24, 2018
		7417042	Jul 20, 2026	DS DP	I-722	Jan 21, 2019
		7491704	Apr 14, 2025	U-1260	I-723	Jan 21, 2019
		7737112	Dec 07, 2027	DP	NCE	Jul 20, 2017
		8129346	Apr 14, 2025	U-1260	ODE	Jul 20, 2019
		8207125	Apr 14, 2025	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1679			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	9457036	Jan 13, 2024	DP U-257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9399036	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	9415007	Jul 28, 2024	U-1896			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	>A> 8629111	Aug 27, 2024	DP			
	>A> 8633162	Aug 27, 2024	U-1479			
	>A> 8642556	Aug 27, 2024	DP			
	>A> 8648048	Aug 27, 2024	U-1483			
	>A> 8685930	Aug 27, 2024	DP			
	>A> 9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	9421192	Aug 08, 2027	DS U-1724		D-161	Feb 05, 2019
	9421192	Aug 08, 2027	DS U-1725		D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	9421192	Aug 08, 2027	DS U-1724		D-161	Feb 05, 2019
	9421192	Aug 08, 2027	DS U-1725		D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAKLINZA - DACLITASVIR DIHYDROCHLORIDE</u>						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
<u>DALVANCE - DALBAVANCIN HYDROCHLORIDE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>ACZONE - DAPSONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>CUBICIN RF - DAPTOMYCIN</u>						
N 021572 003	9138456	Nov 23, 2030	DP			
<u>VIEKIRA PAK (COPACKAGED) - DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>VIEKIRA XR - DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR</u>						
N 208624 001	7148359	Jul 19, 2019	DP		NCE	Dec 19, 2019
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
<u>JADENU - DEFERASIROX</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>JADENU - DEFERASIROX</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>JADENU - DEFERASIROX</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFITELIO - DEFIBROTIDE SODIUM</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>FIRMAGON - DEGARELIX ACETATE</u>						
N 022201 001	9415085	Apr 27, 2032	U-1895			
<u>FIRMAGON - DEGARELIX ACETATE</u>						
N 022201 002	9415085	Apr 27, 2032	U-1895			
<u>OZURDEX - DEXAMETHASONE</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	>A> 9320712	Jan 04, 2032	DP			
	>A> 9320712*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	>A> 9320712	Jan 04, 2032	DP			
	>A> 9320712*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	>A> 9320712	Jan 04, 2032	DP			
	>A> 9320712*PED	Jul 04, 2032				
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003					PC	Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385 9242986	Oct 05, 2027 Dec 08, 2029	DS DP DS DP		NCE	Aug 12, 2018
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385 9242986	Oct 05, 2027 Dec 08, 2029	DS DP DS DP		NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 003	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	>A> 9486437	May 18, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	>A> 9486437	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 005					PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM</u>						
A 203593 001					PC	Apr 09, 2017
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9457036	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9302009	Oct 24, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELBASVIR; GRAZOPREVR - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	9364489	Jul 07, 2028	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	9364489	Jul 07, 2028	U-1709			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 14, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 14, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
	8551957	Oct 14, 2029	DP U-1651			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004					M-174	Mar 18, 2019
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020			U-257	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022			U-257	
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLEXA</u>						
N 202123 001	7125879	Apr 21, 2025	DS DP U-257			
	9457036	Jan 13, 2024	DP U-257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCovy</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	9457036	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-1892			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
					M-181	Jun 01, 2019
					>A> M-190	Oct 18, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
					M-181	Jun 01, 2019
					>A> M-190	Oct 18, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
					M-181	Jun 01, 2019
					>A> M-190	Oct 18, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	6369085	May 25, 2018	DS DP U-1509			
	6369085	May 25, 2018	DS DP U-1875			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810	Nov 03, 2019	DP U-1874			
	6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031		U-1781		
	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029		U-1781		
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029		U-1781		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	8486907	Jun 28, 2025		U-1904	NCE	Sep 19, 2021
	9018368	Jun 28, 2025	DS DP		ODE	Sep 19, 2023
	9416361	May 04, 2021	DS			
	>A> 9506058	Mar 14, 2034		U-1918		
	>A> 9506058	Mar 14, 2034		U-1919		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	8486907	Jun 28, 2025		U-1904	NCE	Sep 19, 2021
	9018368	Jun 28, 2025	DS DP		ODE	Sep 19, 2023
	9416361	May 04, 2021	DS			
	>A> 9506058	Mar 14, 2034		U-1918		
	>A> 9506058	Mar 14, 2034		U-1919		
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025		U-1368	I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022		U-1396		
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025		U-1368	I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022		U-1396		
	8436010*PED	Aug 22, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9387191	Jul 21, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	9468639	Oct 16, 2022	U-1734			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2017	DS		NCE	May 27, 2021
	9387266	Nov 28, 2026	U-1879			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	6858596	Aug 03, 2021	DP U-1890			
	7101866	Aug 03, 2021	DS DP U-1890			
	7541350	Aug 03, 2021	DP U-1890			
	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
	9415009	May 28, 2030	U-1841			
	9463161	May 28, 2030	DP U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001					NCE ODE	Jun 01, 2021 Jun 01, 2023
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	9402874	Aug 19, 2030	U-441			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP		NCE	Jul 01, 2016
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	6613355	Jun 28, 2021	DP		NDF	Aug 09, 2019
	6790458	May 11, 2021	DP			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 001					PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 002					PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 003					PC	Apr 24, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
>A>	9492390	Aug 24, 2027	U-1556			
>A>	9492391	Aug 24, 2027	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027	U-1556			
	>A> 9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027	U-1556			
	>A> 9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027	U-1556			
	>A> 9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027	U-1556			
	>A> 9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027	U-1556			
	>A> 9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027	U-1556			
	>A> 9492391	Aug 24, 2027	U-1556			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165	May 06, 2019
					I-729	Mar 04, 2019
					I-736	May 06, 2019
					I-737	May 06, 2019
					ODE	Mar 04, 2023
					ODE	May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	>A> 9469643	Sep 02, 2033	DS			
	>A> 9492449	Mar 11, 2030	U-1914			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	>A> 9469643	Sep 02, 2033	DS			
	>A> 9492449	Mar 11, 2030	U-1914			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 020833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 020833 002	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 020313 001	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 020314 001	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 020314 002	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 0208583 001	>A> 6268343	Aug 22, 2022	DS DP		>A> NC	Nov 21, 2019
	>A> 6458924	Aug 22, 2017	DS DP		>A> NCE	Sep 25, 2020
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7235627	Aug 22, 2017	DS			
	>A> 7615532	May 25, 2025	DS DP			
	>A> 7686786	Aug 03, 2026	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8846618	Jun 27, 2022	DS DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 8937042	May 05, 2029	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
	>A> 9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	5866538	Jun 20, 2017	DP			
	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004	5866538	Jun 20, 2017	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			
	9408979	Mar 02, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001					>A> NC	Nov 21, 2019
					>A> NCE	Jul 27, 2021
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
	>A> 9492442	Jun 12, 2033	U-1848			
	>A> 9492442	Jun 12, 2033	U-1899			
	>A> 9492442	Jun 12, 2033	U-1917			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8324242	Aug 05, 2027	U-1311		NCE	Jan 31, 2017
	8324242	Aug 05, 2027	U-1906			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8324242	Aug 05, 2027	U-1311		NCE	Jan 31, 2017
	8324242	Aug 05, 2027	U-1906			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8324242	Aug 05, 2027	U-1311		ODE	Sep 28, 2023
	8324242	Aug 05, 2027	U-1911			
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8846718	Dec 04, 2028	U-1717			
	8846718	Dec 04, 2028	U-1908			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Aug 05, 2027	U-1911		NPP	Sep 28, 2019
	8410274	Dec 28, 2026	DP		ODE	Jul 02, 2022
	8507534	Sep 20, 2030	DS DP		ODE	Sep 28, 2023
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
	9399040	Jul 30, 2023	DP			
	9486406	Oct 23, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	9339504	Jul 02, 2028	DP U-1596			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158	Feb 12, 2019
	9393256	Sep 14, 2032	U-1470		D-159	Feb 12, 2019
					D-160	Feb 12, 2019
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 206263 001					PC	Feb 11, 2017
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	7252839	Nov 13, 2023	DP		NP	Sep 16, 2019
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7691411	Mar 14, 2024	DP			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	9358338	Apr 27, 2035	U-1870			
	9370622	Sep 28, 2035	U-1870			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	7314938	Mar 10, 2025	DS DP		NCE	Jul 11, 2021
	7745460	Nov 05, 2024	DS DP	U-1880		
	7790743	Nov 05, 2024		U-1880		
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029		U-1880		
	8367701	Apr 15, 2029	DP	U-1880		
	8592450	May 17, 2026		U-1880		
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
	9447077	Apr 15, 2029		U-1900		
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	8802628	Nov 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	8802628	Nov 17, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
	>A> 9486526	Aug 05, 2029			U-1915	
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017			U-802	
	6340475	Sep 19, 2016	DP		U-1852	
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019			U-803	
	7078381	Feb 02, 2019			U-803	
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019			U-803	
	8119648	Aug 12, 2023			U-802	
	8178541	Aug 12, 2023	DP		U-1853	
	8673927	May 04, 2027			U-1503	
	8846695	Jun 04, 2030			U-1503	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP		U-1503	
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017			U-802	
	6340475	Sep 19, 2016	DP		U-1852	
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019			U-803	
	7078381	Feb 02, 2019			U-803	
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019			U-803	
	8119648	Aug 12, 2023			U-802	
	8178541	Aug 12, 2023	DP		U-1853	
	8673927	May 04, 2027			U-1503	
	8846695	Jun 04, 2030			U-1503	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP		U-1503	
	9415016	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					M-188	Oct 14, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					M-188	Oct 14, 2019
<u>LISINOPRIL - QBRELIS</u>						
N 208401 001	9463183	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1884			
	9169213	Dec 06, 2032	U-1885			
	9169213	Dec 06, 2032	U-1886			
	9169213	Dec 06, 2032	U-1887			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9370629	May 20, 2024	DP			
	9439907	Oct 26, 2021	DP			
	9440034	Oct 26, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001	>A> 6586430	Dec 01, 2019	DS DP U-824			
	>A> 6667314	Aug 06, 2021	DS DP U-824			
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7576097	May 25, 2021	DS			
<u>MEBENDAZOLE - VERMOX</u>						
N 208398 001					NS	Oct 19, 2019
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	9382191	Mar 07, 2026	DP			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>MESALAMINE - CANASA</u>						
N 021252 001					M-187	Sep 02, 2019
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	6559158	Nov 03, 2017	U-1185		NP	Jul 19, 2019
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
	9314461	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP		>A> M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP		>A> M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP		>A> M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP		>A> M-189	Oct 02, 2018
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001					M-185	Sep 27, 2019
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001					M-185	Sep 27, 2019
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 019599 002					>A> M-191	Nov 10, 2019
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7786133	Dec 19, 2027	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7786133	Dec 19, 2027	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9468747	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Jan 22, 2027	DP			
>A>	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
>A>	9511066	May 10, 2022	U-1921			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
>A>	9511066	May 10, 2022	U-1921			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
>A>	9511066	May 10, 2022	U-1921			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 001	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 002	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 003	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 004	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 005	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 006	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	9271975	Sep 09, 2031	U-528			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	9364564	Dec 26, 2027	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001 >A>	9061029	Apr 07, 2032	DP U-1374			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002 >A>	9061029	Apr 07, 2032	DP U-1374			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 001					PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 002					PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 003					PC	Apr 24, 2017
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS	U-864		
	5900424	May 04, 2016	DS	U-1817		
	6428810	Nov 03, 2019	DP	U-864		
	6428810	Nov 03, 2019	DP	U-1817		
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS	U-864		
	5900424	May 04, 2016	DS	U-1817		
	6428810	Nov 03, 2019	DP	U-864		
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016		U-588		
	6489346	Jul 15, 2016	DP	U-588	Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016		U-588	Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016		U-588		
	RE45198	Jul 15, 2016		U-588		
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016		U-623		
	5840737	Jul 15, 2016		U-624		
	6489346	Jul 15, 2016	DP	U-623	Y	
	6489346	Jul 15, 2016	DP	U-624	Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016		U-623	Y	
	6699885	Jul 15, 2016		U-624	Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016		U-623		
	7399772	Jul 15, 2016		U-624		
	RE45198	Jul 15, 2016		U-623		
	RE45198	Jul 15, 2016		U-624		
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016		U-588		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; Sodium Bicarbonate - Zegerid</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2017	DS DP U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPemifene - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001 >A>	9492443	May 26, 2024	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002 >A>	9492443	May 26, 2024	DS DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Aug 03, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457021	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 001					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					>A> ODE	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 002					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					>A> ODE	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 003					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					>A> ODE	Oct 18, 2023
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
	9393237	Aug 04, 2026		U-904		
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	>A> 9492476	Oct 08, 2033		U-1766		
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	>A> 9492476	Oct 08, 2033		U-1766		
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	>A> 9492476	Oct 08, 2033		U-1766		
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Jun 18, 2019	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026		U-1844		
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024		U-1845		
	8921393	Jan 15, 2024		U-1846		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9296694	Mar 06, 2021	DS DP			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	>A> 9480652	May 12, 2032	DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 006					PC	Jan 01, 2017
<u>PRASTERONE - INTRAROSA</u>						
N 208470 001	>A> 8268806	Mar 19, 2031	DP		>A> NCE	Nov 16, 2021
	>A> 8629129	Aug 07, 2028	DP			
	>A> 8957054	Aug 07, 2028	U-1922			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>QUETIAPINE FUMARATE - QUETIAPINE FUMARATE</u>						
A 090681 004					PC	Apr 30, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9289446	Jun 22, 2019	DP U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	9458107	Apr 08, 2031	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	8207191	Aug 30, 2024	U-805			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					NP ODE ODE	Apr 15, 2019 Apr 15, 2023 Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					NP ODE ODE	Apr 15, 2019 Apr 15, 2023 Jul 15, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9271968	Feb 27, 2026	DP			
	9421195	Mar 10, 2030	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					PC	Oct 29, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	9388134	Nov 08, 2026	U-1723			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	9433624	Nov 17, 2024	U-1589			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127 001					>A> NPP	Nov 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP		>A> NPP	Oct 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP		>A> NPP	Oct 25, 2019
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2017	DS U-1468			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	5686060	Nov 11, 2017	DS DP		I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8536130	Sep 22, 2028	U-1276			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	9439985	Sep 27, 2033	DS DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	>A> 7390791	May 07, 2022	DS DP		>A> NCE	Nov 05, 2020
	>A> 7803788	Feb 02, 2022	U-999		>A> NP	Nov 11, 2019
	>A> 8754065	Aug 15, 2032	DS DP U-999			
	>A> 9296769	Aug 15, 2032	DS DP U-999			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 002	5733919	Oct 23, 2016	DS			
	5965581	Oct 23, 2016	DP			
	5972967	Oct 23, 2016	DP			
	5978698	Oct 08, 2017	U-1897			
	6136794	Jan 29, 2019	U-1898			
	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003 >A>	6770660	May 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956041	Dec 08, 2020	DP		NCE	Nov 06, 2017
	6965027	Mar 25, 2023	DS			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	RE42353	Jun 27, 2022	DS DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-183	Aug 12, 2019
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-183	Aug 12, 2019
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035	U-1857			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	9447089	Jun 06, 2032	DP		M-184	Aug 31, 2019
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm